Clinical practice guideline for the prevention and management of peritoneal dialysis associated infections in children: 2024 update

Bradley A Warady[1] (iD), Rebecca Same[2] (iD),
Dagmara Borzych-Duzalka[3], Alicia M Neu[4], Ibrahim El Mikati[5],
Reem A Mustafa[5], Brandy Begin[6], Peter Nourse[7] (iD),
Sevcan A Bakkaloglu[8], Vimal Chadha[1], Francisco Cano[9],
Hui Kim Yap[10], Qian Shen[11] (iD), Jason Newland[12], Enrico Verrina[13],
Ann L Wirtz[1], Valerie Smith[1] (iD) and Franz Schaefer[14]

Abstract

Infection-related complications remain the most significant cause for morbidity and technique failure in infants, children and adolescents who receive maintenance peritoneal dialysis (PD). The 2024 update of the Clinical Practice Guideline for the Prevention and Management of Peritoneal Dialysis Associated Infection in Children builds upon previous such guidelines published in 2000 and 2012 and provides comprehensive treatment guidance as recommended by an international group of pediatric PD experts based upon a review of published literature and pediatric PD registry data. The workgroup prioritized updating key clinical issues contained in the 2012 guidelines, in addition to addressing additional questions developed using the PICO format. A variety of new guideline statements, highlighted by those pertaining to antibiotic therapy of peritonitis as a result of the evolution of antibiotic susceptibilities, antibiotic stewardship and clinical registry data, as well as new clinical benchmarks, are included. Recommendations for future research designed to fill important knowledge gaps are also provided.

[1]Division of Pediatric Nephrology, Children's Mercy Kansas City, Kansas City, Missouri, USA

[2]Department of Pediatrics, Division of Infectious Diseases, Children's Hospital of Philadelphia, Philadelphia, Pennsylvania, USA

[3]Department of Pediatrics, Nephrology and Hypertension, Medical University of Gdańsk, Gdańsk, Poland

[4]Division of Pediatric Nephrology, Johns Hopkins Children's Hospital, Baltimore, Maryland, USA

[5]Division of Nephrology and Hypertension, University of Kansas Medical Center, Kansas City, Kansas, USA

[6]Doernbecher Children's Hospital at Oregon Health & Science University, Portland, Oregon, USA

[7]Department of Paediatrics and Child Health, Red Cross War Memorial Children's Hospital, Cape Town, South Africa

[8]Division of Pediatric Nephrology, Gazi University Hospital, Ankara, Turkey

[9]Luis Calvo Mackenna Children's Hospital, Santiago, Chile

[10]Division of Pediatric Nephrology, National University Hospital, Singapore, Singapore

[11]Children's Hospital of Fudan University, Shanghai, China

[12]Division of Pediatric Infectious Diseases, St. Louis Children's Hospital, St Louis, Missouri, USA

[13]Nephrology, Dialysis and Transplantation Unit, IRCCS Istituto Giannina Gaslini Children's, Genoa, Italy

[14]Heidelberg University Center for Pediatrics and Adolescent Medicine, Heidelberg, Germany

Corresponding author:
Bradley A Warady, Division of Pediatric Nephrology, Children's Mercy Kansas City, Kansas City, Missouri, USA.
Email: bwarady@cmh.edu

What's New in the 2024 Update of the ISPD Pediatric Peritonitis Guidelines?

Introduction

Infection-related complications remain the most significant cause of morbidity and peritoneal dialysis (PD) discontinuation in infants, children and adolescents who receive maintenance peritoneal dialysis (PD). The clinical, emotional and economic impact associated with these infections prompted publication of the initial, largely opinion based recommendations pertaining to the prevention and treatment of catheter-related infections and peritonitis in pediatric patients receiving PD in 2000.[1] Subsequent to that work, the International Pediatric Peritonitis Registry (IPPR) was established to collect infection related data and to evaluate the influence of implementation of the guidelines on the pediatric PD population. The information made available from the IPPR served as the foundation for the second set of guidelines published in 2012.[2] Over the past decade, further data collection by the International Pediatric Peritoneal Dialysis Network (IPPN) and the Standardizing Care to Improve Outcomes in Pediatric End-stage Kidney Disease (SCOPE) quality improvement collaborative, complemented by a variety of publications, has created a new evidence base that allowed the creation of this update to the 2012 consensus guidelines.

Methods

As was the case with the two prior sets of guidelines, the workgroup consisted of an international team of experts comprised of pediatric nephrologists, pediatric infectious diseases specialists, a pediatric dialysis nurse, and methodology experts. Pediatric pharmacologists were added to the workgroup for this set of guidelines. Panel discussions took place face-to-face, during conference calls, and by email.

The current set of guidelines was developed using the Grading of Recommendations Assessment, Development and Evaluation (GRADE) approach for evidence assessment in collaboration with the Evidence Based Practice and Implementation Center (EPIC) at the University of Kansas Medical Center. The workgroup prioritized updating questions addressed in the 2012 guidelines and developed a list of additional questions for good practice and implementation using the PICO format (Population, Intervention, Comparison, Outcomes).[3] In addition to peritonitis rates, workgroup members also considered other outcomes such as PD catheter exit-site/tunnel infections, resolution of clinical symptoms, and transfer to hemodialysis in the process. Details around both sets of questions and corresponding outcomes can be found in Supplemental Tables S1 and S2.

Literature search and article selection

Ovid Medline, Embase, and Cochrane databases were searched for relevant articles published through November 2021. A combination of keywords and subject headings were used for a more comprehensive search. As an additional step, a reference list of existing peritonitis guidelines and resources suggested by workgroup members was reviewed.[2,4–6] Supplemental Table S3 provides the search strings we used across databases.

All titles and abstracts of the references identified by the search strategy were screened by two independent workgroup members using the online platform Rayyan.[7] Any article that was included by at least one reviewer was included for full-text screening. A similar process was carried out for the full-text screening of articles using the software Covidence.[8] Disagreements around inclusion or exclusion of articles at the full-text screening stage were resolved through workgroup meeting discussions.

Any studies that addressed at least one of the 54 prioritized PICO questions were included. This included randomized studies, non-randomized studies with a comparison (e.g., cohort, case-control, cross-sectional), and non-randomized studies without a comparison (i.e., case series).

We excluded non-English studies, studies describing only the adult population, and case reports. Supplemental Figure S1 provides detailed information about inclusion and exclusions, using the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) flow diagram.[9] Supplemental Table S4 provides information around the included studies.

Data collection and analysis

Two independent workgroup members extracted information in duplicate from the eligible studies using a standardized data extraction form. The two extractions were collated into one and any disagreements were resolved through discussions. For each study, general characteristics (e.g., publication year, country, study design), details about the population (age, gender, duration of PD treatment), details about the intervention (e.g., dose, route of administration), and details around outcomes (e.g., frequency of peritonitis episodes, change in dialysis modality) were extracted. When studies reported a mix of children and adults, only the results from children were included. When studies used more than one intervention and reported on the combined results of all interventions, the results of the intervention were summarized only if more than 80% of the study participants received that intervention. Since performing a quantitative synthesis of the results was not possible with the heterogeneity of the eligible studies, the study results were synthesized narratively.

Risk of bias and certainty of evidence

We used the Risk of Bias in Nonrandomized Studies of Interventions (ROBINS-I) tools[10] to appraise the risk of bias in prevalence studies and in case series.[11] Supplemental Tables S5 and S6 provide a summary of those judgments. The GRADE framework was used to assess the overall certainty of the evidence by evaluating the body of evidence for each outcome in the following domains: risk of bias, imprecision, inconsistency, indirectness, and publication bias.[12,13] The GRADE summary of findings tables were developed using the GRADEpro Guideline Development Tool.[14] Supplemental Tables S7–S47 provide details around those summaries and the certainty of evidence judgments.

Unpublished data

For questions that have no or sparse published data to inform them, the guideline workgroup communicated with the leadership of the IPPN registry and the SCOPE Collaborative requesting analyses be completed to answer these questions. When feasible, published or unpublished evidence from IPPN and SCOPE was utilized to inform questions.

Evidence to recommendations

The workgroup used the Evidence-to-Decision (EtD) framework for developing recommendations using GRADEpro software.[14] This included considering the certainty of evidence and the balance between desirable and undesirable effects, in addition to other domains (e.g., feasibility, resource use, acceptability) for developing recommendations. Supplemental Tables S48–S85 provide details around the considerations and judgments for each recommendation.

These recommendations are based on contemporary evidence when such evidence is available. As per GRADE methodology, within each recommendation, the strength of recommendation is indicated as Level 1 (We recommend), Level 2 (We suggest) or Not Graded, and the quality of the supporting evidence is shown as A (high quality), B (moderate quality), C (low quality) or D (very low quality). The recommendations are not meant to be implemented in every situation indiscriminately. Each PD unit should examine its own pattern of infection, causative organisms and antibiotic susceptibilities and adapt the protocols to local conditions as necessary. Supplemental Figure S2 provides the suggested interpretation of strong and weak recommendations for the population, health care workers, and policy makers.

Statements that are not supported by a systematic review of the pediatric literature (often times as a result of the absence of pediatric literature), there is no supporting pediatric registry data, they are opinion based or the recommendation might have been extrapolated from pediatric literature published subsequent to November, 2021, are based on the adult experience without a systematic review of the supporting evidence or are based on a non-systematic review of other pertinent literature, were Not Graded (We suggest).

Finally, when possible, the workgroup attempted to harmonize the recommendations for children with the recently published adult recommendations. However, where the adult and pediatric recommendations differed, the adult recommendation has been included in the rationale which supports the pediatric recommendation following the specific guideline statement. In addition, supporting information (e.g., reporting of peritonitis rates, definitions, stability of antimicrobials) included in recent publications pertaining to adult PD patients that is equally applicable to the pediatric PD population has been included in this publication.

Guideline 1 – Training

1.1 PD training should be performed using a formalized teaching program with clear content, objectives, and consideration of the previously published ISPD syllabus for

teaching peritoneal dialysis to patients and their caregivers (Not Graded).

1.2. We suggest that the training session length and total duration of training be tailored to the needs of the child on PD and their caregivers, with an emphasis on providing longer total training duration rather than shorter, whenever possible (2D).

1.3. We suggest that a formal assessment, including post-training written and demonstration competency testing, be performed as part of home PD training for children on PD and/or their caregivers (2D).

1.4. We suggest that a home visit be performed as part of the training process for children on PD (2D).

1.5. We suggest regular retraining/reassessment of all children on PD and/or their caregivers (2D).

Rationale

Guideline 1.1: Peritoneal dialysis (PD) performed in the home requires appropriate training of the patient and/or their caregiver(s) to minimize the risk of complications, including infection. As healthcare educators, we must consider the elements of adult learning principles when providing home PD training, as well as the patient and/or caregiver's readiness to learn.[15] It is necessary to identify barriers that prevent effective delivery of healthcare information including literacy, culture, language, and physiological barriers.[15]

When training patients and caregivers to perform home PD, current guidelines suggest the use of a formalized training program that has clear objectives and criteria, and

Table 1. Peritoneal dialysis training contents.

1. Design
    a. Training course should be based on Knowle's 6 principles for Adult Education[17,398]
    b. ISPD Training Course Syllabus should be used as a guide for planning training sessions.[17]
    c. Assess learning style using the VARK Questionnaire and modify the training content to meet the needs of the type of learner (Visual, Aural, Read-write, Kinesthetic).[17,399]
    d. Assess health literacy of the learner prior to beginning training[17]
    e. Assess and address any barriers to learning PD[17]
    f. Establish rapport and develop a relationship with the patient/caregiver prior to beginning training[17]
    g. Discuss course overview and describe the goals and plans for each training session.[17]
2. Theory
    a. Functions of the kidney
    b. Overview of PD (osmosis, diffusion, PD prescription)
    c. Fluid balance
    d. Prevention of infection
    e. Dietary Management
3. Practical
    a. Hand hygiene
    b. Aseptic technique
    c. Dialysis therapy: cycler and/or manual exchanges
    d. Troubleshooting alarms on the cycler
    e. Obtaining and documenting vital signs (blood pressure, HR, temperature)
    f. Obtaining, documenting and managing fluid weight
    g. Exit-site care
    h. Review use of any technology applications used for recording/communicating treatment data
4. Complications
    a. Emergency measures for contamination
    b. Signs, symptoms and treatment of peritonitis
    c. Signs, symptoms and treatment of exit-site and tunnel infections
    d. Drain problems (constipation, fibrin)
    e. Fluid balance (hypertension, hypotension)
    f. Other (leaks, pain)
5. Other
    a. Administration and storage of medications
    b. Ordering and managing supplies
    c. Managing life with PD (school, sports, activities, holidays, travel)
    d. How to contact the PD team
    e. Clinic visit expectations
    f. Home visit expectations
    g. Community resources
    h. Emergency/disaster preparedness
    i. Domestic pets and zoonotic infection (link)

incorporates adult learning principles (Table 1).[16,17] Health literacy assessments[18] and learning style assessments[19] are commonly used to tailor patient and/or caregiver education to the learning style, literacy and health literacy level of each learner. The ISPD published a syllabus for teaching PD to patients and caregivers in 2016, based on theories and principles of adult education, which is currently being updated. The current syllabus provides a 5-day training course of 3 hours each day. Each training day has an objective, a list of topics to be covered, and incorporates adult learning principles and teaching tips for the nurse about each topic (ISPD Syllabus). The syllabus also includes an assessment and checklist which documents who the learners are, who the trainers are, dates for training, total training hours per day, patient and/or caregiver's learning styles (based on VARK assessment) and patient and/or caregiver's barriers to learning (such as low literacy, low health literacy, depression, anxiety, language barrier). Duration of training and specific content of the syllabus used should be modified to accommodate the learner.

The ISPD training syllabus suggests that "after completion of the content contained in the PD training syllabus, the PD nurse will have provided education to a patient and/or caregiver such that the patient/caregiver has the required knowledge, skills and abilities to perform PD at home safely and effectively."[17] While this training syllabus was intended for the adult learner and the adult PD patient population, it can be modified to include pediatric specific content that the learner would need to know to be successful in providing PD care to children on PD.

The training should be performed by an experienced PD nurse, ideally with pediatric training, and should include content related to infection prevention such as hand hygiene, aseptic technique, exit-site care and appropriate treatment for contamination.[16,17]

Training can take place in the clinic, the patient's home, in the hospital or any location that can accommodate all of the components of PD training. There is no evidence to suggest that any location is superior to the others.[17]

Guideline 1.2: Overall, studies have shown inconsistent associations between peritonitis risk and training duration. An international survey from 2001 of centers which cared for children on PD showed that the greater the amount of training time spent on theory and practical/technical content, the lower the associated peritonitis rate.[20] In contrast, a survey from 2016 in one country failed to demonstrate a correlation between training time and peritonitis rate. The SCOPE Collaborative evaluated whether compliance with 4 key components of PD training as suggested by the ISPD guidelines, was associated with risk for infection at the patient level; limiting training sessions to under 3 hours was one component. The analysis found that there was no significant difference in median days to first peritonitis episode or first peritonitis episode within 3 months of training completion between the ISPD compliant ($\leq$3 hours per training session) and the ISPD non-compliant

groups. The median total training hours was 21.5 hours. There was no difference in peritonitis risk for patients with less than or greater than 20 hours total training time.[21] In contrast, a recent international survey from the IPPN did show that the overall peritonitis rate was significantly higher in centers performing training for less than a total of 20 hours.[22] This survey also showed a higher risk for gram-positive peritonitis in centers performing training for less than 20 hours. This same survey showed no associations between training practices and exit-site infection (ESI) rates.

Additional Considerations: Whereas a longer duration of training may be required in some instances, this may be limited by the number of trained staff available, and the labor costs associated with prolonging training, despite the clinical and economic benefits associated with preventing peritonitis.

Guideline 1.3: Subsequent to the completion of training, a formal training assessment is recommended. The type of assessment performed at the completion of home PD training to determine if the objectives of training have been met, should be determined by each dialysis training program (eg oral, written, demonstration).[17] The SCOPE Collaborative recommends concept and demonstration testing at completion of training and every 6 months thereafter.[23] In the SCOPE collaborative, 96% of trainings complied with the post training protocol, including a concept and demonstration test at the completion of training. Although compliance with the training bundle has not been associated with peritonitis rate, compliance with this bundle was quite high at 96%, which may have limited the ability to detect associations between compliance and peritonitis rate.[23,24]

Guideline 1.4: Although studies have not demonstrated that home visits impact peritonitis risk, an assessment of the home environment may provide valuable information that informs delivery of care.[25] Findings during the home visit may warrant recommendations from the dialysis staff about the home dialysis treatment room setup, storage of supplies and medications, and general cleanliness of the treatment space. Equipment should also be inspected during a home visit and may prompt necessary maintenance and/or replacement.[25] An assessment of the sinks used at home for hand hygiene and the showers/tubs used for bathing may yield findings that mandate continued education about the importance of routine cleaning of these areas to prevent bacteria growth.

In a retrospective pediatric study, patients on home automated PD (APD) had their initial home visit conducted by a trained dialysis nurse. The authors suggested that home visits be performed soon after initiation of home PD and that follow-up home visits should occur every 12 months, after episodes of peritonitis, or when other concerns arise.[25] The recommendation was made that the following should be recorded as part of the home visit assessment: type of surrounding community, type of dwelling, presence of a working dialysis machine, thermometer, smoke

detector, and fire extinguisher, assessment of the room where dialysis is performed each night, assessment of the space where handwashing occurs, assessment of where disposal of fluids occurs, location of storage of dialysis supplies, and a review of medications and their proper storage. A review of the findings at each home visit should then be discussed with the interdisciplinary team and recommendations made based on the findings.[25]

In terms of peritonitis risk, an international survey from 2001 showed no correlation between home visits and peritonitis rates, whereas a survey from 2016 in one country demonstrated a significant correlation between home visits and peritonitis rates.[26] A recent international survey from the IPPN registry showed that there was no significant difference in the rate of peritonitis between those pediatric patients who received a home visit and those who did not, after adjusting for country gross domestic product (GDP) and center size.[22] The SCOPE Collaborative also evaluated whether compliance with a home visit was associated with risk for infection at the patient level. This assessment revealed that there was no significant difference in median days to first peritonitis or first episode of peritonitis within 3 months of PD training completion between those patients who did and did not have a home visit.[21]

As part of training and home visits, an assessment should be performed regarding pets in the home. Education of children on PD and their caregivers should include risks of peritonitis when the child on PD and/or the PD equipment has direct contact with animals. The *ISPD peritonitis guideline recommendations: 2022 update on prevention and treatment* describes specific infectious complications and should be referred to during training, home visits and when a diagnosis of peritonitis with unusual organisms suspicious of zoonoses occurs.[27] These guidelines suggest that pets not be allowed in the room where PD exchanges takes place and where dialysis tubing, equipment and the machine are stored.[27]

Additional Considerations: In the IPPN survey, a significantly lower prevalence of home visits were noted in countries with a low GDP. A lack of resources, staffing, logistical and financial constraints along with distance between the hospital/PD center and the patient home are possible limitations to the capacity to perform home visits.

Guideline 1.5: Studies and registry data have shown inconsistent associations between peritonitis risk and the frequency of retraining. A study from 2021 revealed that the adjusted peritonitis rate decreased by 0.38 episodes per patient year from Phase 1 (no re-training) to Phase 2 (re-training).[28] The curriculum for this study included modules on exit-site care, hand hygiene, peritonitis, PD setup and trouble-shooting and home visit.

Data from the SCOPE Collaborative has demonstrated that provider compliance with the follow-up bundle and a regular (e.g., monthly during clinic visit) review of catheter care practice recommendations, as well as demonstration of competency with these procedures every 6 months, was associated with a significantly lower risk of peritonitis at the patient level.[24] Compliance with the individual elements of the follow-up bundle including review of hand washing, exit-site care and aseptic technique was significantly lower in those patients with peritonitis compared with the no peritonitis group.

In contrast, a recent international survey from the IPPN found no significant difference in peritonitis rates between those centers who conducted regular periodic training reassessments and those who provided a training reassessment post peritonitis only, after adjusting for GDP and center size. However, these results may be confounded by the small number of centers in the survey who regularly conducted retraining sessions.[22]

Additional Considerations: There is an assumed cost saving if peritonitis is prevented by retraining. However, a lack of resources, staffing, logistical and financial constraints are possible limitations for retraining.

Limitations: There is a very low quality of evidence regarding the relationship between the duration of training and peritonitis risk as the data and publications that exist are largely derived from surveys and expert opinion. Clarification is also needed regarding what "duration of PD training" means, as studies reference total training time as well as training time per session. Since formal post-training assessment is almost universally included as standard practice among pediatric dialysis programs world-wide and home visits are commonly practiced, the capacity of clinical practice surveys to determine the impact of these interventions on peritonitis rate is limited.

Research Recommendations

● Future studies should clearly define duration of PD training and evaluate the relationship between training duration and cost, patient and caregiver satisfaction, and peritonitis rate.
● Future studies should attempt to determine the form of post-training assessment which is most informative regarding future performance of PD and the risk of peritonitis.
● Future research should be conducted to address the impact of the timing and content of retraining on peritonitis rate. Studies looking at the cost and potential cost savings associated with retraining are also needed.

Guideline 2 – Catheter Type and Placement

2.1 We suggest the use of a double-cuff PD catheter with a downward or lateral exit-site orientation (2D).

2.2 We suggest that the technique used for PD catheter placement be based on patient suitability and expertise of the operator (2D).

2.3 We suggest that perioperative intravenous antibiotics be provided prior to insertion of a PD catheter (2C).

Rationale

Guideline 2.1: Efforts to minimize the risk for peritonitis and exit-site infection begin with placement of the PD catheter. The Tenckhoff catheter remains the most commonly used catheter for children on PD, but various catheter characteristics, including the number of dacron cuffs in the subcutaneous tunnel and the orientation of the catheter as it exits the skin, may influence the risk for infection.[29–31]

The theoretical benefit of a PD catheter with two cuffs in the subcutaneous tunnel, rather than one, is the additive barrier against migration of organisms from the skin to the peritoneal cavity. In fact, early data from the North American Pediatric Renal Trials and Collaborative Studies (NAPRTCS) revealed a higher risk for peritonitis in children with a PD catheter with a single cuff rather than 2.[32] Those early data influenced clinical practices, and data from the SCOPE Collaborative and the IPPN reveal that two-cuffed catheters are now placed in the majority of children on maintenance PD.[30,31] However, observational studies in children on PD have failed to show a consistent benefit of a second cuff in terms of infection prevention. Data from a single center retrospective review and several analyses of SCOPE data have shown no difference in peritonitis rates and/or rate of exit-site infection between catheters with one or two cuffs.[24,30,33–35] A single center study of children on PD published by Macchini et al. noted higher exit-site infection rates associated with catheters with two cuffs, while data from the IPPR Registry demonstrated that the presence of a single cuff catheter was associated with a higher rate of relapsing peritonitis and gram negative peritonitis.[36–38] Data from the IPPN shows no difference in the rates of catheter revision or obstruction between single and double cuffed catheters.[31] One potential complication of a double cuff catheter is the risk of cuff extrusion, with extrusion rates between 2 and 10% reported in studies of children on PD, and 0–13% in studies of adults on PD.[39,40] Placement of the outer cuff at least 2 cm from the exit site may reduce the risk for extrusion.[41,42]

In adults on PD, a small, potentially underpowered randomized controlled trial showed no difference in peritonitis rates with one versus two cuffed catheters, while a large retrospective study did reveal a lower peritonitis rate associated with two cuffs.[43,44] However, the impact seen in the latter study may have been era related, with no difference in peritonitis rates noted in the era after the use of prophylactic exit-site and/or intranasal antibiotics had been widely adopted.[44] In fact, previous guidelines for adults on PD emphasized that placement of a catheter with two cuffs may be particularly beneficial when prophylactic antibiotics are not used.[41] However guidelines published in 2023 suggest that no catheter design, including the number of cuffs, has been shown to be superior to another in terms of reducing the risk for catheter-related infections.[45]

Early data from the NAPRTCS registry demonstrated a higher risk for exit-site infection and/or peritonitis with an upward, rather than a lateral or downward orientation of the catheter exit site.[32] Subsequently, data from the IPPN and SCOPE revealed that the majority of catheters placed in children have a downward or lateral orientation of the exit site.[30,31] Data from the SCOPE collaborative support the earlier findings from NAPRTCS, with multivariable analyses revealing a higher risk for peritonitis with an upward orientation of the exit site (rate ratio, 4.2; 95% confidence interval, 1.49 to 11.89).[37] A separate analysis of SCOPE data did not, however, find an association between exit-site orientation and rate of exit-site/tunnel infection.[35] These findings support the notion that unrecognized factors, including patient factors or center preference, also likely influence catheter choice.[30,31]

Additional Considerations: Other catheter characteristics to consider include the shape of the subcutaneous tunnel, which may be straight or have a preformed arc or swan-neck configuration, and the intraperitoneal catheter segment, which may be straight or coiled. The potential benefit of a swan-neck tunnel configuration is that the arc facilitates a downward orientation of the exit site and allows the distal end of the catheter to be positioned in the pelvis in an "unstressed condition", reducing the risk for catheter migration out of the pelvis.[46,47] Observational studies in children on PD have not demonstrated significant associations between infection, including peritonitis and/or exit-site infection, and the shape of the subcutaneous tunnel or the intraperitoneal segment.[24,32,34,35] Of note, data from the IPPR did show an increased rate of post-peritonitis PD discontinuation with the use of a straight intraperitoneal catheter segment and an analysis of data from the IPPN demonstrated a higher risk for catheter revision with a swan neck tunnel and a curled intraperitoneal segment.[31,48]

A final consideration is the adapter that connects the catheter to the transfer set. Most PD catheters are supplied by the manufacturer with a plastic adapter, but this may be exchanged for a titanium adapter. Studies from the SCOPE collaborative have demonstrated a higher risk of peritonitis with the use of a plastic, rather than a titanium adapter.[24,30]

Guideline 2.2: Optimal placement of a PD catheter is vital to ensure a well-functioning access and to minimize the risk for infection. Historically, PD catheters were placed using an open technique, but increasingly a laparoscopic approach has been used for PD catheter insertion in children.[30,49] The potential benefits of the laparoscopic approach include that it is less invasive, with a smaller-diameter perforation which may aid healing and reduce the risk for leakage of dialysate. It also allows complete visualization of the peritoneal cavity, which may facilitate lysis of adhesions and identification and repair of internal hernias.[50]

Unfortunately, there have not been any prospective trials comparing outcomes in children with PD catheters based on insertion technique. Data from observational studies include an analysis of 1106 PD catheter insertions among children enrolled in the SCOPE Collaborative which investigated risk factors for early peritonitis, defined as peritonitis in the first 90 days after catheter placement.[30] In univariate analysis, catheter placement technique was not associated with the risk for early peritonitis (p = 0.440).[30]

A more recent analysis of SCOPE data included 1826 PD catheters of which 1416 were inserted using the laparoscopic technique, and 410 inserted using an open technique. In multivariable analyses, there was also no significant association between laparoscopic PD catheter placement and the occurrence of peritonitis within 7 days (aOR = 2.50, 95% CI 0.64–9.80, p = 0.19) and 30 days of PD catheter insertion (aOR = 1.20, 95% CI 0.67–2.18, p = 0.54).[51]

A retrospective study by Lindley et al. compared the peritonitis rate among 10 patients who received simultaneous laparoscopic-assisted placement of a percutaneous endoscopic gastrostomy (PEG) and PD catheter placement with the rate among 23 children who received simultaneous PD catheter and gastrostomy creation using an open technique.[52] There was no significant difference in peritonitis rates per catheter year between the two groups (0.89 versus 0.59, p = 0.12).[52] This study also evaluated exit-site infection rates and catheter survival and found no difference in these outcomes based on insertion technique.[52] Whereas a higher percentage of peritonitis episodes due to *Candida species* was observed in the laparoscopic group, the difference was not statistically significant (27% versus 14%, p = 0.42).[52] It should be noted that this study included infection events well beyond the early post-operative period when the impact of implantation technique on the risk of infections is less obvious.[52]

As stated above, there may be additional benefits of laparoscopic PD catheter insertion including improved healing, but these outcomes are not routinely captured in large national or international registries. A single center, retrospective study found no difference in catheter rates of leakage or obstruction after 25 laparoscopic and 23 open PD catheter placements in children.[50]

Studies in adults with side-by-side comparisons of various PD catheter insertion techniques including percutaneous needle-guidewire with or without image guidance, peritoneoscopy, laparoscopy, and open dissection, as well as systematic reviews and meta-analyses comparing laparoscopic and open placement have not demonstrated consistent superiority of one technique with regard to infection prevention.[41,45,53–63] However, a meta-analysis published in 2018 differentiated between basic and advanced laparoscopic catheter placement, with basic laparoscopic technique defined as using laparoscopy only to monitor the position of the catheter tip in the peritoneal cavity, while advanced laparoscopic placement includes various preemptive procedures to optimize catheter function such as rectus sheath tunneling,

omentopexy, and lysis of adhesions.[41,64,65] This meta-analysis found that advanced laparoscopic placement provided better outcomes than open dissection or basic laparoscopy, with outcome metrics including catheter tip migration, obstruction and catheter survival.[64]

Additional Considerations: Although this recommendation focuses on the technique used for catheter placement, good clinical practice includes other practices to minimize the risk of infection. This includes determination of the location of the exit site, with placement away from the beltline in older children and the diaper area in infants.[2] The presence of stomas (e.g., vesicostomy, ureterostomy, colostomy, gastrostomy) will also influence the preferred exit-site location. To optimize function of the PD catheter, pre-placement care should include screening for and treatment of constipation.[66]

The PD catheter may be inserted through either a lateral or midline incision. In infants and children, a paramedian insertion is typically recommended to minimize the risk for herniation or dialysate leakage.[2,61,62,67,68] An omentectomy is routinely performed at the time of PD catheter placement, to minimize the risk for PD catheter obstruction.[66,68]

Once inserted, the catheter should be securely anchored to optimize healing and minimize the risk for traction injury-related exit-site infection. A suture should not be placed at the exit site, as the presence of sutures increases the risk for bacterial colonization and subsequent infection.[2] The application of fibrin glue to the peritoneal cuff during implantation may be used, and was shown to reduce the risk for dialysate leakage in an open-label randomized study in a single pediatric center, but that study did not find an association between application of fibrin glue and the development of either exit-site infections or peritonitis.[69]

Previous guidelines for children on PD recommended delaying catheter use for 10–15 days following catheter insertion.[2] In fact, data from the SCOPE collaborative identified use of the PD catheter for dialysis within 14 days of catheter insertion as an independent risk factor for peritonitis in the first 60 days after catheter insertion.[30] Data in adults on PD has shown an association between early use of the PD catheter and risk of dialysate leak, but uncertain effect on the risk for exit-site infection.[45,70]

Guideline 2.3: Administration of perioperative antibiotics is widely employed to reduce the risk for surgical site infection, and previously published guidelines for the prevention of peritonitis have advocated for this approach to minimize the risk of peritonitis following insertion of a PD catheter.[2,27] Data on the effectiveness of this strategy in children are limited. Sardegna et al. conducted a retrospective study of 73 children who received 89 PD catheters and demonstrated that peritonitis in the first 14 days after PD catheter insertion was less common in children receiving prophylaxis with a cephalosporin (cefazolin, cefuroxime, ceftriaxone), vancomycin, ampicillin, or nafcillin–gentamicin, than in patients who did not receive prophylaxis. A step-wise logistic regression analysis demonstrated that the

only independent variable which correlated with a reduction in the frequency of peritonitis episodes was antibiotic administration in the perioperative period.[71] The reduction in peritonitis was not specific to any antibiotic class.[71] An analysis of more than 1000 PD catheters inserted in children as part of the SCOPE collaborative sought to identify risk factors for early onset peritonitis, defined as peritonitis in the first 60 days after catheter insertion.[30] In the analysis, intravenous antibiotics were given within 60 minutes of PD catheter insertion in 98.8% of procedures as recommended in the 2012 ISPD guidelines, precluding assessment of an association between this practice and the risk for infection.[30]

Data in adults on PD include four randomized controlled studies that compared the use of perioperative intravenous antibiotic prophylaxis (cefuroxime, gentamicin, cefazolin, and vancomycin) versus no antibiotic treatment.[72–75] Follow-up periods ranged from 10 to 28 days. The most compelling data comes from a 3 arm study published by Gadallah et al., which included 221 adults randomly assigned to receive intravenous vancomycin (1 g 12 h before the procedure, n = 86), intravenous cefazolin (1 g given 3 h before placement n = 85) or no antibiotic (n = 83). The incidence of peritonitis within 2 weeks of catheter placement was significantly lower for both vancomycin (1%) and cefazolin (7%) treated patients compared to controls (12%) (p = 0.02), and vancomycin was superior to cefazolin.[75]

A subsequent systematic review published in 2017 concluded that pre- or peri- operative intravenous antibiotic prophylaxis compared to no treatment *may* reduce the risk of early peritonitis based primarily on the results of the study published by Gadallah et al., but found that there was no difference demonstrated in the three other studies using different antibiotics.[72–76] In fact, an update to the ISPD-catheter related infection recommendations published in 2023 qualifies the 1A recommendation by stating that the effects of antibiotics administered immediately before catheter insertion on catheter-related infections are uncertain.[45]

Although the studies in adults on PD suggest that cefazolin may not be as effective as vancomycin for prevention of peritonitis following PD catheter placement, given the risk for development of vancomycin resistant organisms, cefazolin is the preferred agent for perioperative prophylaxis. A single dose of cefazolin (25 mg/kg, maximum 2 g) is given within 60 min prior to the surgical incision (Table 2). It has been suggested that the efficacy of vancomycin, especially when compared to cefazolin, may be related to its relatively long half-life in the setting of end-stage kidney disease.[76] Local antibiograms should help guide antibiotic choice at the unit level, and infection history, including infection with and/or carriage of methicillin-resistant *S. aureus,* should guide antibiotic choice at the patient level.

Additional Considerations: The ability to provide appropriate perioperative antibiotics may vary by region and may be impacted by the cost of intravenous antibiotics. Provision of prophylactic antibiotics should, however, be cost effective as the treatment for peritonitis would likely exceed the cost of a single dose of antibiotics at the time of catheter insertion.

Recently published guidelines for adults on PD suggest provision of nasal antibiotic prophylaxis when pre-PD catheter placement screening identifies nasal carriage of *S. aureus* (1C recommendation).[45] This suggestion is supported by data from a systematic review and meta-analysis which showed that while use of nasal antibiotic prophylaxis had uncertain effects on the risk of exit-site and tunnel infections in general, there was evidence of a significant reduction in catheter-related infections with use of intranasal mupirocin among patients who were *S. aureus* nasal carriers.[76] Data from SCOPE suggests that the practice of pre-PD catheter placement screening for *S. aureus* currently occurs in a minority of children enrolled in that collaborative, with only 529 screenings reported prior to 1998 PD catheter placements (26.5%) (B. Warady - personal communication).

Limitations: As noted above, several randomized controlled trials in adults, but not children, on PD informed the guideline regarding provision of antibiotics prior to PD catheter placement.[72–76] Multiple factors including the presence of co-morbidities, previous intra-abdominal events, previous procedures including PD catheter placement, and requirement for other abdominal procedures (e.g., ostomy creation or revision) may influence both the implantation technique and outcomes, but are not regularly captured in registry data.[64] Finally, it is intuitive that the experience of the implanting surgeon or interventional nephrologist will impact outcomes, but experience and expertise is difficult to quantify, and therefore this variable is not routinely included in studies/registry data.

Research Recommendations

● Future observational studies should seek to quantify surgical experience and explore associations between experience and PD catheter insertion outcomes.
● Studies evaluating the impact of insertion technique on risk for infection should uniformly focus on peritonitis and exit-site infections in the early post-implantation period (e.g., initial 30 days).
● Research should address the impact of pre-PD catheter placement screening for *S. aureus* and decolonization on the risk for PD catheter related infection in children, particularly in the early post-operative period.

Guideline 3 – Early Exit Site Care

3.1 We suggest delaying the first PD catheter dressing change for at least seven days post-PD catheter insertion unless the dressing is soiled, loose, or damp (2C).

Rationale

Guideline 3.1: Early exit-site care is crucial to optimize healing and minimize the risk for infection. Compared to late onset peritonitis, early onset peritonitis in children on PD, defined by the SCOPE collaborative as peritonitis occurring within 60 days of catheter insertion, is associated with higher rates of subsequent peritonitis episodes and PD discontinuation.[30,77,78] Unfortunately, very few studies have addressed PD catheter exit-site care in the early post-operative period and most guidelines rely on work done by Twardowski and Prowant.[79] In order to allow wound healing by primary intention and epithelialization, good surgical practice recommendations have suggested that all incisions be covered and dressings left undisturbed for three to five days. It follows that immobilization of the PD catheter after insertion and delayed initiation of dressing changes is also required to allow optimal healing of the PD catheter exit site, and to reduce the risk for bacterial colonization, which is a significant risk factor for infection.[80] In all cases, the dressing used should be clean, dry and non-occlusive. Data from the SCOPE collaborative showed that among newly placed catheters, peritonitis occurred in 40/625 (6.4%) that had no dressing change before 7 days and in 44/404 (10.9%) of those that had a dressing change before 7 days (p < 0.001).[30]

The suggestion has also been made that subsequent PD catheter exit-site dressings should ideally be changed only weekly until the exit site is healed as long as the dressing remains dry and intact.[80] Typically, the exit site may not be completely healed for 4–6 weeks post insertion.[79]

Additional Considerations: ISPD guidelines for adults on PD recommend that immobilization of the catheter post-insertion using properly applied surgical dressings is important to prevent traction injury and exit-site contamination.[41,45] Nonocclusive gauze dressings are preferred over transparent occlusive dressings as the former allow for drainage away from the exit site and the surgical incision.[81,82] The transfer set should be taped away from the dressing to allow for access to the catheter for flushing by the trained PD nurse without disturbing the exit-site dressing.[41]

It is generally accepted that dressing changes be performed using sterile technique by trained staff until the exit site is healed.[2,81] Previously published ISPD guidelines for children on PD also recommended that the exit site be cleansed with a non irritating, nontoxic agent followed by application of a topical antibiotic cream or ointment.[2] In particular, cytotoxic agents such as povidone-iodine or hydrogen peroxide should be avoided during the healing phase.[45,80] Unfortunately, there are no studies evaluating the use of specific cleansing agents or placement of any antimicrobial agent at the exit site in newly placed PD catheters in children.

Limitations: There is a low certainty of evidence for this recommendation as supporting data are primarily derived from observational studies in multicenter cohorts and international registries. It is possible that factors such as early dialysate leakage may have influenced both the frequency of dressing changes and the risk for peritonitis.

Research Recommendations

● Studies evaluating the use of antimicrobial agents at the exit-site in the post-implantation period should include the use of antimicrobial impregnated dressings.

Guideline 4 – Chronic Exit Site Care

4.1 We suggest that routine PD catheter exit-site care with a sterile cleansing solution be conducted 2–3 times per week and after water exposure, vigorous exercise or soiling of the dressing (2D).

4.2 We suggest that a topical antibiotic be applied to the PD catheter exit site whenever exit-site care is performed (2D).

Rationale

Guideline 4.1: Data supporting optimal exit site care practices in children in PD are scarce. The IPPR has provided pediatric-specific data on the topic of chronic exit-site care, with clear differences in practice patterns observed around the globe.[48] With regard to the frequency of exit-site care, data from the IPPR revealed that chronic exit-site care is conducted daily in 93% of centers in America and Asia, in 64% of centers in eastern Europe and Turkey, but in only 8% of western European centers.[48] This observational study found that peritonitis caused by *Pseudomonas* spp. (total of 28 cases) was significantly more common in patients from centers where exit-site care was performed more than twice per week (P < 0.005).[48,83] *The ISPD Catheter-related Infection Recommendations: 2023 Update for* adult patients recommend exit-site care at least twice a week, and whenever there is water contamination of the exitsite.[45] We agree that water exposure, vigorous exercise or soiling of the dressing are additional indications for exit-site care.

Numerous exit-site cleansing agents are available including povidone-iodine, chlorhexidine solution, hydrogen peroxide and electrolyte chloroxidizing solutions. An observational study in children on PD revealed a reduction in exit-site infections, peritonitis and infection-related catheter removal when exit-site cleansing with sodium hypochlorite and application of mupirocin were routinely used, compared to application of mupirocin alone.[84]

Studies in adults on PD have not consistently demonstrated superiority of one solution for prevention of exit-site infection or peritonitis. In fact, a systematic review

concluded that the use of any topical disinfectant had an uncertain effect on the risk for these infections.[45,76,85–93]

Additional Considerations: There is a labor and equipment cost associated with more frequent exit-site care and the use of sterilizing agents, but there is no published evidence on the resources required and cost effectiveness of the procedure.

Guideline 4.2: Nasal carriage and exit-site colonization with *S. aureus* is associated with a higher risk for exit-site infection and peritonitis in people on PD, including children.[2,94–98] It follows that antimicrobial prophylaxis may reduce the development of these infections. While oral rifampin and intranasal mupirocin have been employed for prophylaxis against PD catheter related infections in the past, current guidelines for adults on PD and the previously published guidelines for children on PD encourage the routine application of a topical antibiotic to the PD catheter exit site as prophylactic therapy.[2,27,45,85] There are no studies comparing infection rates with application of an antimicrobial agent to the PD catheter exit site versus no antimicrobial agent in children on PD, but an observational study suggested that exit-site infections, peritonitis and infection-related catheter removal were reduced when exit-site cleansing with sodium hypochlorite and application of mupirocin were used in combination, compared to exit-site application of mupirocin alone.[84] However, an analysis of data in the IPPR registry, which included 28 episodes of Pseudomonas peritonitis, revealed that Pseudomonas peritonitis was more common at centers where mupirocin was applied to the PD catheter exit site.[48] This study also demonstrated that implementation of this practice in children on PD varies considerably by region.[48]

As stated above, guidelines for adults on PD recommend daily topical application of an antibiotic cream or ointment at the catheter site.[85] This was included as a 1A recommendation in the ISPD guidelines published in 2017, although an update to these guidelines published in 2022 acknowledges that this practice varies among centers around the world.[27,85] The recommendation was based on studies in adults on PD demonstrating daily application of mupirocin to the exit site as an effective strategy to reduce PD catheter-related infections.[85,99–104] A meta-analysis published in 2004 found that topical administration of mupirocin to the nares of people on PD who were colonized with *S. aureus* significantly reduced the overall rates of exit-site and tunnel infections, but it did not reduce the rate of peritonitis.[61] Topical nasal application of mupirocin was subsequently found to have an uncertain effect on exit-site infections in a systematic review and meta-analysis published in 2017, but application of mupirocin to the exit site was grouped with oral antibiotic prophylaxis in this review.[76] More recently, a meta-analysis of six randomized controlled trials in adults on PD concluded that it was uncertain whether application of mupirocin to the exit site prevents exit-site infections, peritonitis or technical failure.[105] In light of these findings, the 2023 update to the ISPD catheter-related infection recommendations downgraded the recommendation for topical application of antibiotic cream or ointment to the catheter exit site from 1A to 1C.[45] The guideline workgroup commented that the certainty of evidence was reduced by highly variable approaches to the administration of mupirocin (intranasal versus exit site).[105]

With the broad adoption of mupirocin as a topical prophylactic agent, early reports of mupirocin resistance and an increase in infections due to *Pseudomonas* spp. led to a search for alternative agents.[106] Studies in adults on PD revealed that gentamicin cream was at least as effective as mupirocin in reducing exit-site infections caused by both *Pseudomonas* spp. and *S. aureus*.[101,107] However, subsequent observational studies suggested conversion from mupirocin to gentamicin was associated with an increase in *Enterobacteriaceae* and *Pseudomonas spp.* exit-site infections and that alternating between mupirocin and gentamicin may increase the risk of fungal peritonitis.[108,109] A recent meta-analysis included 2 randomized controlled trials in adults on PD comparing exit-site application of gentamicin and mupirocin and found no difference in the rate of exit-site infections.[105] Guidelines published by ISPD in 2017 and 2023 suggest that topical gentamicin may be considered as an alternative to mupirocin.[45,85]

The HONEYPOT Study was an open-label trial in 26 centers in Australia and New Zealand in which 371 adults on PD were randomly assigned to daily topical exit-site application of antibacterial honey plus standard exit-site care versus standard exit-site care plus intranasal mupirocin in nasal carriers of *S. aureus*.[110] The median PD-related infection-free survival times were not significantly different in the antibacterial honey and control groups (unadjusted hazard ratio 1.12, 95% CI 0.83–1.51; p = 0.47).[110] In contrast, in a single-center case series of children on PD, the incorporation of antibacterial honey to the exit site as part of routine care was associated with a significant decrease in peritonitis rates.[76]

Additional Considerations: When implemented, the optimal frequency of topical antibiotic application for prophylaxis has not been determined. Case reports suggest that mupirocin may damage PD catheters made from polyurethane, while gentamicin cream may damage catheters made from silicone.[111–113] Contact between these creams/ointments and the PD catheter should therefore be minimized.[45]

Chronic exit-site care should also include efforts to minimize stress or tension on the exit site, including catheter immobilization. While use of a dressing is important to protect the healing exit-site, the benefit of a dressing once the exit site is healed for infection prevention has not been studied in children. Whereas current guidelines for adults on PD suggest that a dressing to cover the exit site is not mandatory, the use of a dressing in children with incontinence, including infants and toddlers, is crucial to minimize exposure of the exit site to stool and urine.[45]

There is a cost associated with the use of antimicrobial prophylaxis, which varies significantly by region and the antimicrobial agent used. There are no cost-effectiveness studies in children, but a study in adults on PD demonstrated that daily application of mupirocin to the PD catheter exit site was a cost-effective preventive measure for gram-positive peritonitis.[114]

Limitations: The level of certainty pertaining to the frequency of exit-site care is very low as the only study in children was observational and there was a very low number of peritonitis events, which may have limited the ability to detect difference in peritonitis rates between the various treatment strategies. The level of certainty regarding topical antibiotic usage is also very low as the studies in children were observational, there were very low numbers of infectious events which may have limited the ability to detect differences in outcomes among the different treatment strategies, and there were other aspects of exit-site care that may have impacted development of PD catheter-associated infection.[48,84,115]

Research Recommendations

● Future studies are required to clarify the relationship between infection rate (overall peritonitis rate, *Pseudomonas spp.* and *S. aureus* peritonitis rate, ESI rate) and the frequency of exit-site care.
● Ongoing studies should seek to clarify the risk and benefit of various antimicrobial agents, in terms of the efficacy of infection prevention and the development of antibiotic-resistant organisms.

Guideline 5 – Connectology

5.1 We recommend the use of flush before fill of the tubing system as part of an infection prevention strategy for children on PD (1A).

Rationale

Guideline 5.1: Touch contamination when establishing connections between the dialysate bag tubing and the transfer set on the PD catheter is a well-recognized cause of peritonitis. One of the most impactful modifications of the dialysis procedure to minimize the risk for infection is the "flush before fill" procedure, i.e., flushing the dialysate tubing with sterile dialysate before instilling dialysis solution into the abdomen. Early observations in people on continuous ambulatory peritoneal dialysis (CAPD) demonstrated that flushing the dialysate tubing with 100 mL of fresh dialysis fluid was able to remove 1000 colony-forming units of *Staphylococcus epidermidis* if there was no prior incubation.[116] This was dependent on the inoculum size, the contact time between bacteria and tubing, bacterial adherent

properties and the flush volume. The development of a two-bag system for CAPD, with either an O- or Y-set, not only made flush before fill inherent, but reduced the need to connect the dialysis tubing to the dialysate bag. In automated PD (APD), the cycler flushes the dialysate tubing with sterile dialysate prior to instilling fluid into the peritoneal cavity. Thus, the flush before fill maneuver is available for both CAPD and APD.

Studies evaluating the impact of flush before fill in children have included a randomized, prospective study published by Warady et al. in which children on APD using flush before fill had a peritonitis rate of 1 infection per 16.8 patient months, whereas patients in the no flush group had a peritonitis rate of 1 infection every 12.6 patient months (p = 0.193).[117] The 1-year estimated infection-free survival was 59.7% in the flush group and 47.5% in the no flush group (p = 0.196).[117] In a retrospective observational study in children on CAPD, the traditional spike system (37 patients) and disconnect systems (16 patients) that comprised the O-set system (10 patients) and the basic Y-set system (6 patients) were compared.[118] Peritonitis rates were 1 episode every 10 months for the conventional spike system, versus 1 episode every 58 months for disconnect systems with flush before fill (p < 0.05).

The majority of the high-level evidence comes from studies in adults on CAPD, where a systematic review showed that twin-bag systems were superior to conventional single bag systems (7 trials, 485 patients, RR 0.64, 95% CI 0.53 to 0.77) in preventing peritonitis.[119] On the other hand, there was no difference in the number of patients with exit-site or tunnel infections (3 trials, 226 patients; RR, 1.00; 95% CI, 0.70 to 1.43) or in the exit-site and tunnel infection rates (2 trials, 2841 patient-months; RR 1.24; 95% CI, 0.91 to 1.69).[119] When comparing the two different systems of flush before fill, there was no significant difference between double-bag systems compared with the Y-set in terms of the number of patients with peritonitis (3 trials, 292 patients; RR 0.59; 95% CI, 0.35 to 1.01) and peritonitis rates (4 trials, 4319 patients-months; RR 0.90; 95% CI, 0.49).[119–135]

Additional Considerations: The resources required for the intervention in CAPD includes the cost of the twin-bag system, which may limit implementation in low resource areas where the conventional system continues to be widely used.

Limitations: The strength of the data in adults on PD supports this as a strong recommendation. Whereas there is only one investigation in children on APD, it was a randomized, controlled study. Studies in children on CAPD are observational.

Research Recommendation

● Randomized controlled trials should be conducted to determine whether the reduction in peritonitis rates due to

the use of the twin-bag systems is also observed in children on CAPD in low resource settings.

Guideline 6 – Ostomy Patients

6.1 We suggest placing a gastrostomy tube (GT) either prior to or concurrently with PD catheter insertion (2D).

6.2 We suggest that a gastrostomy tube can be placed using an open surgical procedure or laparoscopically for children receiving PD. In children not yet receiving PD, gastrostomy placement can be performed using either an open or laparoscopic surgical technique or by percutaneous endoscopic technique (PEG) (2D).

6.3 We suggest providing prophylactic antibiotic and antifungal therapy to children on PD in association with gastrostomy placement (2D).

Rationale

Guideline 6.1: Enteral tube feeding has become standard of care in children with chronic kidney disease and on PD who are unable to meet nutritional requirements by oral feeds alone. In many centers, a gastrostomy is placed when long-term enteral support is anticipated.[31,136] The literature is divided as to whether the presence of an established gastrostomy incurs a higher risk for infection or compromised PD catheter survival.[137–141] Recent evidence from the IPPN database suggests a higher risk of PD catheter loss from infection when patients on PD have a gastrostomy, whereas there was not a higher risk of peritonitis as per the SCOPE database.[24,142] The timing and technique of placement may be important factors in determining the risk of peritonitis.

A report by Ledermann et al., showed a lower annual peritonitis rate in 15 pediatric patients undergoing PEG or Nissen fundoplication and gastrostomy (NG) or open gastrostomy (OG) prior to initiation of PD (annualized peritonitis rate: 0.6) compared with 9 pediatric patients undergoing NG or OG (annualized peritonitis rate: 1.4) and 5 pediatric patients undergoing PEG (annualized peritonitis rate: 1.0) while receiving PD. In the group of patients receiving a PEG after initiation of PD, the majority of infections occurred in the immediate postoperative period suggesting that it may not have been the timing, but the placement technique that was more important.[143] In a study by Ramage et al., no significant difference was found between nine patients who had a gastrostomy tube placed prior to commencement of PD (one episode every 7.5 patient-months) compared to 14 patients who had insertion of the gastrostomy while receiving PD.[140] There was also no statistical difference in the ESI rate of those undergoing gastrostomy tube placement prior to initiation of PD (one episode every 17.5 patient-months) and those undergoing placement while receiving PD.[140]

The SCOPE collaborative investigators analyzed peritonitis rates in 204 patients who underwent gastrostomy placement before or at the same time as PD catheter insertion and compared this to the experience of 406 patients with gastrostomy placement after the initiation of PD.[51] Per multivariable analysis, timing of gastrostomy placement in relation to PD catheter insertion was not associated with risk of peritonitis within 30 days of gastrostomy placement (aOR = 1.72, 95% CI 0.87–3.38, p = 0.12). The association between gastrostomy placement after PD catheter insertion and the development of peritonitis within 7 days of gastrostomy placement did, however, reach borderline statistical significance (aOR = 3.19, 95% CI 0.90–11.28), p = 0.07), suggesting a potentially higher risk of peritonitis when a gastrostomy is placed after the PD catheter procedure. Further evidence supporting this comes from previous SCOPE data focusing on infants.[34] In this study, gastrostomy tube placement after PD catheter insertion was associated with a nearly threefold higher risk of peritonitis (OR 2.81, 95% CI 1.31, 6.01; p < 0.01). There is a further concern regarding a possible increased rate of fungal peritonitis when a gastrostomy tube, particularly a PEG, is placed after the initiation of PD. A report by von Schnakenburg, et al., showed that fungal episodes accounted for around 20% of all peritonitis episodes in those patients who had a PEG placed while receiving PD.[144] In the report by Lederman, et al., there was also a higher fungal peritonitis rate in those patients for whom gastrostomy tube placement (largely in those receiving a PEG) took place after PD had been established compared to the rate when gastrostomy placement occurred prior to PD establishment (0.36/pt-year vs. 0.093/pt-year).[143]

Additional Considerations: The resources required for the placement of a gastrostomy is the same whether it is placed before or after the initiation of PD. In turn, timing of gastrostomy placement that is associated with a higher risk of peritonitis should be discouraged because of the patient morbidity and cost that results from the infection.

Guideline 6.2: Because of the concern regarding a higher risk of peritonitis in patients having a gastrostomy placed while already receiving PD, the recommendation is that an open surgical or laparoscopically placed gastrostomy be placed rather than a percutaneous endoscopic gastrostomy (PEG) in children receiving PD because of a higher risk of infection and complications with the latter procedure. A report by Ledermann et al., showed that 4 out of 5 children given a PEG while on PD developed peritonitis in the immediate post-operative period, whereas only one of the nine children who underwent an open procedure developed peritonitis in the immediate post-operative period.[143] In this study, there was also an increased rate of fungal peritonitis in the patients already established on PD who received a PEG compared to open gastrostomy (0.97 episodes/year vs 0.18 episodes/year). In a retrospective, multicenter survey carried out in Germany that included 27 pediatric patients who had a gastrostomy placed (25 by PEG) while already receiving PD, peritonitis occurred in 10 of the 27 (37%) within 7 days of PEG

insertion, and fungal peritonitis occurred in 7 of the 27 (26%).[144] Furthermore, 8 of the 27 required replacement of their PD catheter, 4 were transferred to HD, and another 2 experienced late deaths because of the associated complications. In contrast, in a recent retrospective single center review of 8 children which reported outcomes within 28 days of PEG placement after PD initiation, only one patient developed bacterial peritonitis. There were, however, no comparisons made to patients not undergoing PEG placement in this study.[145] In patients who are receiving simultaneous gastrostomy and PD catheter insertion, placement of a PEG may be acceptable. In a retrospective review, Lindley et al., compared ten patients with simultaneous laparoscopic PD catheter insertion and PEG placement to 23 patients who had open gastrostomy and PD catheter insertion.[52] In this study, the risk of peritonitis was not related to the method of gastrostomy placement, but the small number of patients limits the ability to draw definitive conclusions.

Laparoscopy, where available, has largely supplanted open gastrostomy as the surgical technique of choice in non-CKD children.[146,147] There are, however, no studies directly comparing open vs laparoscopic surgical gastrostomy placement in children on PD. In a recent retrospective study of children receiving a laparoscopic gastrostomy (11 patients) after initiation of PD, all patients were able to initiate gastrostomy use by postoperative day 2, and peritoneal dialysis was resumed in all patients between post-operative day 0 and 4.[148] The post gastrostomy peritonitis rate of 0.36 per patient year during a median follow-up time of 404 days was not significantly different than the rate experienced during the period before gastrostomy placement, and there were no fungal peritonitis episodes. In a study from New Zealand of 15 children, most of whom had a gastrostomy inserted using an open surgical procedure (2 laparoscopic) after PD had been initiated, the peritonitis rate increased from 0.6 to 1.21 episodes per patient year post gastrostomy placement. The increase did, however, not reach statistical significance and there were also no fungal peritonitis episodes in this study. Follow up before and after gastrostomy was 160 months.[149]

Additional Considerations: There is a cost associated with the laparoscopic technique for gastrostomy placement and thus the technique may not be available in low-income countries and the surgical expertise may be minimal.

Guideline 6.3: There is good evidence for the use of antibiotic prophylaxis to prevent surgical site infection from adult and some pediatric studies when inserting PEGs in patients not on PD. A Cochrane review including 12 randomized, controlled trials (RCT) showed a reduced infection rate in adult non-PD patients receiving prophylactic antibiotics before PEG placement.[150–152] In a recent RCT in non-CKD children receiving PEGs, those who received prophylactic antibiotics showed a significantly reduced infection rate compared to those not receiving antibiotics.[153]

The evidence supporting the use of prophylactic antibiotic and antifungal therapy in PD patients comes from a single comparative study of children who received a PEG after initiation of PD.[144] In this multi-center retrospective study, one-third of patients (7/21) who received antibiotic prophylaxis (with or without antifungal therapy) developed bacterial peritonitis, while 7/19 (37%) patients who received no fungal prophylaxis (with or without antibiotics) developed fungal peritonitis. One out of 8 patients who received antibiotic and antifungal therapy developed peritonitis within the first week following PEG insertion, with no fungal infections. In contrast, peritonitis occurred in 3/6 patients (2 bacterial, 1 fungal/bacterial) who did not receive any prophylactic agents. There was also an increased incidence of modality change and death on PD in patients who did not receive antifungal therapy.

Dorman et. al. studied 11 children who received a laparoscopic gastrostomy after initiation of PD.[148] All patients received antibiotic and antifungal prophylaxis, and after a median follow-up of 404 days, the post-gastrostomy peritonitis rate of 0.36 episodes per patient year was not significantly different than the rate experienced during the period before gastrostomy insertion in the same group of patients. There were no episodes of fungal peritonitis.

A retrospective review from New Zealand reported on 15 children who received either an open gastrostomy (90%) or a laparoscopic gastrostomy after initiation of PD.[149] All patients received prophylactic antibiotics, but not prophylactic anti-fungal therapy. There was no statistically significant increase in the peritonitis rate post gastrostomy insertion, and there were no fungal infections. The follow up period was 160 months before and after insertion.

Analysis of data from the SCOPE Collaborative revealed that in 76 patients who underwent gastrointestinal procedures (type not specified) while on PD, there was no difference in the peritonitis rate within 7 or 30 days of the procedure in the 56 patients who were given antibiotics prior to these procedures when compared to those who did not receive prophylactic therapy.[51] Nevertheless, because of the devastating consequences of fungal peritonitis, this workgroup remains in favor of prophylactic antifungal therapy in addition to antibiotic prophylaxis in patients who require a gastrostomy and who are already receiving maintenance PD. Whereas the use of prophylactic antibiotics generally raises concern regarding antibiotic resistance and side effects, the risks appear to be low based on adult data regarding prophylactic antibiotics for PEG placement.[152]

Additional Considerations: The duration, type and route of therapy that has been studied varies and an optimal anti-infectious regimen has not yet been determined. In studies describing prophylaxis in patients receiving a gastrostomy while already on PD, the antimicrobial prophylaxis has generally been continued for longer periods post procedure. In the study by Dorman et. al., all patients received an intravenous cephalosporin or vancomycin prior to the procedure, and antibiotics

(cephalosporin) for up to four days post-operatively.[148] All patients were also on prophylactic fluconazole (duration not stated). In the New Zealand study of surgical gastrostomy insertion, intravenous second- or third-generation cephalosporin or co-amoxyclav was administered for 24 h after the procedure.[149] Typically, patients are given a single dose of a parenteral cephalosporin, with completion of the infusion within 60 minutes prior to initiation of the surgical procedure. If the risk for MRSA is high, vancomycin is provided over 60–90 minutes to conclude within 60 minutes prior to gastrostomy insertion. Antibiotic choice should take into consideration local susceptibilities. Antifungal prophylaxis can be provided by giving fluconazole or echinocandins. Both antimicrobials have often been continued by the intravenous route for an additional 3–5 days.

Regardless of the gastrostomy placement technique used, PD should preferably be withheld for a period of time after gastrostomy placement. The optimal duration the patient should be maintained off PD is not known, but various publications have reported 0–4 days.[143,148] If the gastrostomy is inserted using a PEG technique, a longer time off PD is probably warranted.[145] It is generally advisable to reinitiate dialysis with a lower PD fill volume and then gradually increase to the maintenance volume over the next 5–7 days. In the patient receiving CAPD, consideration may also be given to temporarily changing the PD modality to APD, with a diminished or absent daytime fill volume.

The presence of a concurrent colostomy in infants on PD is becoming more common in centers where neonatal maintenance PD is practiced. Recent data from the IPPN database identified 20 children on PD who also had a colostomy.[154] In this report, children with a colostomy had a significantly higher annualized peritonitis rate than a matched control group (1.13 vs 0.7). The authors of this report suggest that alternative strategies may be necessary to reduce the risk of infectious complications, such as placement of the PD catheter exit-site on the chest wall.

Limitations: The level of certainly regarding the relationship between the timing of PD catheter and gastrostomy placement is very low as the studies in children were observational. The low number of patients and the low number of events also lowers the degree of certainty. Likewise, the certainty of evidence regarding gastrostomy placement technique is very low as there are rare direct comparisons of the techniques. Finally, in the study of von Schnakenburg et. al., upon which guideline 6.3 is largely based, the low number of patients and low event rates, as well as the use of a survey and concerns regarding recall bias, resulted in lowering the certainty of the evidence supporting the recommendation.

Research Recommendations

● Additional data should be sought that provides direct comparisons between laparoscopic and open surgical procedure for gastrostomy placement with respect to infection risk, longevity of a functional gastrostomy and patient well-being.
● Future research should be conducted to determine the optimal antibiotic and antifungal prophylactic regimen for surgically placed gastrostomies (laparoscopic or open) in children receiving PD.
● Infection prevention strategies should be developed to decrease the risk of peritonitis in children on PD with a concurrent colostomy.

Guideline 7 – Adjunctive Prophylactic Antimicrobial Therapy

7.1 We suggest the use of prophylactic nystatin or fluconazole therapy for children on PD receiving intraperitoneal or systemic antibiotic therapy (2D).

7.2 We suggest using prophylactic antibiotics for pediatric PD patients undergoing certain GI (eg. colonoscopy) or GU procedures (e.g., invasive gynecological), in accordance with local guidelines (2D).

7.3 We suggest NOT using prophylactic antibiotics for pediatric PD patients undergoing dental procedures (2D).

7.4 We suggest that prophylactic antibiotics be administered after wet contamination of the PD system to prevent the development of peritonitis (2D).

Rationale

Guideline 7.1: Fungal peritonitis is a serious, but relatively uncommon complication of PD, accounting for 2–8% of all episodes of peritonitis in children.[155–158] The majority of fungal peritonitis episodes are caused by Candida species. Young age (<2 years) and antibiotic use have been identified as risk factors for the development of fungal peritonitis.[155,158,159] In observational studies, 56–100% of fungal peritonitis episodes in children are preceded by antibiotic use during the previous month, with variable proportions of this use (17–86%) specifically for an episode of bacterial peritonitis.[159] Antibiotic use is presumed to disrupt the intestinal microbiome, eliminating beneficial bacteria and allowing increased growth of fungi, which can subsequently invade the peritoneal cavity and lead to fungal peritonitis.

A number of historically controlled studies, including one pediatric study and several studies in adults, have shown a decrease in fungal peritonitis after introduction of antifungal prophylaxis during the administration of antibiotics.[160–164] Two randomized controlled trials in adults on PD have also demonstrated a reduction in fungal peritonitis in patients prescribed antifungal prophylaxis during the course of antibiotic therapy.[165,166] In one study, patients were randomized to receive placebo or nystatin for the duration of any antibiotic administration, regardless of the indication for antibiotics. Those randomized to nystatin

Table 2. Antifungal and antibacterial prophylaxis in peritoneal dialysis patients.

Situation	Indication	Antimicrobial
Surgical prophylaxis for peritoneal dialysis catheter placement	PD catheter placement	Antibiotics per local guidance based on procedure type. Preferred option[a]: Cefazolin (25 mg/kg IV; maximum 2 g)
Presence of risk factors for fungal peritonitis	- Gastrostomy tube placement - Use of systemic or intraperitoneal antibiotics	Nystatin PO 5000 units/kg twice daily (maximum: 500,000 units/dose) Fluconazole 3–6 mg/kg IV or PO every 24–48 h (maximum: 200 mg/dose)
Touch contamination	- Instillation of PD fluid after disconnection of system - Disconnection during PD	Cefazolin (125 mg/L IP), or vancomycin (25 mg/L IP) if known colonization with MRSA[b]
Antibiotic prophylaxis for surgical procedures associated with increased risk of peritonitis	-High-risk procedures including gastroscopy, colonoscopy, and invasive or instrumental gynecological procedures[c] -Gastrostomy tube placement	Antibiotics per local guidance based on procedure type. Suggested options include[a]: Cefazolin (25 mg/kg IV; maximum 2 g) Ceftriaxone (50 mg/kg IV; maximum 2 g)

PO = oral; IV = intravenous; IP = intraperitoneal

[a]Antibiotic prophylaxis has not been shown to be beneficial in pediatric studies, though data is limited. Adult data suggests benefit with endoscopic or invasive gynecological procedures

[b]May consider vancomycin for patients with a history of methicillin-resistant coagulase-negative *Staphylococcus* infection

[c]High-risk procedures reflect those determined to be high risk in the 2022 ISPD peritonitis guideline recommendations for adult patients.

experienced fewer episodes of Candida peritonitis (1.9/100 vs. 6.4/100; p < 0.05).[165] In the other trial, patients were randomized to receive fluconazole or a placebo while they were treated with antibiotics for peritonitis.[166] There were significantly fewer episodes of fungal peritonitis (3 vs 15, p = 0.005) in the group receiving fluconazole. Of note, only 4 of 10 cases of Candida peritonitis were fluconazole susceptible, raising concerns about the potential for the development of resistance. A Cochrane review of the use of antimicrobials for the prevention of peritonitis in patients on PD found a significant benefit to the administration of antifungal therapy during treatment with antibiotics.[76] More recent data from SCOPE and IPPN did not identify a difference in the risk for development of fungal peritonitis between children who did and did not receive antifungal prophylaxis during episodes of bacterial peritonitis; however, 77% of 586 patients in SCOPE and 95% of 2000 patients in IPPN received antifungals during antibiotic treatment for peritonitis.[167,168] Therefore, there were relatively few patients in the unexposed groups, which, combined with the rarity of fungal peritonitis, limits the conclusions that can be drawn from these data.

Additional Considerations: The most important intervention to reduce the risk of fungal peritonitis is to limit antibiotic use as much as possible, especially in children <2 years of age who are already at highest risk for fungal peritonitis. The 2012 ISPD pediatric peritonitis guideline recommended use of antifungal prophylaxis only when antibiotics were used for peritonitis. However, in one of the two randomized controlled trials of antifungal prophylaxis in adults, antifungals were administered with antibiotics that were given for any reason, not limited to peritonitis. In retrospective studies in

children, antibiotics for any indication are associated with a higher risk of peritonitis. In turn, when intraperitoneal or systemic antibiotics are required, whether for peritonitis or for another indication, we suggest administration of prophylactic antifungals. (Table 2) At the same time, there are no data regarding prolonged use of antifungal prophylaxis in children receiving extremely long courses of antibiotics, such as antibiotics for prophylaxis of urinary tract infections. The expert opinion of the workgroup is that the risks of antifungal-associated adverse events and development of antifungal resistance likely outweighs the possible benefit of such prolonged antifungal exposure. There are no head-to-head comparisons of nystatin vs. fluconazole, but concerns for the development of fluconazole resistance, which would seriously limit treatment options for fungal peritonitis, may favor the use of nystatin when it is available. Thus, lacking any data to support a longer duration of antifungals and balancing the risk of development of antifungal resistance and drug-associated adverse events, we suggest that antifungal therapy be continued for the duration of antibiotic therapy and not longer.

Guidelines 7.2 and 7.3: Data from the SCOPE Collaborative demonstrated no significant difference in peritonitis rates between those receiving prophylactic antibiotics versus those who did not receive prophylactic antibiotics when undergoing any invasive procedure including dental, GI, or GU procedures when adjusting for age, race, sex, cause of kidney failure, touch contamination, and upward catheter orientation.[51] An important limitation of this study was that 79% of the patients in these settings and enrolled in the SCOPE collaborative received prophylactic antibiotics.

When evaluating the impact of prophylactic antibiotics on peritonitis rates with dental procedures, no difference

was observed. This finding is consistent with the recommendation not to administer prophylactic antibiotics for the prevention of subacute bacterial endocarditis in most children with underlying heart disease when they undergo a dental procedure.[169]

The adult ISPD guideline recommends prophylactic antibiotics prior to colonoscopy and invasive gynecological procedures based on rates of peritonitis for these procedures being as high as 8.5% and 38.5%, respectively. With consideration of the combination of the pediatric and adult data, we also suggest that antibiotic prophylaxis may be indicated for certain GI and GU procedures such as colonoscopy and invasive gynecological procedures. However, the local setting experience should help guide the decision regarding which procedures should be conducted with antibiotic prophylaxis. (Table 2)

The main harms associated with the use of antibiotics include common adverse drug events including *Clostridium difficile* infection, for which even a single dose of antibiotics can put an individual at significant risk.[170] Furthermore, as antibiotic resistance becomes more prevalent, data has demonstrated that each additional day of antibiotic use confers a 4% risk for the development of resistance.[171] On the other hand, the loss of the peritoneum as a modality for dialysis can have significant consequences to a child, so weighing the risk and benefits of the use of prophylactic antibiotics for GI and GU procedures is not trivial.

Additional Considerations: Data are limited on the best prophylactic antibiotics to use for GI/GU procedures. The most common bacteria reported in adult studies causing peritonitis is *E. coli*. For this reason, antibiotics targeting this bacterial pathogen including cefazolin and ceftriaxone are often utilized. Additionally, the timing of the administration of this antibiotic likely is important, and data supporting the use of antibiotics for surgical prophylaxis would suggest that administration within one hour prior to the start of the procedure to be optimal.

Guideline 7.4: Dry contamination is "contamination outside a closed PD system, such as disconnection distal to a closed clamp," which does not require prophylactic antibiotics. Wet contamination is defined as "contamination in an open system, when either dialysis fluid is infused after contamination or if the catheter administration set has been left open for an extended period." Some examples of wet contamination listed in the 2022 adult guidelines include: leaks from dialysate bags, breaks or leaks in tubing proximal to tubing clamp, improper or breaks in aseptic technique, or any touch contamination during a PD exchange.[27] If questions exist as to whether the clamp was open or closed, the assumption should be that it was open and antibiotics should be prescribed for possible wet contamination.

In children receiving PD, touch contamination is a well recognized risk factor for the development of peritonitis. The risk of peritonitis following touch contamination in children was significantly higher in the SCOPE collaborative (rate ratio 2.22, 1.44–3.34) based on data collected from 734 children enrolled in the collaborative. Touch contamination can be divided into two categories. In the adult ISPD guidelines and in this guideline, the type of touch contamination, wet or dry, determines the need for the administration of prophylactic antibiotics.

Data supporting the use of antibiotics as prophylaxis following wet contamination include a single center study of 548 episodes of touch contamination in adults on PD, in which the overall rate of peritonitis following touch contamination was relatively low (3.1%) and all episodes of peritonitis (N = 17) occurred after wet contamination (5.6%).[172] Among these cases of peritonitis, only one received prophylactic antibiotics following the wet contamination and prophylactic antibiotic use following touch contamination was associated with a significantly lower risk for peritonitis. In this study, the episodes of peritonitis following touch contamination were culture negative or caused by MSSA, methicillin-susceptible and methicillin-resistant coagulase negative *Staphylococcus* and gram-negative bacteria such as *Pseudomonas aeruginosa* and *Acinetobacter baumanii*.

The optimal antibiotic to be administered following an episode of touch contamination has not been established. Given the predominance of culture-negative peritonitis, MSSA, and methicillin-susceptible coagulase-negative *Staphylococcus* peritonitis following touch contamination, and weighing the risks of broader or longer antibiotic treatment, a single dose of intraperitoneal (IP) cefazolin is reasonable for most patients. IP vancomycin could be considered in patients known to be colonized with MRSA.

Limitations: There are no randomized studies evaluating the use of fungal prophylaxis during antibiotic use in children on PD and the historically controlled study that demonstrated benefit of antifungals included too few patients to allow definitive conclusions. As noted above, data from pediatric registries are limited by the rarity of fungal peritonitis and the near ubiquitous use of antifungal prophylaxis.

The SCOPE collaborative data is limited as nonspecific GI, GU, and dental procedures were included in the multivariate model demonstrating that prophylactic antibiotics are not beneficial in preventing peritonitis.

Research Recommendations

● Research is needed to evaluate the safety, efficacy, and risk of development of antifungal resistance associated with the use of antifungal prophylaxis in children with administration of antibiotics for indications other than peritonitis.
● Further research is needed to compare the efficacy of nystatin vs. fluconazole as prophylactic agents in PD patients and to better understand the optimal duration of

antifungal prophylaxis during treatment with systemic antibiotics.

● More research is needed, specifically in children undergoing GI and GU procedures, to determine which invasive procedures should be preceded by prophylactic antibiotics.

Guideline 8 – Diagnosis of PD-Related Peritonitis

8.1 Cloudy peritoneal effluent should be sent for cell count, differential count, gram stain and culture when the diagnosis of peritonitis is suspected (Not Graded).

8.2 An empiric diagnosis of peritonitis should be made when at least two of the following are present: effluent white blood cell count greater than 100/mm3, with at least 50% of the WBCs as polymorphonuclear leukocytes, clinical signs and symptoms (fever, abdominal pain) and growth of microorganisms in PD effluent culture (Not Graded).

8.3 We suggest that inoculation of blood culture bottles be used for bacterial culture of PD effluent, with the addition of centrifugation to enhance the bacterial yield (Not Graded).

Rationale

Guideline 8.1: Investigations of patients suspected of having peritonitis should include a peritoneal fluid cell count, differential count, gram stain, and culture. A blood culture should also be obtained if the patient appears septic.

Microscopy is essential to confirm the presence of white blood cells (WBCs), because cloudy fluid can also be a result of the presence of eosinophilic peritonitis, blood, chyle, fibrin, chemical peritonitis, specimen taken from a "dry" abdomen, and rarely, malignancy. Eosinophilic peritonitis in particular is a common differential diagnosis, accounting for more than one third of culture-negative peritonitis episodes in children.[173] The condition usually occurs early in the course of PD and may be caused by mechanical irritation related to the PD catheter, allergenic chemicals including antibiotics and fibrinolytics, PD fluid contaminants (e.g.,peptidoglycan in icodextrin soluton), or non-PD related allergic reactions.[174]

As an early screening test for the presence of WBCs, leukocyte esterase reagent test strips have been used at some centers in patients suspected of having peritonitis.[175,176]

For patients on CAPD or APD with a daytime exchange, the first cloudy bag or the manual drain should be sent for cell count, differential count, gram stain, and culture. For the child on APD without a daytime dwell, the fill volume should be instilled for a minimum of 2 hours, with the subsequent effluent being sent for cell count, differential count, and culture.

To guide empiric therapy, it is useful to perform a gram stain on all samples; however, the sensitivity of a gram stain is low. Cytocentrifugation of samples is recommended to increase the sensitivity of gram staining.[177,178] Despite a large number of WBCs, microorganisms may not be visible or may be low in yield because of their sequestration within phagocytes. Still, the gram stain could be the first clue to a fungal infection, because budding yeast may be seen.

Guideline 8.2 Patients on PD who have peritonitis usually present with cloudy effluent and abdominal pain.[179,180] Other symptoms include fever, chills and rigors, anorexia, vomiting, abdominal distension, and in late cases, septic shock. In the PD patient with abdominal pain and clear fluid, peritonitis must also be excluded. Some of the peritonitis episodes collected by the IPPR were associated with clear effluent at presentation.[181] In such cases, a repeat assessment of the effluent for cloudiness should be conducted with subsequent exchanges. Other causes of abdominal pain in children on PD include constipation, acute gastritis, gastroenteritis, and acute appendicitis or pancreatitis.

The abdominal pain in peritonitis is typically generalized and is often associated with guarding and rebound tenderness. The degree of pain is variable, being mild to moderate in coagulase-negative Staphylococcus (CoNS) peritonitis and more severe in infections involving _Streptococcus_, gram-negative rods, and _S. aureus_. If the pain and tenderness are localized, acute appendicitis must be considered. If subsequent peritoneal fluid cultures grow multiple organisms, viscus perforation must be excluded.

A Disease Severity Score, defined by the sum of points for pain (0 = no pain; 1 = moderate pain, or nausea not requiring specific therapy; 2 = severe pain usually requiring analgesic therapy, or vomiting; 3 = peritoneal pain with a tense abdomen or paralytic bowel) and fever based on oral temperature (0 = <37.5°C; 1 = 37.5°C – 38.9°C; 2 = >38.9°C) has been used to objectively evaluate the severity of the clinical status.[182,183]

After a dwell time of at least 2 hours, a peritoneal effluent WBC count of more than 100/mm3 in an uncentrifuged specimen, with a differential count of at least 50% neutrophils, is highly suggestive of peritonitis.

For the child on APD without a daytime dwell, the absolute WBC count may not fulfill the standard diagnostic criteria if the dwell time is too short, as in the case of many patients receiving APD; in this case, the presence of 50% or more neutrophils, even if the total cell count is less than 100/mm3, is highly suggestive of peritonitis. In equivocal cases, or in patients with systemic or abdominal symptoms in whom the effluent appears clear, a second exchange with a dwell time of at least 2 hours should be performed and a second effluent sample evaluated.

In an IPPR report, 2.8% of clinical peritonitis episodes had peritoneal effluent WBC counts less than 100/mm3, and 8.5% of cases had less than 50% neutrophils.[181] If the eosinophil count exceeds 10%, a diagnosis of eosinophilic peritonitis should be considered, especially if the peritoneal fluid cultures are negative.[173]

Guideline 8.3 Obtaining the sample correctly and using proper culture techniques are crucial in establishing the diagnosis of peritonitis and in determining the proper choice of antibiotics. The rate of culture-negative peritonitis should not exceed 15% of peritonitis episodes in any center, and in an ideal setting, the goal is to achieve a culture-negative peritonitis rate of less than 10%.[184,185]

Specimens should be sent to the laboratory and processed within 6 hours. Should there be any delay in either transport or processing for culture, effluent samples must be refrigerated at 4°C until processed. A delay of more than 12 hours is unacceptable and will likely generate spurious results.[184,186] Patients who reside in areas far from medical facilities should be taught the recommended technique for collecting the cloudy peritoneal effluent and either inoculating it in blood culture bottles for transport or for refrigerating (not freezing) the effluent bag until the sample can be brought to the dialysis center for transport to the laboratory.

Centrifuging a large volume (50 mL) of peritoneal effluent at 3000 g for 15 minutes to obtain sediment for culture[187] has increased the yield by 5–10 times . The sediment is resuspended in 6–10 mL of sterile normal saline and inoculated directly on to solid-culture media and into standard blood-culture media.[27,188] At a minimum, blood and chocolate agar plates should be inoculated with re-suspended sediment; ideally, MacConkey agar plates should also be plated. The solid-culture media should be incubated in aerobic conditions. Anaerobic cultures may also be performed as required. Concentration techniques such as this one have yielded a culture-negative rate of less than 5%.[188,189]

Rapid blood culture techniques such as Bactec (Becton–Dickinson, Franklin Lakes, NJ, USA), Septi-Chek (Becton–Dickinson), and BacT/Alert (bioMérieux, Marcy l'Etoile, France) are useful in reducing the time to identification of microorganisms. The total number of microorganisms recovered has been found to be significantly better from inoculated blood culture bottles than from routine culture on solid media.[190] Bedside-inoculated bottles have yielded similar results compared to laboratory-inoculated bottles.

Using the foregoing culture techniques and associated concentration methods, most cultures will become positive within 24 hours. Certain situations, such as suspicion of a slow growing organism per clinical history, may call for additional incubation time. Agar plates should be incubated at 35°C to 37°C in 5% CO_2 for 24 hours. Anaerobic plates should be incubated at 35°C to 37°C under anaerobic conditions for a minimum of 7 days. Blood culture bottles should be incubated in a blood culture system for 5 days. A microbiologic diagnosis can be obtained in more than 75% of specimens by 72 hours.

Polymerase chain reaction can be a sensitive method for identifying causative organisms. Broad-spectrum polymerase chain reaction with sequencing, and quantitative bacterial DNA polymerase chain reaction assays can complement, but not replace, culture methods in the diagnosis of peritonitis, especially if the patient is receiving antibiotic therapy.[191,192]


Figure 1. Management algorithm for empiric antibiotic therapy.

Limitations: Pediatric data regarding when to recommend use of the effluent WBC differential counts as a means to diagnose peritonitis when the total effluent WBC count is low in patients receiving APD are limited.

Research Recommendations

● The factors contributing to elevated rates of culture-negative peritonitis (>15%) in pediatric centers should be explored.
● Prospective trials should be used to compare the sensitivity and specificity of the various diagnostic technologies available in the setting of PD-related peritonitis.

Guideline 9 – Empiric Antibiotic Therapy

9.1 Empiric antibiotic therapy should be initiated as soon as possible after appropriate microbiological specimens for the diagnosis of peritonitis have been obtained (Not Graded).

9.2 Center-specific antibiotic susceptibility patterns and patient history should help guide the selection of empiric antibiotic therapy (Not Graded).

9.3 We suggest using either a) intraperitoneal cefepime monotherapy or b) gram-positive coverage with a first-generation cephalosporin or vancomycin AND gram-negative coverage with ceftazidime (preferred) or an aminoglycoside (if ceftazidime is unavailable). In patients with features of sepsis, intravenous antibiotics should be used (2D).

Rationale

Guidelines 9.1 and 9.2: Empiric antibiotic therapy for pediatric patients suspected to have PD associated peritonitis must provide coverage for both gram-positive and gram-negative bacteria (Figure 1). These antibiotics should be started as soon as peritonitis is suspected as data in adults demonstrate greater rates of PD discontinuation, catheter removal and death with delays in therapy.[193,194] The choice of empiric antibiotic regimen should be center-specific and should take into account local epidemiology, the relative prevalence of different organisms, as well as local antibiograms and rates of resistance.

Guideline 9.3: The 2012 ISPD Pediatric guidelines recommended intraperitoneal (IP) cefepime monotherapy as one option for empiric therapy to provide empiric treatment for both gram-positive and gram-negative bacteria.[2] Cefepime has proven effective in the treatment of peritonitis in multiple studies, including two randomized controlled trials and a prospective observational study, and the use of a single agent may be more convenient than the use of multiple agents.[195–197] However, in some countries cefepime is not available and/or is not affordable. For institutions in which cefepime is not available or is prohibitively

expensive, empiric treatment with vancomycin or cefazolin for gram-positive coverage combined with either ceftazidime or an aminoglycoside for gram-negative coverage, is a reasonable alternative. Data from the IPPN registry demonstrated that when comparing empiric treatment with aminoglycosides to cefepime or ceftazidime, no difference in PD continuation (88% vs. 92%) or peritonitis relapse (7% vs 8%) was observed after adjusting for age, severity of symptoms and therapy duration.[168]

We suggest the use of ceftazidime over the aminoglycosides due to concerns for adverse events including ototoxicity and nephrotoxicity/loss of residual kidney function associated with aminoglycoside therapy. However, from observational studies and a randomized controlled trial, empiric IP aminoglycoside therapy has not been shown to negatively impact residual kidney function.[198–200] Ototoxicity has, however, been observed in patients receiving IP aminoglycosides and in adults the use of N-acetylcysteine appears protective.[201–205] Furthermore, individuals with specific variants in the MT-RNR1 gene should not receive aminoglycosides due to the risk of ototoxicity with just a single dose. The impact of this gene in patients receiving IP aminoglycosides is not known. In some areas, individuals can be tested for this specific gene variants.[206] Furthermore, the United States Clinical Laboratory Standards Institute (CLSI) and the European Committee on Antimicrobial Susceptibility Testing (EUCAST) no longer recommends gentamicin for the treatment of *P. aeruginosa* infections due to emerging data that gentamicin is inferior for treating this pathogen.[207,208] CLSI recommends amikacin for *P. aeruginosa* only in urinary tract infections. The aminoglycoside with the best activity for invasive *P. aeruginosa* infections is tobramycin. If aminoglycosides are used, intermittent daily IP dosing is preferred to continuous dosing. This strategy takes advantage of the concentration-dependent mechanism of action of aminoglycosides by allowing for high peak concentrations and lower trough concentrations to minimize toxicity. Studies in adults have shown no difference in efficacy between continuous and intermittent dosing strategies, but have shown higher serum troughs in patients receiving continuous dosing, which are associated with a higher risk for ototoxicity.

Intraperitoneal administration of cephalosporins has also been associated with systemic absorption. Most importantly, neurotoxicity has been observed with IV cefepime in the form of seizures, encephalopathy and depressed consciousness. Primary risk factors have included the elderly and those with kidney dysfunction and requiring intensive care.[209] There is a report of cefepime-associated neurotoxicity in 2 patients receiving IP cefepime; in both cases, symptoms resolved with dose reduction or discontinuation of the antibiotic.[210] In a larger study of 87 episodes of peritonitis treated with IP cefepime, it was very well tolerated with no evidence of neurotoxicity.[196]

In institutions where MRSA accounts for a high percentage of peritonitis episodes (for example, >10% of all episodes of peritonitis), the center should consider

vancomycin instead of cefepime or cefazolin for gram-positive coverage. The workgroup also suggests that providers choose vancomycin as part of the empiric treatment regimen in patients with a personal history of MRSA infection. In these cases, vancomycin should be combined with ceftazidime for gram-negative coverage.

Finally, intravenous therapy should be used initially in patients who are critically ill with signs of sepsis so as to ensure the achievement of therapeutic antibiotic blood levels.

Additional Considerations: While gentamicin and amikacin are not preferred for definitive treatment of *P. aeruginosa,* data suggests that their empiric use is not associated with increased treatment failures. Additionally, recommendations against the use of gentamicin and amikacin for invasive *P. aeruginosa* infections are based on clinical and pharmacokinetic data for IV administration of these antibiotics and it is not clear whether IP administration could overcome the limitations of systemic dosing.

Limitations: No direct comparative data from prospective studies are available to inform empiric treatment recommendations.

Data are limited on the rate of systemic absorption of IP aminoglycosides and cephalosporins in children and the potential for associated adverse effects.

Research Recommendations

● More comparative clinical outcome data are needed to further evaluate the different empiric antibiotics regimens utilized to ensure their efficacy and safety.

● Given the recent recommendations to avoid the use of gentamicin and amikacin in the treatment of *P. aeruginosa*, more data are needed to evaluate the impact of this empiric antibiotic recommendation on clinical outcomes in patients with *P. aeruginosa* peritonitis.

Guideline 10 – General Principles of Antibiotic Therapy for Peritonitis

10.1 Antibiotic therapy should be adjusted once a causative pathogen is identified, and antibiotic susceptibility data should guide the definitive antibiotic selection (Not Graded).

10.2 Providers should select the narrowest effective agent and treat for the shortest effective duration to reduce the risks for development of resistance, antibiotic-associated adverse events, and time at risk for fungal peritonitis (Not Graded).

10.3 The IP route of antibiotic administration should be preferred as long as the compatibility and stability of the IP antibiotics allow, unless the patient has features of sepsis, in which case intravenous antibiotics should be used (Not Graded).

Rationale

Guideline 10.1: Definitive antibiotic selection should be guided by culture and antibiotic susceptibility results. (Tables 3 and 4). Clinicians should select the narrowest effective antibiotic. Broad-spectrum antibiotics are associated with **higher** risks for the development of antibiotic

Table 3. Intraperitoneal antibiotic dosing recommendations for treatment of peritonitis.

| | Therapy Type[a] | | |
| | Continuous | | |
Antibiotic Type	Loading Dose	Maintenance Dose	Intermittent
Intraperitoneal (IP)			
Aminoglycosides[b]			
Amikacin	N/A	N/A	2 mg/kg[400]
Gentamicin	N/A	N/A	0.6 mg/kg[401]
Tobramycin	N/A	N/A	0.6 mg/kg[402]
Beta-Lactams			
Cefazolin	500 mg/L	125 mg/L[197]	20 mg/kg[402]
Cefepime	500 mg/L	125 mg/L[197]	15 mg/kg[403] (Max dose: 1000 mg)
Ceftazidime	500 mg/L	125 mg/L[197]	20 mg/kg[404]
Imipenem/cilastatin	250 mg/L	50 mg/L[405]	N/A
Meropenem	N/A	125 mg/L[406]	N/A
Miscellaneous			
Daptomycin	100 mg/L	20 mg/L[407]	N/A
Ciprofloxacin	N/A	50 mg/L[408]	N/A
Vancomycin[c 225]	500 mg/L	25 mg/L	30 mg/kg; repeat dosing: 15 mg/kg every 3–5 days

[a]For continuous therapy, the exchange with the loading dose should dwell for 6 hours; all subsequent exchanges during the treatment course should contain the maintenance dose. For intermittent therapy, the dose should be applied once daily in the long-dwell, unless otherwise specified.
[b]Aminoglycosides and penicillins should not be mixed in dialysis fluid because of the potential for inactivation.
[c]In patients with residual kidney function, glycopeptide elimination may be accelerated. If intermittent therapy is used in such a setting, therapeutic drug monitoring may be considered to help guide dosing, especially in patients who are not responding to vancomycin or have evidence of toxicity. Redosing may be considered when serum concentrations are < 15 mcg/mL.

Table 4. Systemic antibiotic dosing recommendations for treatment of peritonitis.

Antimicrobial	Route	Recommended Dose	Dose Frequency	Per-dose maximum
Beta-Lactam Antibiotics				
Amoxicillin	PO	20 mg/kg/dose	Daily	1000 mg
Cefazolin	IV	25 mg/kg/dose	Every 24–48 h	1000 mg
Cefepime	IV	25–50 mg/kg/dose	Every 24–48 h	2000 mg
Ceftazidime	IV	50 mg/kg/dose	Every 48 h	2000 mg
Meropenem	IV	10–20 mg/kg/dose	Daily	1000 mg
Fluoroquinolone Antibiotics				
Ciprofloxacin	IV/PO	10–15 mg/kg/dose	Daily	IV: 400 mg; PO: 500 mg
Levofloxacin	IV/PO	10 mg/kg/dose	Every 48 h	500 mg
Other Antibiotics				
Linezolid	IV/PO	10 mg/kg/dose	< 12 years old: Three times daily ≥ 12 years old: Twice daily[a]	600 mg
Minocycline	IV/PO	4 mg/kg/dose for first dose, then 2 mg/kg/dose thereafter	Once daily for first dose; then twice daily	200 mg
Sulfamethoxazole/ trimethoprim (based on trimethoprim)	IV/PO	4–6 mg/kg/dose	Daily	160 mg
Rifampin	IV/PO	5–10 mg/kg/dose	Twice daily	600 mg
Antifungals				
Amphotericin B Liposomal	IV	3–5 mg/kg/dose	Daily	N/A
Fluconazole	IV/PO	6 mg/kg/dose	Every 24–48 h	Treatment: 400 mg
Isavuconazonium sulfate (Isavuconazole)	IV/PO	10 mg/kg/dose of isavuconazonium sulfate[409]	Three times daily for 6 doses then once daily	372 mg (isavuconazonium sulfate)
Posaconazole[b]	PO (delayed release tablets)	300 mg	Twice daily for 2 doses, then once daily	
	PO (immediate release suspension)	4.5–6 mg/kg/dose	Four times daily	200 mg
Voriconazole[b]	PO	2 to < 12 years old: 9 mg/kg/dose ≥ 12 years old and < 50 kg: 9 mg/kg/dose ≥ 12 years old and ≥ 50 kg: 200 mg	Twice daily	350 mg
Caspofungin	IV	< 3 months: 25 mg/m2/dose ≥ 3 months: 70 mg/m2/dose for first dose, then 50 mg/m2/dose	Daily	70 mg (first dose); 50 mg (subsequent doses)
Micafungin	IV	< 4 months old: 10 mg/kg/dose ≥ 4 months old: 2 mg/kg/dose	Daily	100 mg

PO = oral; IV = intravenous
[a]May consider reducing to 300 mg Q12hr after 72 hours if a prolonged duration (>10 days) is anticipated and patient is at risk for development of thrombocytopenia based on limited data[410,411]
[b]Avoid intravenous (IV) formulations if possible due to accumulation of cyclodextrin-component and potential kidney toxicity

resistance, as well as higher rates of antibiotic-associated adverse drug events.[211] Specific recommendations based on the organism identified and susceptibility patterns are summarized in Figures 2 to 5.

The approach to management of children with penicillin allergies has changed over time. While 5–10% of people report penicillin allergies, only about 10% of those who undergo testing have a true penicillin allergy.

Figure 2. Management algorithm for gram-positive bacteria on culture.

Figure 3. Management algorithm for gram-negative bacteria on culture.

Children with penicillin allergy labels are more likely to receive guideline-discordant antibiotics that are broader than necessary and are more likely to experience antibiotic-associated adverse events.[212] It is, in turn, important to remove inaccurate penicillin allergy labels and multiple organizations recommend a proactive approach to penicillin allergy delabeling when appropriate.[213,214]

Even for patients with a true penicillin allergy, most cephalosporins can be used safely. Cross-reactivity between penicillins and cephalosporins was initially thought to be as high as 8% but is now understood to be

Figure 4. Management algorithm for culture-negative peritonitis.

Figure 5. Management algorithm for fungal peritonitis.

much lower.[215,216] Patients with non-anaphylactic penicillin allergies can receive any cephalosporin without additional testing. Patients with anaphylaxis to penicillin can safely receive cephalosporins with side chains that are different from penicillin, in particular cefazolin. Children with penicillin allergies, including anaphylaxis, can receive carbapenems when clinically appropriate.[217] If a child is thought to have an allergy to a preferred agent or an antibiotic with a similar side chain that would preclude use of the preferred agent, we recommend involvement of an allergist to facilitate optimal prescribing, rather than using second-line antibiotics.

Guideline 10.2: The shortest effective duration of therapy should be used to treat peritonitis. Longer durations of antibiotics increase the risk for development of resistance, antibiotic-associated adverse events, and increased time at risk for fungal peritonitis.[155,158,159,171,218] Comparative data regarding optimal durations of therapy are limited, but registry data from the IPPN does shed some light on this question. The sections below and Figures 2 to 5 outline recommended durations of therapy, which are generally 2–3 weeks and dependent on the causative organism. Resistant organisms do not require longer durations of therapy.

Guideline 10.3: Use of IP antibiotics is preferred for treatment of peritonitis to deliver optimal concentrations of the antibiotic to the site of infection and to minimize systemic absorption and associated toxicities. Some patients may also find it easier to administer antibiotics by the IP route than to remember to take multiple doses of oral antibiotics daily. For some agents, IP administration is not possible due to concerns about compatibility or safety associated with IP administration, or the lack of pharmacokinetic or pharmacodynamic data to identify an appropriate dose. In these cases, intravenous (IV) or oral administration of antibiotics may be required. Intravenous therapy may also be needed initially in patients who are critically ill with signs of sepsis. In these cases, there is no particular obligatory duration of IV therapy before transition to oral or IP antibiotics.[219] In patients who are able to tolerate and absorb oral antibiotics and for infections where there are reasonable options for oral administration based on susceptibilities, enteral antibiotics are preferred over IV medication to reduce the need for intravenous catheters, which are associated with high rates of complications (both infectious and mechanical) in children.[220,221] Avoidance of IV access when possible is particularly important in children on PD who may eventually require vascular access for hemodialysis.

Limitations: Data comparing specific treatment regimens or routes of administration of antibiotics are lacking. Most of the data regarding IP dosing of antibiotics is based on published clinical experience rather than formal pharmacokinetic studies.

Guideline 11 – Modification for Gram-positive Peritonitis

11.1 We suggest that peritonitis caused by methicillin-susceptible *S. aureus* (MSSA) be treated with IP cefazolin for a duration of 2 weeks (2D).

11.2 We suggest that peritonitis caused by methicillin-resistant *S. aureus* (MRSA) be treated with IP vancomycin for a duration of 2 weeks (2D).

11.3 We suggest the addition of PO rifampicin for peritonitis caused by either MSSA or MRSA if there is a poor initial response (2D).

11.4 We suggest that coagulase-negative staphylococci should be treated with IP cefazolin or vancomycin, according to susceptibilities, for a period of 2 weeks (Not Graded).

11.5 We suggest that peritonitis caused by enterococci should be treated according to susceptibilities with PO amoxicillin (for ampicillin-susceptible enterococci), IP vancomycin (for ampicillin-resistant, but vancomycin-susceptible enterococci), or with IP daptomycin or PO linezolid (for vancomycin-resistant enterococci) for a duration of 2–3 weeks (Not Graded).

11.6 We suggest that peritonitis caused by *Streptococcus spp*. should be treated with IP cefazolin, if susceptible, or IP cefepime or IP vancomycin if not susceptible to cefazolin, for a duration of 2 weeks (Not Graded).

11.7 We suggest that other gram-positive bacteria should be treated with the narrowest available agent for a duration of 2 weeks (Not Graded).

Rationale

Gram-positive organisms are the most commonly identified pathogens in pediatric PD-associated peritonitis, accounting for 50–60% of cases in which an organism is identified.[24,48] Coagulase-negative Staphylococci are most common, followed by *Staphylococcus aureus*, then Enterococci and Streptococci. Outcomes for gram-positive peritonitis in children tend to be quite good, with resolution as characterized by the lack of impairment in ultrafiltration capacity and absence of clinically apparent intraperitoneal adhesions in 85% of episodes. Treatment regimens, both antibiotic choice and duration, should be tailored to the identified organism (Figure 2).

Guideline 11.1 and 11.2: Antistaphylococcal beta lactams, including cefazolin, are the preferred treatment for serious MSSA infections.[222] Numerous studies have shown that antistaphylococcal beta lactams, including cefazolin, are superior to vancomycin for the treatment of MSSA bacteremia, including one study demonstrating lower mortality in children.[223] Prior data from the IPPR had suggested more frequent peritonitis relapses in patients treated with a first-generation cephalosporin compared to other antibiotics.[37] This evaluation included peritonitis caused by any organism and did not specifically evaluate outcomes in patients with MSSA. The dosing that was reported in that study was also lower than currently recommended dosing, which is very important for beta lactam antibiotics whose activity depends on time above the minimum inhibitory concentration. More recent data from the IPPN has shown more favorable outcomes in patients who received cefazolin compared to other beta-lactams. After adjusting for age, disease severity, and therapy duration, PD continuation was higher in those who received cefazolin (218/223 (98%)) vs. other beta-lactams

(52/57(91%)), with an odds ratio of 0.24 (0.063, 0.91) and a p-value of 0.036.[168] Relapse was also less common in those treated with cefazolin (12/223 (5%)) compared to those who received other beta-lactams (6/57(11%)), with an odds ratio of 2.22 (0.77, 6.25) and a p-value of 0.14.

Previous concerns about worse outcomes in children with PD-associated peritonitis treated with cefazolin have not persisted in analyses of more recent data with improved cefazolin dosing and are consistent with data in other serious MSSA infections, where cefazolin is preferred. Cefazolin also has a narrower antibiotic spectrum than other cephalosporins or glycopeptides, reducing the risk for development of resistance. It is very well tolerated, and its use avoids the risks of nephrotoxicity associated with vancomycin or the neurotoxicity associated with cefepime, and it is inexpensive. Allergy to cefazolin is rare, and there is little cross-reactivity between cefazolin and other beta lactams, so it can be used safely even in children with reported allergy, including anaphylaxis, to penicillins or other cephalosporins. Therefore, in children with PD-associated peritonitis confirmed to be caused by MSSA, we suggest transition to IP cefazolin alone for treatment.

Intraperitoneal vancomycin is the treatment of choice for MRSA infections. Use of teicoplanin is not recommended because its activity against MRSA biofilm is impaired in PD solutions.[224] Optimal dosing for IP vancomycin is not clear. Several studies, including those with pharmacokinetic modeling, have demonstrated significant interindividual variability in serum levels of vancomycin with fixed IP dosing strategies. Previous iterations of this guideline recommended higher loading doses of IP vancomycin for patients undergoing continuous PD, but more recent literature has demonstrated that lower loading doses may be utilized to minimize potential toxicity.[225,226] It is also unclear whether there is a role for modifying dosing based on therapeutic drug monitoring (TDM). Whereas the utility and optimal parameters for IP vancomycin TDM are not clearly defined, clinicians may consider TDM in consultation with pharmacy experts for some patients, including those at high risk of toxicity or with poor clinical response.

The 2012 ISPD pediatric peritonitis guidelines and the *ISPD peritonitis guideline recommendations: 2022 update on prevention and treatment for adult patients*, recommend 3 weeks of therapy for S. aureus peritonitis. The recommendation is based on limited retrospective data from two studies in adult patients with *S. aureus* peritonitis, which suggested better outcomes in patients treated with 3 weeks of therapy in one study compared to worse outcomes in another study in which patients received an average of 2 weeks of therapy.[2,27,227,228] No definitive conclusions can be drawn from this comparison across studies that were conducted in different geographic locations (Hong Kong vs. Australia) and across different time periods (1994–2005 and 2003–2006). Importantly, data from the IPPN registry did not show a difference in outcomes for patients

with S. aureus peritonitis treated with 2 vs 3 weeks of antibiotics.[168]

A comparison of 106 patients with MSSA peritonitis who received antibiotic therapy for a median of 14 days (range 12–17) to 94 patients treated for a median of 21 days (range 19–24), revealed no difference in full functional recovery (p = 0.91), PD discontinuation (p = 0.83) or catheter removal (p = 0.97).

Among 73 patients with MRSA peritonitis treated with vancomycin maintenance therapy (42% intermittent IP, 25% continuous IP, 33% iv), full functional recovery was achieved in 95% of 22 episodes treated for a median of 14 days (range 12–17 days), as compared to 73% of 51 episodes treated for a median of 21 (range 19–24 days) (p = 0.03). The relapse rate was similar in both groups (4% vs. 5%, p = 0.91).

While the data from IPPN are also limited by their retrospective nature, this does provide important evidence that 2 weeks of therapy appears to be safe and effective for children with both methicillin susceptible and methicillin resistant *S. aureus* peritonitis.

Guideline 11.3: Data from the IPPN showed that among all gram-positive infections, there was no significant difference in PD continuation rates between those who received rifampicin (34/38 (89%)) and those who did not receive rifampicin (859/915 (94%)), with an odds ratio of 1.23 (0.38, 3.92) and a p-value of 0.72 after adjusting for age, disease severity, and therapy duration.[168] Similarly, there was no significant difference in relapse rates between those who received rifampicin (1/38 (2.6%)) and those who did not (69/915 (7.5%)), with an odds ratio of 2.5 (0.33, 18.8) and a p-value of 0.37. An analysis based on *S. aureus* and CoNS infections showed that 28/588 *S. aureus* and CoNS infections were treated with rifampicin. The PD discontinuation rate was similar in the treated and non-treated groups; 2/28 (7%) vs. 33/560 (6%) p = 0.78, and the relapse rate was nominally higher in the non-treated group: 43/560 (8%) vs. 1/28 (4%) p = 0.42.

In a retrospective, observational single-center study of 245 *S.aureus* episodes that occurred in 152 adult patients, primary response rate was similar between patients with and without adjuvant rifampicin therapy (82.4 *v.* 89.8%; *P* = 0.11), as was the complete cure rate (77.9 *versus* 72.9%; *P* = 0.4).[227] However, adjuvant rifampicin treatment was associated with a significantly lower risk for relapse or repeat *S.aureus* peritonitis than was treatment without rifampicin (21.4 *versus* 42.8%; *P* = 0.004). Adjuvant rifampicin treatment resulted in a 49.9% relative risk reduction in relapse or repeat *S. aureus* peritonitis (95% CI 14.6 to 70.6%). The effect of rifampicin remained substantial even after exclusion of cases with early relapse (within 4 weeks after completion of antibiotics). Adjuvant rifampicin significantly reduced the risk for repeat peritonitis (23.3 *v.* 38.0%; *P* = 0.012).

Guideline 11.4: Coagulase-negative Staphylococci (CoNS), including *Staphylococcus epidermidis*, are among the most common causes of peritonitis in children.

Coagulase-negative staphylococcal peritonitis is often associated with touch contamination. Coagulase-negative staphylococci tend to be less virulent than *S. aureus*, but a significant proportion of CoNS are resistant to methicillin, 40–70% in adult series.[229–231] Treatment should be modified according to susceptibilities once they are available, using IP cefazolin for methicillin-susceptible and IP vancomycin for methicillin-resistant isolates. We do not recommend using the CoNS resistance rate to determine an institution's empiric therapy, because coagulase-negative peritonitis tends to be clinically mild and treatment failure is rare, as long as patients are placed on appropriately targeted definitive therapy once susceptibilities are known.[232,233] Two weeks of therapy are as effective as 3 weeks in the treatment of coagulase-negative staphylococcal peritonitis.[232]

Guideline 11.5: Enterococci are part of the normal genitourinary and intestinal flora. Enterococcal peritonitis may be related to intraabdominal pathology, but can also occur through touch contamination. In adults, outcomes appear to be worse when *Enterococcus spp.* are isolated along with other pathogens, which is more suggestive of intraabdominal pathology.[234–236] There are few data in children about polymicrobial peritonitis specifically, and overall outcomes for enterococcus peritonitis in children seem to be better than in adults. This holds true even when empiric treatment is not effective against enterococcus, which is relatively common since enterococci are intrinsically resistant to cephalosporins.[237]

Many enterococci are susceptible to ampicillin, which was the first-line recommendation for treatment of susceptible isolates in the 2012 guideline. However, newer data suggest that ampicillin's activity is significantly impaired by PD fluid and so IP administration of ampicillin is not recommended.[238] In turn, we suggest that treatment of ampicillin-susceptible enterococci consist of oral amoxicillin. In children who are unable to tolerate or absorb PO amoxicillin, IV ampicillin/amoxicillin may be used. When there are viable alternatives, we do not recommend vancomycin for treatment of ampicillin-susceptible enterococci due to a higher risk for colonization with vancomycin-resistant enterococci (VRE). For enterococcal isolates that are resistant to ampicillin but susceptible to vancomycin, the group recommends treatment with IP vancomycin.

Treatment of VRE can be challenging and so we encourage consultation with a local infectious diseases specialist in this case. Intraperitoneal daptomycin appears to have acceptable pharmacokinetics and there are case reports of successful treatment of VRE with IP daptomycin in adults.[239,240] Both oral and IV linezolid appear to achieve adequate IP concentrations and have also been used successfully for treatment of VRE peritonitis, although IP administration of linezolid is not recommended due to similar concerns to ampicillin regarding impaired activity in PD fluid and unknown dosing regimens.[241,242]

The optimal duration of therapy for enterococcal peritonitis is not clear. While the *ISPD peritonitis guideline recommendations: 2022 update on prevention and treatment for adult patients,* recommend 3 weeks of therapy for enterococcal peritonitis, large case series of adults with enterococcal peritonitis reveal that most are treated with 2 weeks of antibiotics and there are no comparative data suggesting that 3 weeks is superior.[234,235] In turn, we suggest treatment with antibiotics for 2–3 weeks, with longer durations considered for patients who are slower to improve.

Guideline 11.6: Streptococcal peritonitis can be caused by skin flora and exit-site or tunnel infection (*Streptococcus pyogenes*) or be related to transient bacteremia (viridans group Streptococci and *Streptococcus pneumoniae*). Susceptibility patterns for Streptococci vary by species and region. Infections should be treated according to susceptibilities with either IP cefazolin, IP cefepime, or IP vancomycin. While organisms may be susceptible to ampicillin, as discussed above, ampicillin's activity is significantly impaired by PD fluid and so IP ampicillin is not recommended. Oral amoxicillin has been used in some patients with enterococcal peritonitis and may be an option for patients with ampicillin-susceptible Streptococcal peritonitis, but this is not well-studied.[235]

Guideline 11.7: Other gram-positive bacteria are rarer causes of peritonitis in children and so clinical experience is often limited to case reports. Consultation with an infectious diseases specialist is suggested for uncommon organisms. In general, treatment should be guided by antimicrobial susceptibility testing and the narrowest available agent should be administered for two weeks.

Limitations: No data are available about adverse effects of rifampicin use in addition to current antibiotic treatment in slowly resolving and/or severe peritonitis and/or catheter exit-site infections. Data suggesting inactivation of IP ampicillin relate to its activity against enterococcus rather than in treatment of streptococci, but it is likely that the impaired activity would also decrease efficacy for streptococcus.[243] There are no clinical outcome data evaluating the efficacy of IP ampicillin, or any comparative data about any specific treatment regimens for Streptococcal peritonitis.

Research Recommendations

● Additional research is needed to determine the optimal dosing strategy for intraperitoneal vancomycin and whether there is a role for therapeutic drug monitoring, either universally or in a subset of children.

● Further evaluation of oral amoxicillin vs. vancomycin or other strategies for Streptococcal peritonitis should be conducted.

Guideline 12 – Modification of Therapy for Gram-Negative Peritonitis

12.1 We suggest that peritonitis caused by gram-negative organisms that are not otherwise specified

below (i.e., not Pseudomonas aeruginosa, Acinetobacter sp., Stenotrophomonas maltophilia, Enterobacter cloacae, Klebsiella aerogenes, Citrobacter freundii) and that do not have specified markers of resistance, extended-spectrum beta-lactamases (ESBL) or carbapenem-resistant Enterobacterales (CRE), be treated according to susceptibilities with either IP cefazolin or IP ceftazidime for a duration of 2 weeks (2D).

12.2 We suggest that peritonitis caused by Extended-spectrum beta-lactamase producing Enterobacterales (ESBL-E) be treated with IP or IV meropenem or IP or PO ciprofloxacin according to susceptibilities for a duration of 2 weeks (2D).

12.3 We suggest that peritonitis caused by organisms with high risk for AmpC beta-lactamase production, defined as *Enterobacter cloacae, Klebsiella aerogenes,* and *Citrobacter freundii,* be treated with IP cefepime if susceptible, or IP or IV meropenem or IP or PO ciprofloxacin if not, for a duration of 2 weeks (2D).

12.4 We suggest that peritonitis caused by Carbapenem-resistant Enterobacterales (CRE) be treated according to susceptibilities, in consultation with an infectious diseases expert, for a duration of 2 weeks (2D).

12.5 We suggest that peritonitis caused by *Pseudomonas aeruginosa* be treated according to susceptibilities with a single agent, either IP ceftazidime or cefepime if susceptible, or IP or IV meropenem or IP or PO ciprofloxacin if not, for a duration of 3 weeks (2D).

12.6 We suggest that peritonitis caused by *Acinetobacter* spp. be treated according to susceptibilities with a single agent, either IP cefepime, IP ceftazidime, or IP or IV meropenem, for a duration of 3 weeks (Not Graded).

12.7 We suggest that peritonitis caused by carbapenem-resistant *Acinetobacter baumannii (CRAB)* be treated according to susceptibilities with at least two active agents when possible, including high-dose IV ampicillin-sulbactam + IV or PO minocycline/tigecycline, IV poly-myxin B, or IV cefiderocol, for a duration of 3 weeks. Consultation with an infectious diseases specialist is also suggested (Not Graded).

12.8 We suggest that peritonitis caused by *Stenotrophomonas maltophilia* be treated with PO trimethoprim-sulfamethoxazole in combination with another active agent, such as IV or PO levofloxacin, mino-cycline, tigecycline, or cefiderocol, for a duration of 3 weeks (Not Graded).

Rationale

Outcomes for gram-negative peritonitis tend to be worse than for gram-positive peritonitis. Previous analysis of data from the IPPR showed that full functional recovery was achieved in 86% of episodes of gram-negative peritonitis.[38] Treatment of gram-negative infections can be particularly challenging due to rising resistance and the numerous different mechanisms of resistance that can make antibiotic selection complex. Studies comparing different treatment strategies for specific gram-negative causes of peritonitis are lacking, so most recommendations are extrapolated from general principles for the management of gram-negative infections. (Figure 3)[244] As antibiotic resistance continues to increase worldwide, it is increasingly important to prioritize therapies that limit negative consequences (i.e., narrow-spectrum antibiotics, shorter treatment time) for the treatment of susceptible organisms, as long as these are not associated with inferior outcomes.

Guideline 12.1: For susceptible isolates, IP cefazolin is preferred to ceftazidime due to its narrower spectrum. Out of 154 gram-negative Enterobacterales peritonitis (*E.coli, Klebsiella* spp., Enterobacter, Citrobacter and *Serratia* spp.) episodes reported to the IPPN Registry between 2011 and 2022, monotherapy with IP cephalosporins as post-empiric therapy was prescribed in 56 cases (45 ceftazidime or cefepime and 11 cefazolin).[168] Full functional recovery was reported in 10 (91%) episodes treated with cefazolin monotherapy (8 *E.coli*, 3 *Klebsiella* spp.), as compared to 42 (93%) receiving ceftazidime or cefepime treatment (p = 0.79). There was also no significant difference in the relapse rate, with no relapses reported in cefazolin treated patients and 4 relapses in the ceftazidime/cefepime group (p = 0.29).

Although previously reported data from the IPPR cohort suggested that cefazolin monotherapy was associated with a higher risk of relapse as compared to treatment with a glycopeptide, ceftazidime or aminoglycoside monotherapies, the published analysis did not specify the type of causative bacteria.[37] In addition, the reason for inferior outcomes with cefazolin for treatment of organisms that are *in vitro* susceptible, might be attributed to the previously advocated lower dosing of cefazolin that we now recognize to be inadequate. This association did not hold true in more recent analyses in patients receiving higher doses of cefazolin. Given the risk for development of resistant organisms (ESBL, AmpC-producing bacteria) with use of a third generation cephalosporin, cefazolin use for the treatment of susceptible gram-negative bacteria is a reasonable option.[245] In addition, cefazolin is well-tolerated and inexpensive, in addition to having a narrow spectrum of activity making it less likely to induce broader antimicrobial resistance.

The suggested duration of therapy for most gram-negative organisms, with the exceptions of *Pseudomonas aeruginosa, Acinetobacter baumanii,* and *Stenotrophomonas maltophilia,* is 2 weeks. Data from the IPPN registry found no difference in full functional recovery from peritonitis in cases of non-*Pseudomonas* gram-negative peritonitis in patients treated with 2 vs. 3 weeks of antibiotics.[168] Among 140 patients treated for a median of 14 (range 12–17) days, 91% experienced full functional recovery versus 88% recovery among 106 patients receiving therapy for a median of 21 (range 19–24) days (p = 0.45). When performing a multivariate analysis controlling for age, presence of preceding exit-site infection, severity of

symptoms at presentation and early treatment response, there was still no difference in full recovery between patients treated with short vs. long durations of therapy.[168] *Prior versions of this guideline and current guidelines for the management of peritonitis in adults have recommended 3 weeks of therapy for all gram-negative peritonitis*, but there are no studies showing better outcomes with 3 weeks of antibiotics compared to shorter durations of therapy.[27] The data from the IPPN registry, in addition to the risks associated with prolonged antimicrobial therapy including development of antimicrobial resistance, adverse events, and cost of therapy, favor the use of a 2-week duration. The use of shorter durations of treatment is also consistent with emerging evidence supporting shorter durations of therapy for gram-negative infections in general, including serious infections such as bacteremia.[246] Clinicians may consider longer durations of therapy if patients are slow to improve or there is concern for concomitant exit-site/tunnel infection, though these factors may also lead providers to consider catheter removal for source control.

Guideline 12.2: ESBL-E are among the most common resistant gram-negative organisms identified in clinical infections. Infections with ESBL-E tend to be less common in children than adults, but have also increased rapidly and rates and risk factors vary widely by geography.[247–249]

ESBLs are enzymes that inactivate most penicillins, cephalosporins, and aztreonam. Most ESBL-E remain susceptible to carbapenems and non-beta lactams (fluoroquinolones, TMP/SMX, aminoglycosides), although some may also have additional mechanisms of resistance that lead to broader resistance. ESBLs are most common in *Escherichia coli, Klebsiella pneumoniae, Klebsiella oxytoca*, and *Proteus mirabilis*, although they can be found in any gram-negative organism. Most clinical laboratories do not perform ESBL testing, so non-susceptibility to ceftriaxone is used instead as a proxy for ESBL production. While some organisms may be resistant to ceftriaxone for reasons other than ESBL production, Enterobacterales that are resistant to third generation cephalosporins (ceftriaxone, cefotaxime, or ceftazidime) should be presumed to be ESBL-E.[244]

A large randomized clinical trial in adults found higher mortality in patients with ESBL-E bacteremia treated with piperacillin/tazobactam compared to meropenem.[250] IDSA guidelines recommend extending the preference for carbapenems for treatment of serious infections with ESBL-E to other sites, including intraabdominal infections, particularly for initial treatment. Intraperitoneal administration is preferred, and with optimal dosing for intermittent administration in children unclear, this would require continuous administration. If this is not possible, intravenous administration can be used.

Oral or IP fluoroquinolones can be used as step-down therapy in patients who have shown clinical improvement, or may be reasonable options for first-line treatment in children who are not critically ill.[251,252] Both ciprofloxacin and moxifloxacin appear to be compatible with PD solutions and to have bactericidal activity in PD fluid.[238,253,254] Fluoroquinolones are highly orally bioavailable and thus when given orally, can achieve adequate IP concentrations.[255,256] If given orally, it is important to note that fluoroquinolone absorption is impaired by calcium-, magnesium-, aluminum-, zinc-, or iron-containing products (eg, antacids, dairy products, tube feeds) as well as phosphorus binders, and so administration of fluoroquinolones should be timed to be several hours before or after receipt of these products. Fluoroquinolones have been used extensively in children with very rare reports of musculoskeletal adverse events, primarily tendinitis and tendinopathy that is generally short-term and reversible.[257–259] Observational data in adults suggest fluoroquinolones may be associated with an increased risk of aortic aneurysm or dissection.[260–264] Unless no other treatments are available, fluoroquinolones should be avoided in children known to have an aortic aneurysm or who have risk factors for aneurysm, such as Marfan syndrome or Ehlers Danlos syndrome.[265]

There is no evidence to suggest that resistant infections require longer durations of treatment than susceptible ones, as long as they are ultimately treated with an effective antibiotic.[244] Since these patients may have been started on empiric treatment with an antibiotic to which their isolate was ultimately found to be non-susceptible, it is recommended that they complete 2 weeks of treatment with an effective agent.

Guideline 12.3*: AmpC beta lactamases are enzymes that hydrolyze a number of beta lactams. Some gram-negative organisms exhibit inducible AmpC production. These organisms may initially test susceptible *in vitro* to third generation cephalosporins (ceftriaxone, cefotaxime, and ceftazidime), but use of these antibiotics can induce increased AmpC production leading to rapid development of resistance. Based on both clinical and in vitro data, IDSA guidelines consider *Enterobacter cloacae* complex, *Klebsiella aerogenes* (formerly *Enterobacter aerogenes),* and *Citrobacter freundii* to be at moderate to high risk for clinically significant AmpC production due to an inducible ampC gene.[266,267] As many as 20% of isolates of these organisms exhibit clinically significant inducible AmpC beta lactamases.[268–272] While prior classification schemes included organisms such as *Proteus* spp., *Serratia marcescens*, and *Morganella morganii* as AmpC producers, more current data show that clinically significant AmpC production occurs in less than 5% of these organisms and they can be treated according to *in vitro* susceptibilities.[268,273,274]

For the three groups of organisms with the highest risk for inducible AmpC expression, *E. cloacae, K. aerogenes,* and *Citrobacter freundii,* even if *in vitro* susceptibility testing indicates susceptibility to third generation cephalosporins, these antibiotics should be avoided. Intraperitoneal cefepime is recommended because it is a weak inducer of

AmpC beta lactamases and can withstand hydrolysis by AmpC beta lactamases. For organisms that are resistant to cefepime, the workgroup recommends use of either IP or IV carbapenem or an IP or PO fluoroquinolone. Carbapenems are also resistant to hydrolysis by AmpC beta lactamases and fluoroquinolones are not susceptible to beta lactamases.

Guideline 12.4: CRE are gram-negative organisms that are resistant to at least one carbapenem antibiotic or that produce carbapenemase enzymes. They are a heterogenous group of organisms with a variety of different mechanisms of resistance, including carbapenemases, other beta lactamases, and porin mutations. The prevalence of CREs and mechanisms of resistance varies widely worldwide.[275]

Knowledge of a specific CRE isolate's mechanisms of resistance, including whether it produces a carbapenemase and, if so, which carbapenemase, is critically important for determining optimal treatment.[244] For example, the most common carbapenemases in the United States are *K. pneumoniae* carbapenemases (KPCs), which can be found in many Enterobacterales in addition to *K. pneumoniae*. Novel beta lactam/beta lactamase inhibitor combinations such as ceftazidime-avibactam, meropenem-vaborbactam, and imipenem-cilastatin-relebactam are active against most Enterobacterales that produce KPC enzymes.

Because management of carbapenem-resistant infection is complex and nuanced and may vary according to local susceptibility patterns and antimicrobial availability, consultation with an infectious diseases expert is recommended. In general, beta lactam/beta lactamase inhibitor combinations with activity against the isolated organisms are preferred over aminoglycosides and colistin due to improved efficacy and decreased toxicity with such regimens.[244]

Guideline 12.5: Infections secondary to *Pseudomonas* spp. are difficult to treat because of the bacteria's capacity to generate a biofilm that lowers the likelihood of successful treatment without catheter removal. In many cases, a tunnel infection accompanies the peritonitis episode and increases the likelihood of subsequent PD discontinuation.[276] Analysis of the gram-negative peritonitis episodes reported to the IPPR registry revealed that *Pseudomonas* spp. was the most frequent bacterial cause of an exit-site infection or colonization and the association with peritonitis was significant for the latter ($P = 0.01$).[38] In addition, antibiotic use in the preceding 30 days has been identified as a risk factor for the development of peritonitis attributable to *Pseudomonas* spp. in both pediatric and adult patients receiving PD.[277]

Combination therapy with cefepime or ceftazidime and a second agent that has a different mechanism of action (for example, fluoroquinolone or aminoglycoside) and to which the bacteria is susceptible was advocated in the 2012 pediatric ISPD guidelines and *treatment with 2 agents is also recommended in the ISPD peritonitis guideline recommendations: 2022 update on prevention and*

treatment for adult patients. This recommendation is based on an outcomes analysis of 191 Pseudomonas related peritonitis episodes reported to the ANZDATA database between 2003 and 2006. 79% of these episodes were treated with one antibiotic only (most commonly ciprofloxacin) and 21% with two anti-pseudomonas agents (most commonly ciprofloxacin and an aminoglycoside).[278] In patients treated with a single agent, 38% required permanent discontinuation of PD compared to 10% in dual therapy (p = 0.03). This was a retrospective analysis with a number of important limitations, including lack of information about or adjustment for concomitant exit-site/tunnel infection, disease severity, and initial response to antibiotic treatment. In that report, there was also little information given about the specific antibiotic regimens used, which apparently included relatively infrequent use of beta lactams. Most patients were empirically treated with an aminoglycoside and then switched to ciprofloxacin once *Pseudomonas aeruginosa* was isolated in culture. Treatment durations were also relatively short, with a median of 16 days.

In contrast, a more recent analysis of *Pseudomonas aeruginosa* peritonitis episodes reported to the IPPN registry between 2012 and 2020 revealed no difference in outcome between one- and two-agent therapy.[168] Out of 70 episodes, 29 were treated with one anti-pseudomonas agent (ceftazidime, gentamicin, fluoroquinolone or cefepime). The full functional recovery rate was 79%, as compared to 56% in patients treated with two anti-pseudomonas agents (p = 0.04). Patients who received two anti-pseudomonas agents presented with more severe signs and symptoms of infection at 60–72 hours of empiric therapy and more commonly had a preceding ESI (26 vs. 21%). However, multivariate analysis showed no difference in outcome between the groups after adjusting for age, disease severity score, 60–72-hour treatment response and treatment duration.

This is in line with IPPR data from 2008, where although the outcome of infections caused by *Pseudomonas* spp. tended to be least favorable compared to other pathogens, it was influenced independently by the concurrent presence of an exit-site infection and the initial response to treatment.[38] This is also consistent with data from gram-negative infections of other body sites that show no benefit associated with double coverage with multiple antibiotics, including infections secondary to *Pseudomonas aeruginosa*.[279] Current guidance from the IDSA recommends against combination therapy, even for highly resistant *Pseudomonas aeruginosa*.[244] If there is suspicion of an extremely resistant infection based on patient history or local susceptibilities, an aminoglycoside and beta lactam may be considered as combination therapy initially to broaden coverage and increase the likelihood that at least one agent will cover the organism. Once susceptibility to a beta lactam is confirmed, there is no evidence that continued therapy with two agents improves outcomes.[279] Also

noteworthy, combination therapy is associated with an increased risk for adverse events, particularly kidney injury and potential loss of residual kidney function.

Considering the possible risks of adverse events and additional costs associated with combination treatment and the lack of discernible benefit, the balance between desirable and undesirable effects favors definitive treatment with one anti-pseudomonas agent, preferably a beta lactam when possible. We suggest treatment with IP ceftazidime or cefepime if susceptible, or IP or IV meropenem if not. If, once antimicrobial susceptibilities are available, there are no options for IP beta lactams for treatment, PO fluoroquinolones may be a reasonable alternative, especially for step-down therapy after initial improvement.

Importantly, recent updates to The United States Clinical Laboratory Standards Institute (CLSI) recommendations have eliminated breakpoints for gentamicin based on a review of clinical and pharmacokinetic/pharmacodynamic data showing that there is no safe aminoglycoside dosing regimen that can achieve adequate killing of *P. aeruginosa*. Gentamicin has therefore been removed as a treatment option for *P. aeruginosa*.[280] Although the CLSI review focused on systemic treatment rather than IP administration of antibiotics, these changes will impact reporting of susceptibilities for bacteria grown from peritoneal fluid as clinical laboratories are recommended to no longer report *P. aeruginosa* susceptibility to gentamicin, and to only report amikacin for urine isolates. Beta lactams are preferred for treatment of *P. aeruginosa*, including novel beta lactam/beta lactamase inhibitors for highly resistant *P. aeruginosa* isolates. If an aminoglycoside must be used due to lack of susceptibility to a beta lactam, IP tobramycin is preferred over gentamicin or amikacin and may be considered in combination with a beta lactam in consultation with an infectious diseases specialist.

The suggested length of therapy for *Pseudomonas aeruginosa* peritonitis is 3 weeks. In the IPPN database, full functional recovery was achieved in 75% of patients with Pseudomonas peritonitis treated for a median of 21 (range 19–24) days and in 61% of those treated for a median of 14 (range 12–17) days (p = 0.28).[168] Although the difference was not statistically significant due to low patient numbers, there was a trend towards worse outcomes in those treated with shorter durations of therapy. In light of this, as well as the generally poor outcomes associated with Pseudomonas aeruginosa peritonitis compared to other etiologies, including other gram-negative organisms, the workgroup favors 3 weeks of therapy.

Guidelines 12.6 and 12.7*:* Peritonitis caused by *Acinetobacter* spp. should be treated according to susceptibilities. For generally susceptible isolates, this may include either IP cefepime, IP ceftazidime, or IP or IV meropenem.

We recommend consultation with an infectious diseases specialist for peritonitis caused by carbapenem-resistant *Acinetobacter baumannii (CRAB),* which can be very difficult to treat. It often displays resistance not just to carbapenems, but also to other agents that may be active against wild-type *A. baumannii*. In concordance with IDSA guidance, we suggest that treatment regimens should include combination therapy with two active agents.[244] While it is not clear as to whether combination therapy results in better outcomes when compared to treatment with a single agent, combination therapy is suggested because data identifying the optimal single agent to use for treatment are lacking. The high degree of resistance of most CRAB isolates means that in general, if patients are not on appropriate therapy initially, they may in turn have a high burden of disease by the time CRAB is identified, and CRAB may develop resistance to antibiotics during the course of treatment.

We also suggest that regimens include ampicillin/sulbactam, even if the isolate is resistant to ampicillin/sulbactam *in vitro*. Sulbactam is a potent beta lactamase inhibitor that saturates PBP1z/1b and PBP3 of *A. baumannii* and has unique activity against *A. baumannii*. Even if an isolate is resistant to ampicillin/sulbactam, the sulbactam may saturate altered PBP targets and allow the second agent to be more effective. Multiple studies have demonstrated that sulbactam-containing regimens are associated with lower mortality in critically ill patients with CRAB. The optimal dosing of sulbactam in pediatric patients undergoing PD with an active CRAB infection is unknown and should be further discussed with local infectious diseases and pharmacy experts. When used for treatment of CRAB, ampicillin/sulbactam should be given in combination with minocycline, tigecycline, polymixin B, or cefiderocol.

There were too few episodes of *Acinetobacter baumannii* peritonitis in the IPPN database to draw any conclusions about the optimal duration of therapy for Acinetobacter spp. Therefore, we have extrapolated the 3-week duration recommended for *Pseudomonas aeruginosa* to *Acinetobacter* spp.

Guideline 12.8: Infections caused by *Stenotrophomonas maltophilia* can be difficult to treat due to biofilm formation and antimicrobial resistance. Diagnosis can also be challenging because *S. maltophilia* can be a common colonizer of hardware, as well as a true pathogen. *S. maltophilia* isolates often harbor a large number of antimicrobial resistance genes, including beta-lactamases that render it resistant to most conventional beta-lactamases, and efflux pumps that can reduce activity of other antibiotics, including TMP-SMX, tetracyclines, and fluoroquinolones. Studies comparing different treatment regimens for *S. maltophilia* infections (at any site, not only for peritonitis) are lacking. Consistent with IDSA guidance, we suggest treatment with a combination of PO trimethoprim-sulfamethoxazole and either IV or PO levofloxacin, IV or PO minocycline, IV tigecycline, or IV cefiderocol. If PO trimethoprim-sulfamethoxazole is not tolerated, use of two other active agents is recommended. Unfortunately, none of the antimicrobials that are typically recommended

for treatment of *S. maltophilia* can be given by the intraperitoneal route and so these recommendations all include antimicrobials given by the PO or IV route of administration.

TMP-SMX has historically been the preferred treatment for *S. maltophilia* infections and most isolates are susceptible to TMP-SMX (>90% in the US), although there is increasing recognition of resistance.[281,282] Existing data, which are limited to small retrospective studies or observational studies using administrative databases, conflict as to the optimal approach to treatment (eg. combination vs. monotherapy).[283–286] For serious infections, IDSA guidance recommends combination therapy to ensure that at least one antibiotic will be active. Despite the lack of robust data, we suggest inclusion of PO TMP-SMX in combination antibiotic treatment strategies due to the abundance of clinical experience with its use for *S. maltophilia* and no clear evidence of lack of efficacy. We suggest treatment with two agents initially, with consideration of using PO TMP-SMX alone for step down therapy in patients who have exhibited marked clinical improvement or in those with relatively mild infection. If TMP-SMX cannot be used due to resistance, toxicities, or allergy, we recommend the use of combination therapy with two other active agents.

As with *Acinetobacter* spp., there are no data to identify optimal duration of therapy for *S. maltophilia* peritonitis; we recommend a treatment duration of 3 weeks due to its propensity to form biofilms, extrapolated from the recommended treatment duration for *P. aeruginosa*.

Limitations: There are no prospective studies evaluating outcomes in patients with peritonitis caused by specific gram-negative organisms or groups of organisms (i.e., ESBL-E or AmpC producers), including no data comparing one antibiotic regimen to another. Thus, these recommendations are extrapolated from reviews of registry data studies and guidelines regarding management of other serious gram-negative infections.

Research Recommendations

● Since multicenter, controlled studies on gram-negative peritonitis treatment schemes are usually not feasible in pediatrics due to very low patient numbers per center and country, more information should be recovered from international pediatric dialysis registries.
● Further research into the pharmacokinetics and feasibility of intraperitoneal use of carbapenems and fluoroquinolones is needed to help meet the increasing demand for treatment of peritonitis caused by resistant gram-negative organisms.
● Additional research is needed comparing outcomes in patients treated with a single agent versus two agents with different mechanisms of action for *Pseudomonas aeruginosa*.

Guideline 13 – Modification of Therapy for Culture-Negative Peritonitis

13.1 We suggest that antibiotic therapy for culture negative, non-relapsing peritonitis be continued for 2 weeks (2D).

13.2 We suggest that antibiotic therapy be switched to cefazolin monotherapy if the initial PD cultures remain sterile at 72 h and signs and symptoms of peritonitis are improved (2D).

Rationale

Guideline 13.1: Infectious peritonitis in which no causative organism is identified is classified as culture-negative peritonitis. Culture-negative peritonitis poses a therapeutic dilemma both in terms of antibiotic choice and treatment duration, as a negative culture does not allow differentiation between slowly replicating, effectively opsonized or atypical bacterial infection, a non-bacterial (fungal, viral) infection and noninfectious causes of peritoneal leukocytosis (chemical, eosinophilic peritonitis). On the other hand, failure to isolate the causative organism may be related to recent antibiotic use or to the variability of PD fluid sampling and culture technique.[245] Large case series have demonstrated that outcomes of non-relapsing, culture-negative peritonitis are generally favorable. Treatment for culture-negative peritonitis has shown higher success rates and a lower likelihood of catheter removal than culture-positive peritonitis. However, the minimal effective duration of antibiotic treatment in culture-negative peritonitis is unknown.[185] The *ISPD peritonitis guideline recommendations: 2022 update on prevention and treatment for adult patients recommend 2 weeks treatment duration*, based on 1760 culture-negative episodes reported to the ANZDATA database in which outcomes were similar with treatment durations of 2 and 3 weeks.[287]

There are no published pediatric data regarding the optimal treatment duration for culture-negative peritonitis. An analysis of 289 culture-negative peritonitis episodes reported to the IPPN database revealed a detrimental effect of shortening treatment duration below 14 days. The PD discontinuation rate was 15% for 48 peritonitis episodes treated for shorter than 14 days as compared to 5% for 241 episodes treated for at least two weeks (p = 0.008, adjusting for age and disease severity).[168] In light of the above data, it appears safe to continue the initial empiric therapy, which provides gram-positive and gram-negative coverage, for a complete treatment course (at least 14 days) to potentially lower the risk of treatment failure and relapse. (Figure 4)

Guideline 13.2: If the initial peritoneal fluid cultures remain sterile at 72 hours in patients who show clinical improvement and largely cleared dialysate under empiric treatment, it appears justified in most cases to narrow antibiotic coverage to a 1st generation cephalosporin and to discontinue cefepime, vancomycin, and aminoglycosides used

in the empiric scheme. The rationale for this recommendation is based on several considerations: Analysis of the culture-negative peritonitis episodes in the IPPN registry demonstrated no difference in PD continuation and relapse rates between patients who were continued on a glycopeptide and those in whom the glycopeptide was discontinued and switched to cefazolin for gram-positive coverage, after adjusting for age, disease severity and urine output.[168] Likewise and noteworthy are the findings from a recent adult retrospective cohort study of 58 patients which demonstrated a favorable outcome in 95.2% of culture-negative peritonitis episodes treated with cefazolin/ceftazidime combination and 93.7% in those treated with cefazolin monotherapy.[288] Taking into account that extended glycopeptide use increases the risk of drug-induced nephrotoxicity (and potential loss of residual kidney function) and the occurrence of bacterial resistance in non-*Staphylococcus aureus* infections, it seems advisable to discontinue vancomycin at 72 hours in patients with a negative culture who are clinically improved. The same argument holds true for the use of aminoglycosides; their distinct nephro- and ototoxic potential and the low chance of a cefazolin-resistant, aminoglycoside-sensitive organism not growing in culture at 72 hours in a patient with clinical improvement do not define a risk-benefit ratio that would justify extended aminoglycoside use.

Additional Considerations: Patients with culture-negative peritonitis who fail to demonstrate clinical improvement after 72 hours should undergo a repeat PD effluent cell count, differential, and culture. If the culture continues to be negative and the PD effluent cell count has not improved, special culture techniques should be used for the isolation of unusual or fastidious organisms, including fungi, mycobacteria, nocardia and legionella. Patients with culture-negative peritonitis who fail to improve after 5 days of therapy should undergo catheter removal, per the recommendations for refractory peritonitis.

In centers in which the culture-negative peritonitis rate exceeds 15% of peritonitis episodes, sampling and culture techniques should be reviewed with the dialysis staff and the laboratory.[27]

Limitations: There is low certainty for this recommendation as supportive data are from observational registries and retrospective studies, leaving a possibility of bias by various factors including center and regional effects.

Research Recommendations

● Since randomized controlled studies comparing different treatment durations for culture-negative peritonitis are presumably not feasible, more information should be recovered from international pediatric peritonitis registries on the treatment and outcome of culture-negative infections.

● Further research should be conducted to determine if improved culture strategies result in a decrease in the percentage of culture-negative peritonitis episodes.

Guideline 14 – Modification of Therapy for Fungal Peritonitis

14.1 We suggest immediate catheter removal when fungal elements are identified in PD effluent (2D).

14.2 We suggest antifungal therapy be administered for at least 2 weeks after catheter removal in children with PD-associated fungal peritonitis (2D).

14.3 Clinicians should select an appropriate agent based on antifungal susceptibility results, with oral fluconazole preferred for infections caused by susceptible Candida species (Not Graded).

Rationale

Fungal peritonitis (FP) is rare, accounting for 2–8% of episodes of peritonitis episodes in children, but is associated with poor outcomes, including high rates of PD discontinuation.[155,158,159] The two largest series of pediatric fungal peritonitis, from NAPRTCS and SCOPE, demonstrated worse outcomes for FP relative to non-fungal peritonitis; however, in contrast to the adult experience, there does not appear to be a significant increase in mortality associated with FP in children relative to bacterial peritonitis. Retrospective case series have demonstrated mortality rates associated with FP in children of 0–2.6%, compared to 9–28.7% in adults.[155,158,159,289–291] (Figure 5)

Guideline 14.1: Catheter removal is generally recommended following the diagnosis of FP because of the propensity for fungi to form biofilms that cannot be eliminated with antifungal drugs alone. This diagnosis should be made as soon as fungal elements are identified in the PD effluent; clinicians should not wait for fungal culture results or species identification. In observational studies in adults, retaining the PD catheter in patients with FP has been associated with increased mortality and PD discontinuation when compared to catheter removal.[289,290,292] There are no data directly comparing treatment strategies for FP (i.e., antifungals alone, catheter removal in combination with antifungals, or catheter removal alone) in children. Small pediatric series have not demonstrated an association between catheter removal and improved outcomes, including mortality or PD discontinuation.[155,158,159] In the series of 51 cases of FP reported by Warady et al., there were 5 patients in whom the catheter was retained and at 6 month follow up, all were still alive and continuing PD. 53% of all patients who experienced FP continued PD at 6 months.[155] However, in the more recent series of 41 cases from Munshi et al., there was a 68% PD discontinuation rate associated with FP and FP was also associated with a 3-fold higher risk of

hospitalization compared to bacterial peritonitis.[158] The catheter was retained in 15% of episodes, but outcomes were not reported separately for those children in whom the catheter was retained or removed.[158] PD catheters were removed in the majority of children with FP in both series, making the number of children in the comparator group too small to draw definitive conclusions from regarding outcomes.

There are conflicting data regarding the optimal timing for catheter removal. In the NAPRTCS series in which 90% of children underwent catheter removal, 17% were removed within one day of diagnosis and 39% were not removed for four or more days after diagnosis.[155] There was no association between conversion to HD and time of catheter removal following the diagnosis of FP. In three observational studies in adults that evaluated the association between timing of catheter removal and mortality, two found that removal after 24 hours was associated with increased mortality, while the third found no difference in mortality between patients with catheter removal within the first 5 days compared to later removal.[289,290,292] The conflicting results may be explained by different time frames defining early vs. late removal.

As noted above, whereas multiple studies in adults with FP have demonstrated an association between failure to remove the PD catheter or delayed removal (more than 24 hours after diagnosis) and mortality, these studies were observational and were not controlled for confounding by indication, i.e., the fact that patients who are sicker and more likely to fail treatment are also more likely to be unable to have their catheter removed or to have their catheter removed later.

Guidelines 14.2 and 14.3: There are no comparative studies addressing the duration of therapy for FP or the optimal choice of an antifungal agent. We suggest a treatment duration of at least 2 weeks after catheter removal, which is consistent with durations administered in most case series of fungal peritonitis.[159,289,290,293] (Figure 5)

The choice of antifungal agent should be driven by species identification and susceptibility testing. The vast majority of fungal infections are due to *Candida* spp., many of which can be effectively treated with oral fluconazole. Fluconazole is highly orally bioavailable and achieves excellent IP concentrations.[294] For organisms that are not susceptible to fluconazole, including filamentous fungi such as *Aspergillus* spp., voriconazole, posaconazole, and isavuconazole may be chosen, generally in consultation with an infectious diseases specialist. When possible, IV voriconazole and posaconazole should be avoided in PD patients due to the risk of accumulation of cyclodextrin, which may contribute to kidney toxicity. PO voriconazole and posaconazole achieve adequate IP concentrations and are appropriate alternatives in children with adequate absorption.[295] Intravenous echinocandins (micafungin, caspofungin, anidulafungin) may be used for fluconazole-resistant *Candida* spp. Intraperitoneal

administration of echinocandins is discouraged due to concerns about impairment of activity against *Candida* biofilm by PD fluid.[296,297] IV amphotericin B does not penetrate the peritoneum well and is generally reserved for infections that are not susceptible to azoles or echinocandins.[294] Intraperitoneal administration of amphotericin is poorly tolerated with significant peritoneal irritation and abdominal pain.

Limitations: It is unclear how well data from adults can be extrapolated to children, in whom PD discontinuation and mortality are much less common and the burden of catheter removal and possibility of permanent transfer to HD is much greater. Despite these limitations, the association with decreased mortality in adults likely favors the strategy of antifungal therapy in combination with immediate catheter removal in children as well.

Research Recommendation

● Further research dedicated to the optimal treatment strategy for management of FP in children is needed. Because catheter removal has become the standard of care, there is likely not equipoise to conduct a prospective study evaluating retention of the PD catheter compared to removal. However, a larger retrospective series could provide some answers regarding the need and optimal timing for catheter removal in children.

Guideline 15 – Mycobacterial Peritonitis

15.1 We suggest that antituberculosis therapy without PD catheter removal be provided as the primary treatment of peritonitis caused by Mycobacterium tuberculosis (2D).

15.2 We suggest that non-tuberculous mycobacteria (NTM) be treated with both effective antibiotics and catheter removal (2D).

Rationale

Guideline 15.1: PD associated peritonitis secondary to *Mycobacterium tuberculosis* (Mtb) is rare and most cases have been reported in adults from endemic countries with high disease burden.[298–301] The clinical features are nonspecific and indistinguishable from other causes of peritonitis, and the dialysis effluent can have a predominantly polymorphonuclear cellular response similar to bacterial peritonitis.[298] A high index of suspicion is therefore needed, especially in countries with low-disease burden as significant delays (average 6.1 weeks) from symptom onset to diagnosis are commonly reported.[301] When suspected, consultation with an infectious diseases physician with expertise in the diagnosis and management of mycobacterial infections will help facilitate appropriate mycobacterial (acid-fast bacilli) testing and drug therapy. A chest x-ray can assist in early diagnosis as

extraperitoneal tuberculosis is seen in a third of patients, with pulmonary involvement being most common.[301] Additionally, HIV testing should also be conducted in anyone diagnosed with Mtb. Mortality rates associated with infection are high (35%), but there is no evidence to suggest that PD catheter removal is associated with an increased probability of survival.[299,301]

Guideline 15.2: Non-tuberculous mycobacteria (NTM) are a group of environmental organisms that are ubiquitous in soil and water. While more than 130 species of NTMs have been identified, only a few, *M fortitum, M. chelonae, and M abscessus,* have been reported to cause PD associated peritonitis.[302–304] NTM associated peritonitis is an uncommon, but serious disease as the diagnosis is challenging and often delayed.[303,305] NTM are resistant to many antibiotics, the complete cure rate is low (14.8%), and mortality can be as high as 30% despite PD catheter removal, and 43% when the catheter is left in place.[302,304,306] The incidence of NTM peritonitis might be increasing, with several cases reported over the last decade.[302,304,307–310] A hospital-acquired outbreak resulting from colonization of a shower-head affecting 5 infants has been reported from Japan.[311]

The classical clinical presentation is a refractory, culture-negative peritonitis that may or may not be associated with an exit-site infection.[303,304,306,308] In such cases, one should have a high-index of suspicion, and the laboratory should be notified to prolong the incubation time of standard bacterial cultures to 7 days, and/or use selective culture media such as Lowenstein-Jensen medium.[303] Consultation with an infectious diseases physician with expertise in the diagnosis and management of mycobacterial disease is recommended. Identification of NTMs at the species level is important because bacterial susceptibility to antimicrobial drugs is often closely predicted from characterization of the isolated species.[302]

Most NTMs are resistant to standard anti-tuberculous drugs and the majority of antimicrobials, with the exception of amikacin.[303,304,312] The majority of patients require catheter removal as most NTMs have a tendency to exhibit growth in biofilms.[304]

Additional considerations: On gram stain, NTMs can be mistaken for diphtheroids resulting in a delay in the diagnosis of an NTM infection and continuation of unnecessary and/or inappropriate treatment.[303,307]

A previous study had reported topical gentamicin for exit-site care as a potential risk factor for acquiring NTM peritonitis; however, a more recent report failed to validate that association.[304,313]

Limitations: Experience with Mtb associated peritonitis is very limited in children as apart from being an uncommon entity, almost all cases having been reported in adult patients from areas with a high burden of tuberculosis. On the other hand, NTM associated peritonitis might be underreported as many cases might get labeled as culture-negative refractory peritonitis resulting in catheter removal and continuation of antibiotic therapy without a specific diagnosis.

Research Recommendations

● Global registry data should be collected to determine the frequency, clinical manifestations and treatment of children with mycobacterial peritonitis.

Guideline 16 – Relapsing, Recurrent and Repeat Peritonitis

16.1 Following an initial episode of peritonitis, subsequent episodes should be characterized as relapsing, recurrent or repeat to help determine a treatment plan and prognosis (Not Graded).

16.2 We suggest that empiric antibiotic therapy of relapsing/repeat peritonitis be guided by the center specific protocol with consideration of the susceptibilities of the original bacteria (2C).

16.3 Post-empiric antibiotic therapy of relapsing/repeat peritonitis should be guided by in vitro susceptibility results (Not Graded).

Table 5. Terminology for peritonitis.

Types of Peritonitis	Definition
Refractory peritonitis	Peritonitis episode with persistently cloudy effluent or persistent dialysis effluent leukocyte count greater than 100/mm^3 after 5 days of appropriate antibiotic therapy
Relapsing peritonitis	Peritonitis episode that occurs within 4 weeks of completion of antibiotic therapy of a prior episode with same organism or one culture-negative episode
Recurrent peritonitis	Peritonitis episode that occurs within 4 weeks of completion of antibiotic therapy of a prior episode but with a different organism
Repeat peritonitis	Peritonitis episode that occurs more than 4 weeks after completion of antibiotic therapy of a prior episode with same organism
Non-repeat peritonitis	Peritonitis episode that occurs more than 4 weeks after completion of antibiotic therapy of a prior episode but with a different organism
Full-functional recovery	Resolution of peritonitis with no resulting functional impairment (adhesions, decreased ultrafiltration capacity) with or without catheter exchange

16.4 We suggest that the duration of antibiotic therapy for most episodes of relapsing/repeat peritonitis be based on the standard treatment recommendations for the identified organism (2C).

16.5 We suggest that removal of the PD catheter should occur as soon as peritonitis is controlled by antibiotic therapy in the setting of relapsing/repeat peritonitis associated with a persistent or recurrent tunnel infection, or a second peritonitis relapse (2C).

Rationale

Guideline 16.1: Relapsing, recurrent, or repeat peritonitis are serious complications of PD that can lead to loss of peritoneal membrane function and are often associated with poor outcomes including prolonged hospitalization, and eventual PD discontinuation. The definitions are presented in Table 5.[184] The distinctions are made based on the hypothesis that the pathogenesis, management, and outcomes of these entities are likely different.

Relapsing peritonitis follows approximately 5–20% of primary peritonitis episodes in adult and pediatric series.[48,157,314] The largest pediatric experience with relapsing peritonitis has come from the IPPR where out of 490 episodes of non-fungal peritonitis, 52 were followed by a relapse, for a relapse rate of 11%.[37] Recurrent peritonitis is less common than relapsing peritonitis. A multicenter registry study of over six thousand adult PD patients showed that an episode of peritonitis occurring within 4 weeks of completion of treatment of a prior episode is 2 times more likely to be a relapse than a recurrence (14% vs. 6%).[314]

Relapsing, recurrent and repeat peritonitis episodes may be caused by different spectra of bacteria.[314–318] The diagnosis of a relapse / repeat peritonitis episode should not rely solely on the genus and species, but also on the antibiotic susceptibilities of the cultured organism. When available, strain identity can be confirmed by genotype analysis. Gram-positive organisms, *Staphylococcus aureus* and coagulase-negative Staphylococci, are more commonly responsible for episodes of relapsing and repeat peritonitis.[314,316,317] In the IPPR experience, there was no significant difference in the distribution of causative organisms between cases of relapsing peritonitis and non-relapsing peritonitis. Overall, relapsing episodes consisted of 46% gram-positive organisms, 21% gram-negative organisms and 33% culture-negative cases.[37]

The most recent data from the IPPN registry shows that in 217 (8.9%) of 2425 peritonitis episodes, PD had to be discontinued. Slightly more than one-quarter (25.8%) of the latter cases were either recurrent (n = 22; 10%), repeat (n = 20; 9%) or relapsing (n = 14; 6.4%) episodes. Additionally, while the incidence of recurrent peritonitis (5%) was half that of relapsing or repeat episodes, the rate of PD discontinuation was more than double (19.6%) following recurrent peritonitis compared to relapsing or repeat infections.[168]

Additional Considerations: A biofilm inside the dialysis catheter and tunnel infections are common sources of relapsing/repeat peritonitis, thus often resulting in the need for catheter removal and replacement. Occasionally, early relapse with identical bacterial species but with a different susceptibility pattern may be seen secondary to antimicrobial resistance acquired during the antibiotic treatment, especially if there has been sub-therapeutic antibiotic dosing or an inadequate duration of therapy.

Guidelines 16.2 and 16.3: After an initial episode of peritonitis, the presentation associated with a subsequent episode, whether it be characterized as relapsing, recurrent, or repeat, is usually clinically indistinguishable from the initial episode and the causative organism is unknown until culture results are available. Therefore, management should be initiated in accordance with standard empiric therapy recommendations and the center specific protocol, with consideration of the susceptibilities of the bacteria causing the original episode. In a large single center retrospective study of relapsing (n = 157) and recurrent (n = 125) episodes of peritonitis in adults, empiric vancomycin usage was found to be superior to cefazolin (primary response rate 96.1% vs 70.6%; p < 0.001), especially when the previous episode was caused by a gram-positive organism. Similarly, for gram-negative organisms, empiric use of ceftazidime when compared to an aminoglycoside was associated with a significantly higher primary response rate (82.3% vs 62.5%; p = 0.02).[315]

Post-empiric antibiotic therapy should be guided by in vitro susceptibility results. Based on prior IPPR data, the subsequent prescription of monotherapy with a first-generation cephalosporin based on culture and susceptibility results was associated with a higher relapse rate (23% vs. 0 to 9%; p = 0.02) compared to other antibiotic choices.[37] However, it is speculated that these inferior results associated with cefazolin monotherapy could have resulted from the use of intermittent vs. continuous therapy, as well as suboptimal antibiotic dosing in that cohort of patients. Nonetheless, it is suggested that there be close monitoring of clinical response in patients with relapsing peritonitis being treated with cefazolin monotherapy.

Additional Consideration: A single center observational study found that the risk of treatment failure, and recurrent and relapse peritonitis for gram-positive or culture-negative peritonitis was higher in patients with greater residual kidney function compared with anuric patients.[319] As these outcomes could possibly be secondary to subtherapeutic levels of the antibiotics because of increased clearance, we suggest close monitoring of the clinical response in these patients who may be at greater risk for relapsing / repeat peritonitis.

Guideline 16.4: The recommended duration of antibiotic therapy of relapsing and repeat peritonitis episodes is primarily based on observational studies. The recommendations are intended to achieve the right balance between treating peritonitis for a sufficient length of time to minimize the risk of relapse or treatment failure, but short enough

to minimize the risks of promoting antimicrobial resistance and antibiotic related adverse effects. A randomized controlled study showed that extending the antibiotic treatment duration for an additional week beyond that recommended by the ISPD was not advisable because such a strategy did not reduce the risk of relapsing or repeat peritonitis; in fact, it may be associated with a higher risk of repeat peritonitis (15% vs 5.5%, p = 0.01).[320] In addition, prolonging the antibiotic therapy is associated with a higher risk of developing fungal peritonitis.[320] Finally, data from the IPPN registry showed that extended treatment duration in 79 episodes of peritonitis resulted in only a negligible (94% vs. 92%) advantage in terms of continuation of PD therapy when compared with 110 cases treated for the standard duration.[168] Thus, in general, the workgroup does not suggest increasing the duration of antibiotic treatment for relapsing or repeat episodes of peritonitis, beyond that recommended for the original episode.

In contrast, in a retrospective evaluation of 232 peritonitis episodes in adults caused by coagulase negative Staphylococci (CoNS), Szeto et al. found that compared with the conventional 2-week treatment course, 3 weeks of antibiotic therapy for relapsing or repeat episodes was associated with a significantly higher complete cure rate (83.3 vs 46.7%; p = 0.047).[232] However, data from the IPPN failed to show similar results in children as there was no statistical difference between 15 episodes of coagulase negative Staphylococcus (CoNS) relapsing peritonitis treated for a median of 2 weeks compared to 20 episodes treated for a median of 3 weeks (80% vs. 73%; p = 0.64).

Additional Considerations: While there is no laboratory test to accurately predict relapsing peritonitis episodes after completion of antibiotic treatment, bacterial DNA fragment levels in PD effluent have been found to be significantly higher 5 days prior to the completion of antibiotics among patients who subsequently developed relapsing peritonitis in contrast to those who experienced complete cure.[321]

Guideline 16.5: The first episode of relapsing or repeat peritonitis in which a tunnel infection / intra-abdominal abscess has been carefully ruled out, can be treated with IP antibiotics with or without the use of fibrinolytic agents. However, catheter exchange should be strongly considered for relapsing or repeat peritonitis in the presence of an associated tunnel infection/intra-abdominal abscess, peritonitis caused by *Pseudomonas aeruginosa*, *Staphylococcus aureus*, or a second episode of relapsing/repeat peritonitis secondary to any bacteria. The threshold for catheter exchange should be lower for episodes of relapsing/repeat peritonitis that are culture-negative. In cases of relapsing peritonitis, management with catheter exchange has been shown to be superior to intraluminal fibrinolytic agents in terms of the risk of treatment failure.[322,323] Data from the IPPN registry suggests that catheter removal, when compared to conservative treatment, is associated with a reduced relapse rate (6% vs. 17%; p = 0.08), and a somewhat higher likelihood of PD continuation (96% vs. 91%; p = 0.29).[168]

Limitations: The evidence for a recommended duration of antibiotic therapy for relapsing, recurrent or repeat peritonitis is of low certainty and derived from observational data, registry reports or expert opinion, largely pertaining to the treatment of the initial episodes of peritonitis.

Research Recommendations

● Additional research should determine if extending (from 2 to 3 weeks) the therapy for relapse/repeat peritonitis secondary to coagulase-negative Staphylococci (CoNS) in children results in improved outcomes.

Guideline 17 – Adjunctive Therapy

17.1 We suggest that the use of IVIG be considered for adjunctive treatment in selected patients with repeated peritonitis episodes and/or associated sepsis and accompanying hypogammaglobulinemia **(2D).**

17.2 We suggest that cauterization using silver nitrate sticks, in addition to intensified local care with antiseptics (other than with povidone-iodine) and/or a local antibiotic cream be used for treatment of isolated exit-site granulation tissue **(Not Graded).**

17.3 Systemic antibiotics should not be used for treatment of isolated granulation tissue at the catheter exit site without features of infection **(Not Graded).**

Rationale

Guideline 17.1: Hypogammaglobulinemia is commonly encountered in PD patients, but the frequency varies significantly by age from 33% to 93% in different studies[324–326] 33% of PD patients with a mean age of 12 years showed low IgG levels in one study,[324] while another study showed that 23 of 26 (88%) infants demonstrated hypogammaglobulinemia in a longitudinal analysis.[327]

The role of low serum IgG levels as a potential risk factor for the development of peritonitis in patients receiving PD was evaluated in different case series involving infants and children with discrepant results. Although Neu et al. did observe a relationship between low serum IgG levels and the development of peritonitis, others did not.[324–327] The only available longitudinal study, which included a small sample size, demonstrated that the mean serum IgG levels of infants who developed peritonitis (n = 8) versus those who did not (n = 18) were not different (p = 0.39).[327] An adult prospective study showed that low serum IgG levels at the time of PD initiation predicted the occurrence of PD related peritonitis.[328] The mean IgG level at PD start was lower in patients who subsequently experienced peritonitis and an increased IgG level at PD onset was associated with a reduced risk of peritonitis.[328]

Significantly elevated IgG levels after IVIG therapy is evidence of the effectiveness of IVIG in correcting hypogammaglobulinemia in infants receiving PD.[327]

Additional Considerations: The frequent requirement of a hospital admission and an IV route for administration in an asymptomatic patient are limiting factors regarding the routine use of IVIG. The high cost and the associated lack of availability in some centers are additional barriers to this therapy.

Despite the scarcity of evidence, there are several other adjunctive therapies that may be considered. Bacteria trapped in biofilm are less susceptible to antibiotics, such that substantially higher concentrations (100–1000 times) of antibiotics are required to eradicate them.[329] Additionally, viable bacteria may also be engulfed by and persist in peritoneal mesothelial cells.[314] In turn, fibrinolytic agents (alteplase or urokinase) have been tried as a treatment designed to expose trapped bacteria within fibrin or biofilms to the action of the antibiotics. Adult randomized trials showed inconsistent results regarding the beneficial effect of adjunctive urokinase over standard antibiotic treatment in the management of refractory or relapsing peritonitis.[322,330–333] Two randomized controlled trials in adults failed to show any benefit of IP urokinase in the treatment of refractory or relapsing peritonitis in terms of the rates of complete cure, catheter removal, relapsing episodes, or overall mortality when compared to standard antimicrobial treatment..[330,331] However, one showed a benefit of urokinase in peritonitis resolution and the prevention of recurrences.[332] In particular for CoNS, intraluminal urokinase 100,000 IU for 2 hours and oral rifampicin 600 mg daily for 3 weeks, in addition to conventional antibiotics, resulted in a catheter salvage rate of 64%.[334] Similarly, the beneficial effect of adjunctive t-PA (6 mg/mL for 6 hours, multiple times) was observed in the treatment of repeated peritonitis episodes due to CoNS in four patients.[335] Another randomized trial, however, showed that simultaneous catheter removal and replacement was superior to IP urokinase in reducing relapsing peritonitis episodes.[322] Despite limited data, a Cochrane review concluded that for relapsing or persistent peritonitis, simultaneous catheter removal and replacement was better than urokinase at reducing treatment failure rates.[323]

In the only pediatric study, Klaus and colleagues successfully used intraluminal high-dose urokinase (5000 IU/mL) and antibiotic instillation in nine children with relapsing peritonitis. No second relapse occurred in the treated patients. In contrast, 75% of patients from an untreated historical control group experienced a second relapse.[333] In practice, installation of t-PA several times per week during peritonitis treatment to prevent recurrence of peritonitis in children with suspected biofilm may allow PD continuation without having to replace the catheter (B Begin, personal communication). However, its net effect in relapsing peritonitis to prevent treatment failure or persistent/recurrent infection remains unknown.

Thus, although there is no fully convincing pediatric data, prior to proceeding to catheter replacement, a trial of a fibrinolytic agent as part of the management of the first relapsing peritonitis episode not caused by fungi, *Pseudomonas aeruginosa* and *S. aureus*, and not explained by extraluminal pathology such as a tunnel infection or intra-abdominal abscess, may be considered.

Both urokinase and t-PA may be cheaper relative to the cost of catheter replacement. Regulations in the country and/or specific institution, availability of the agents, and insurance coverage may impact the decision regarding usage.

Several other adjunctive measures in the management of peritonitis include IP heparin, initial low fill volume for pain relief, analgesic usage, and icodextrin.

Heparin presumably has an inhibitory effect on fibrin clot formation and also has effects beyond anticoagulation, having antiangiogenic and antiinflammatory properties.[336] Although hypercoagulability and hypofibrinolysis were shown during CAPD peritonitis in a small pediatric patient group, it was not confirmed in a larger adult study.[337,338] Whereas the rationale for routine IP heparin (500 units/L IP) use in the treatment of peritonitis is not strong because of limited clinical evidence, it is often prescribed as an adjunctive option to prevent occlusion of the catheter with fibrin clot in severe peritonitis with turbid dialysate.

The fill volume can be slightly (<25%) lowered during the initial 24–48 h of therapy until clinical symptoms improve and then should subsequently be increased to the standard prescription to prevent a prolonged period of underdialysis. Some patients require analgesics for pain control. Pain not improved by alteration of the fill volume and the initiation of antibiotic therapy, or complicated by emesis and volume depletion, may mandate hospitalization.[2]

In the recent adult guideline, icodextrin use was suggested as a means to control volume overload during acute peritonitis. Since peritoneal permeability typically increases during peritonitis and reduced ultrafiltration may result in fluid overload, temporary use of hypertonic fluids or icodextrin solution during acute peritonitis have been suggested as potential interventions. In a randomized controlled study, the primary cure rate of peritonitis was similar between the icodextrin and original glucose-based dialysis solution treatment groups. However, volume status was better controlled in the icodextrin group.[339]

Guideline 17.2 and 17.3: Improper fixation of the PD catheter may cause excessive tension or trauma to the PD catheter exit-site and lead to the formation of granulation tissue. This may necessitate additional exit-site care because granulation tissue can be associated with breakdown of the exit site.[45] Treatment options include silver nitrate cauterization, topical chlorhexidine application and silver ion based dressing.[340,341] Exuberant granulation tissue can be cauterized with a silver nitrate stick to speed up the healing process and facilitate epithelialization. Cauterization should be restricted to granulation tissue only as accidental touching of the adjacent epithelium can

cause skin burns and pain.[45] One or two applications may be enough in acute cases. In chronic cases, weekly cauterization for several weeks (as long as the exuberant granulation tissue persists) may be necessary.

In a pilot trial in adults, 44 patients with exit-site granulation tissue were equally and randomly allocated to receive treatment with 2% aqueous chlorhexidine swabstick or silver nitrate cauterization. After 6 weeks of follow-up, both agents had similar success rates. Whereas use of the chlorhexidine swabstick was associated with a longer time to resolution of the granulation tissue (13 vs 33 days), both treatments were well tolerated by patients in terms of pain, burning sensation and skin discoloration.[340]

The presence of granulation tissue over the exit site without other features of infection does not typically require systemic antibiotic treatment. Intensified local care is usually effective, although local application of an antibiotic cream has also been recommended.[85]

There is scarce data on children pertaining to the management of exit-site granulation tissue. In one case series, 34 patients used antibacterial honey as a prophylactic agent in routine exit-site care. The effect of topical antibacterial honey as it relates to exit-site granulation tissue was evaluated in a subgroup comprised of 8 patients aged 6 months to 15 years. Although improvement in poor exit-site conditions was reported, only two of 8 patients had isolated exit-site granulation tissue; one was treated solely with medicinal honey and the other with medicinal honey and silver nitrate.[115]

Limitations: The recommendation regarding IVIG therapy is based on small observational studies and small case series. Despite an experience with repeated doses and higher concentrations of t-PA in adults as a strategy for the treatment and prevention of relapsing peritonitis, there are no specific dosing recommendations in children.

Research Recommendations

● In patients with repeated peritonitis episodes or in those with signs of sepsis, the use and efficacy of IVIG as an adjunctive agent to antibiotics should be evaluated.

● Further studies are needed to determine the long-term efficacy of fibrinolytic agents in treating and preventing relapsing peritonitis in pediatric PD patients.
● Future studies should evaluate the use of chlorhexidine swabstick as an alternative to silver nitrate to treat exit-site granulation tissue in children.

Guideline 18 – Catheter Removal and Replacement

18.1 We suggest removal of the PD catheter for refractory bacterial peritonitis (2D).

18.2 We suggest removal of the PD catheter following a diagnosis of fungal peritonitis (2D).

18.3 We suggest PD catheter removal in patients with an exit-site or tunnel infection in conjunction with peritonitis with the same bacteria (2D).

18.4 We suggest a minimum period of 2–3 weeks between PD catheter removal and insertion of a new catheter following fungal and refractory bacterial peritonitis (2D).

18.5 We suggest simultaneous removal and replacement of the PD catheter be considered after clearing of the peritoneal effluent (white blood cells < 100/mm3) following a second episode of relapsing bacterial peritonitis (2D).

18.6 We suggest simultaneous removal and replacement of the PD catheter be considered for management of a refractory exit-site or tunnel infection (2D).

Rationale

Guideline 18.1: Refractory peritonitis is defined as an episode of peritonitis with persistently cloudy bags or persistent dialysis effluent leukocyte count >100/mm^3, after 5 days of appropriate antibiotic therapy.[27] It should be noted that application of the term "appropriate antibiotic therapy" does not pertain to culture-negative peritonitis, where appropriateness of the antibiotic therapy remains uncertain. In most cases of peritonitis, clinical improvement is usually evident within 72 hours of initiation of appropriate antibiotic therapy, and bacterial peritonitis that fails to resolve

Table 6. Indications for PD catheter removal.

Approach to catheter	Indication	Reinsertion
Definite removal	Refractory bacterial peritonitis Fungal peritonitis ESI/TI in conjunction with peritonitis with the same organism	≥ 2–3 weeks
Simultaneous removal and replacement	Refractory ESI/TI (including P. aeruginosa) Relapsing peritonitis	
Relative removal	Repeat peritonitis Mycobacterial peritonitis Peritonitis with multiple enteric organisms because of intra-abdominal pathology or abscess (so called surgical peritonitis)	≥ 2- 3 weeks After 6 weeks Depends on clinical course of the patient; at least 2 −3 weeks

after 5 days of treatment is unlikely to respond to continued medical management and is an important indication for catheter removal (Table 6). Prolonging antibiotic therapy in an attempt to salvage the catheter is associated with an extended hospital stay, a higher risk of fungal peritonitis, the possibility of peritoneal membrane damage, and excessive mortality.[342–344] The same concerns hold true in the setting of refractory culture-negative peritonitis.

The suggestion that a cut-off of 5 days be used when making a decision regarding PD catheter removal should be considered as being somewhat arbitrary. Data from the IPPN registry showed that catheter removal at <7 days (vs. >7 days) was associated with a greater likelihood of PD continuation (100% vs. 91%; p = 0.05). The trajectory of the effluent white cell count and clinical course during the first five days of treatment should also be taken into consideration before making the decision to remove the catheter. There is substantial variation in the rate at which the PD effluent WBC count declines after antibiotic treatment initiation.[345,346] In a large observational study of 644 peritonitis episodes in adults, one-fifth of the cases showed a delayed response with a 34% reduction of effluent WBC count by day 5, and without the need for PD catheter removal.[346] Accordingly, the 2022 ISPD adult guidelines suggest, and we agree, that if the WBC count of the PD effluent is decreasing towards normal by day 5, PD catheter removal could be postponed.[27] On the other hand, the catheter should be removed sooner than 5 days if the patient's condition is deteriorating.

Additional Considerations: A lack of response to treatment after 5 days of treatment should be accompanied by repeat cultures and investigation for unusual pathogens when catheter removal is being considered.

While removal of the PD catheter in patients with refractory peritonitis will necessitate initiation of hemodialysis in most patients, this approach is necessary to prevent excess morbidity and mortality, and to possibly mitigate the possibility of long-term peritoneal membrane damage resulting from prolongation of ineffective therapy.

Guideline 18.2: Refer to Guideline 14.1 for Rationale.

Guideline 18.3: Peritonitis episodes associated with an exit-site and/or tunnel infection with the same bacteria are less likely to resolve, particularly if the infection is caused by *S. aureus* or *P. aeruginosa*.[97] Delaying catheter removal in such circumstances may result in refractory, relapsing or repeat peritonitis. Catheter removal, therefore, should be strongly considered, as the development of peritonitis indicates that the infection has extended along the length of the catheter, a situation extremely difficult to treat successfully with antimicrobial agents alone.[277,347] In a large retrospective study in adults, 13% (n = 87) of all episodes of peritonitis were associated with an exit-site and/or tunnel infection. Patients with a tunnel infection

were more likely to have their catheter removed for successful management of the peritonitis than patients with peritonitis associated with an exit-site infection (86% vs 58%). Infections associated with coagulase-negative Staphylococcus (CoNS) were, however, less likely to result in catheter removal compared with all other organisms (15% vs 82%).[97] In another large series of 104 *Pseudomonas* spp. peritonitis episodes, the presence of an exit-site infection secondary to *Pseudomonas spp.* was demonstrated to be a predictor of a poor therapeutic response of peritonitis to antibiotics alone, supporting the recommendation for catheter removal.[232]

As referred to above, although catheter removal should be considered in most cases when an exit-site and/or tunnel infection and peritonitis occur secondary to the same organism, the same aggressive approach might not be necessary when a catheter-related infection and peritonitis is attributable to coagulase negative Staphylococcus (CoNS). CoNS peritonitis is generally milder and is usually readily responsive to antibiotic treatment.[184,232]

Additional Considerations: For patients with simultaneous exit-site or tunnel infections and peritonitis, PD catheter removal should be followed by temporary HD with no attempted reinsertion of the PD catheter for at least 2 weeks following catheter removal and complete resolution of peritonitis.

Guideline 18.4: The optimal period between PD catheter removal for fungal infection or refractory peritonitis and insertion of a new PD catheter when an interval between the two procedures is deemed advisable is not known.[66] Observational studies have suggested that it should be a minimum of 2 to 3 weeks.[348] In the case of fungal peritonitis, a longer interval before reinsertion has also been suggested by some.[289,349] The optimal timing for placement of a new catheter is likely influenced by the causative organism responsible for the peritonitis episode and the severity of the infection leading to catheter removal.

Re-insertion of a new catheter should ideally be performed using a laparoscopic or mini-laparotomy approach so that adhesions can be directly visualized and addressed during the procedure. In all cases, recommendations regarding the duration of antibiotic therapy and the timing of catheter replacement may require modification based on the clinical response of the patient.

Additional Considerations: Assessment of the abdominal cavity for adhesions by computerized tomography (CT) or peritoneal scintigraphy and selective PD catheter reinsertion based on these results can increase the likelihood of a functional PD post-catheter replacement.[350,351]

Guideline 18.5: Simultaneous removal and replacement of a PD catheter as part of the management of relapsing peritonitis spares the patient creation of a temporary vascular access, the psychological and physical trauma associated with a change in dialysis modality, and a subsequent surgery for insertion of the new PD catheter. Patients with relapsing (and repeat) peritonitis secondary to all but a

select group of infectious etiologies (see below) are considered candidates for simultaneous removal and replacement of the catheter once the antibiotic treatment has resulted in resolution of the clinical signs of infection, and the dialysate leukocyte count is <100/mm^3. The procedure should be performed under continued antibiotic coverage. The infected catheter can be removed, and a new catheter placed simultaneously in the opposite lower quadrant. Following the procedure, changing the dialysis modality from CAPD to APD should be considered for several days while dialyzing only in the supine position to avoid or minimize the increase in IP pressure and the risk for leaks and hernias that occurs with the addition of a daytime exchange.

The removal and replacement procedure has been performed successfully in pediatric and adult patient populations.[39,352–355] In data collected by the Italian pediatric PD registry, simultaneous removal and replacement procedures were successfully performed in 76% of catheter removals.[67] In an adult study, simultaneous catheter removal and replacement was successful in all 22 patients with relapsing peritonitis.[354] In a small, randomized study, a recurrence rate of only 7% was associated with the use of this approach to treat recurrent CoNS and culture-negative peritonitis.[322] However, this procedure should not be attempted in patients with fungal peritonitis, active or refractory peritonitis, or with intra-abdominal adhesions.[348,356]

Regardless of the indication for simultaneous catheter removal and replacement, antibiotic therapy should be continued for 2–3 weeks after the procedure.[353–355] Most clinicians have chosen to insert the new catheter before removing the old catheter, but the alternative approach has been performed with similar results.[353–355]

Additional Considerations: Subsequent to removal of the PD catheter and prior to insertion of the new catheter, the patient should be re-prepped and draped, and new instruments should be used after gown and glove replacement.[355] The success of simultaneous catheter removal and replacement relies upon proper patient selection and experienced technical performance of the procedure.

Guideline 18.6: Exit-site infections sometimes fail to respond to antibiotic therapy, while tunnel infections are very often refractory to therapy. In general, the catheter should be removed if either infection does not respond to therapy or if it progresses after 2 weeks of antibiotic therapy. Simultaneous removal and replacement of the catheter under antibiotic coverage is suggested in this setting as it is generally a successful approach to manage the infection and because timely removal of the catheter can lower the risk of peritonitis.[357]

It is noteworthy that simultaneous catheter removal and replacement is recommended even for treatment of an ESI or tunnel infection secondary to *P. aeruginosa* that persists or progresses despite prolonged and appropriate antibiotic treatment. In a series comprised of 37 adult patients with refractory *P. aeruginosa* exit-site infection, simultaneous catheter removal and insertion of a new PD catheter without interruption of PD was successful in all patients.[357] Late recurrence of *P. aeruginosa* exit-site infection occurred in only 8% of the patients within the first year after the procedure.[357]

The advantages of the simultaneous removal and replacement of a PD catheter and the recommended post-procedure management for patients receiving CAPD are the same as discussed under Guideline 18.5.

Additional Considerations: In select patients with a persistent exit-site or tunnel infection, surgical salvage interventions may be considered as an alternative to catheter removal and replacement as discussed in Guideline 20.

Limitations: Most of the supporting evidence for Guideline 18 is based on observational studies in adult patients. Additionally, there are no long-term studies that have systematically evaluated the relationship between the timing of catheter removal for refractory infection and PD outcome. There are also no trials in adults or children that have studied or determined the optimal duration between PD catheter removal and reinsertion.

Research Recommendations

● Data should be collected to help determine the optimal timing of catheter removal in patients with refractory peritonitis as it relates to preservation of peritoneal membrane function.
● Future research should be carried out to help define the optimal duration between catheter removal and insertion of a new catheter when simultaneous removal and replacement is contraindicated.

Guideline 19 – Diagnosis of Catheter-Related Infection

19.1 We suggest that catheter-related infection (exit-site and tunnel) rates, including organism-specific rates, be separately reported (Not Graded).

Table 7. Exit-site scoring system.[183]

	Score*		
	0	1	2
Swelling	No	Exit-site only (< 0.5 cm)	Including part of or entire tunnel
Crust	No	< 0.5cm	> 0.5cm
Redness	No	< 0.5cm	> 0.5cm
Pain on pressure	No	Slight	Severe
Secretion	No	Serous	Purulent

* In the presence of pericatheter swelling, redness, and tenderness, Infection should be assumed with a cumulative exit-site score of 4 or greater.

19.2 We suggest that an objective scoring system be used to monitor the status of the PD catheter exit site (2D).

19.3 We suggest that a PD catheter insertion-related exit-site and/or tunnel infection be defined as an episode of exit-site or tunnel infection that occurs within 30 days of PD catheter insertion (Not Graded).

19.4 We suggest that a definitive diagnosis of a catheter exit-site infection be made in the presence of purulent discharge at the catheter-epidermis interface (2C).

19.5 We suggest that a tunnel infection be defined by the presence of redness, edema, and tenderness along the subcutaneous portion of the catheter with or without ultrasonographic evidence of a pericatheter fluid collection and with or without purulent drainage from the exit site (2C).

Rationale

Guideline 19.1: Catheter exit site (ESI) and tunnel infections (TI) are important risk factors for PD-associated peritonitis and should be closely monitored in PD programs. 203 PD patients >18 years of age who were followed over 18 months showed that patients who had an ESI had a significantly higher risk of developing peritonitis within 30 days, even if the ESI was appropriately treated. This risk was maximal early on and diminished with time, with hazard ratios of 11.1 at 15 days and 4.9 at 60 days, respectively.[358] In the evaluation of 207 ESIs in 124 children on PD, the median time to ESI was 392 days, ESIs were least frequent in children younger than two years, and children aged 6–12 years were overrepresented among those who experienced an ESI. Catheter characteristics and the presence of a gastrostomy did not influence the rate of infection. Peritonitis developed in only 6% of instances.[35] However, earlier data showed that compared with children not having an ESI or TI, those with such an infection had twice the risk of developing peritonitis or requiring catheter revision, and thrice the risk of hospitalization for catheter-related complications.[32]

A SCOPE collaborative report showed that cultures were obtained in 83% of ESIs, with 92% of cultures growing bacterial isolates. Methicillin-susceptible *S. aureus (MSSA)* was the most common organism (35%), followed by *Pseudomonas* spp. (18%). Methicillin-resistant *S. aureus* (MRSA) occurred in 6.5% of isolates. Culture-negative cases have accounted for 8–11% of infections in pediatric and adult series.[35,358] Catheter-related infection rates should be determined as the organism-specific number of ESI or TI episodes divided by the number of patient years at risk, reported as episodes per patient year. Time at risk begins immediately after PD catheter insertion, irrespective of whether or not PD is being performed. Organism-specific reporting will help guide treatment strategies including empiric antibiotic selection, and will facilitate continuous quality improvement activities.[45]

Guideline 19.2: There have been two scoring systems proposed to monitor exit-site appearance, one by Twardowski et al. and the other by Schaefer et al. in association with the Mid-European Pediatric Peritoneal Dialysis Study Group (MEPPS) (Table 7).[183,359] The former evaluates the presence, absence, intensity, and/or characteristics of specific exit-site attributes such as swelling, color, crust, drainage, granulation tissue, and epithelium in the sinus.[359] Application of the Twardowski et al. criteria in 50 adult PD patients showed a specificity of 100%, but a sensitivity of only 63.6% in diagnosing an ESI.[360] The latter system proposed by pediatric nephrologists is more practical and is commonly used in children. Compared to clinical judgment, the criteria used had a sensitivity of 90% and a specificity of 97% in diagnosing an ESI in a small patient group.[361] In the presence of pericatheter swelling, redness, and tenderness, an ESI should be assumed with a cumulative exit-site score of 4 or greater and a TI with a score of 6 or greater. A score of less than 4 may or may not represent an infection.[183] The combination of swelling, pain, and drainage increased the sensitivity, specificity, and likelihood ratio. By contrast, the presence of crust or redness may not always indicate infection.[362] Even though the pediatric scoring system has not been validated, it allows a standardized assessment of the exit site both acutely and longitudinally. Additionally, it may have a predictive value. Data from the SCOPE collaborative showed that an exit-site score greater than zero was associated with development of an ESI before the next follow up visit.[35] The higher the score, the higher the likelihood of developing an ESI within 8 weeks. In the IPPR experience, an exit-site score greater than 2 in patients with gram-positive peritonitis was associated with a higher likelihood of empiric antibiotic treatment failure 3 days after treatment initiation (odds ratio: 5.46; p < 0.05).[181]

On the other hand, the scoring system outlined by Twardowski et al. is based on photo images. Also, recent pediatric data from the SCOPE Collaborative demonstrated poor reproducibility of both exit-site scoring systems when used simultaneously by two experienced care providers, especially when at least one provider characterized the exit site as abnormal.[362] Agreement and disagreement rates were similar when using either the Schaefer et al. or the Twardowski et al. criteria. This has prompted recognition of the need for additional educational strategies targeted to providers to improve exit-site characterization, both by in person visual inspection and by commonly used smartphone photographs. Thus, any scoring system must complement —but not substitute for— clinical judgment. Despite its limitations, use of a scoring system continues to be suggested for regular monitoring of the exit site and for monitoring patient response to therapy.

Guideline 19.3: Infections occurring within 30 days after PD catheter placement are likely to be related to the surgical procedure and may be associated with different organisms and outcomes when compared to infections that arise later in the course of long-term PD. However, of 31 such infections in the SCOPE

Collaborative, methicillin-susceptible *S. aureus* (MSSA) was the most common organism (n = 8), followed by MRSA (n = 3).[363]

Guideline 19.4: Purulent drainage, by itself, is diagnostic of an ESI based on the commonly used pediatric scoring system and as indicated in the 2022 ISPD adult guidelines.[45,183] Redness or serous drainage may not always indicate an ESI, because pericatheter erythema may be secondary to an allergic reaction, mechanical trauma, or exit-site care. Granuloma or crust formation is also not specific to an ESI. Clinical judgment is therefore usually required to decide whether to initiate therapy or to carefully follow the patient. It is important to recognize that a positive culture is not required for the diagnosis of an ESI; a positive culture from an exit site that is not inflamed often indicates colonization and not infection. The decision about whether to initiate therapy or to follow carefully should be based on the combination of clinical judgment and repeated assessment of the exit site.[45,310]

Evaluation of 35, 354 exit-site assessments during the first year of dialysis in 3297 adult patients from 122 institutions revealed that the agreement between the diagnosis of an ESI based on purulent discharge and the clinical score comprised of hyperemia, edema, pain, scab, and granuloma was 60.6%. These data support the concept that the presence of purulent drainage is sufficient to diagnose an ESI, while the use of scoring systems using other clinical signs does not contribute a great deal more to the diagnosis, but provides a resource for longitudinal assessment of the exit- site appearance.[364] With more than 10,000 patient-months of follow-up data in children on PD, the SCOPE collaborative showed that a higher exit- site score at a routine follow-up visit was strongly associated with a subsequent ESI within 8 weeks. The percentage of visits that had a subsequent ESI increased from 0.8% to 7.4% if the exit site was scored 3, compared to 0 (9.25 times increase).[35]

Guideline 19.5: A tunnel infection (TI) is defined by the presence of inflammation (e.g., redness, edema, tenderness, and induration) along the subcutaneous portion of the catheter. Ultrasonographic evidence of either a superficial cuff infection or a hypoechoic collection along the tunnel tract is also frequently present.[85]

In the presence of an ESI, ultrasound evaluation allows for the diagnosis of a concomitant TI with greater sensitivity than by clinical parameters alone. A hypo/anechoic collection with a diameter of >1–2 mm, and a color Doppler signal located between the catheter wall/cuff and the surrounding tissues, supports the diagnosis of a TI.[365] In addition, ultrasound evaluation may help to more accurately distinguish TIs that will likely resolve with oral antibiotic therapy from those that may require a more aggressive therapeutic approach including intravenous antibiotic therapy, surgical revision of the tunnel or removal of the catheter.[365,366]

In children, 6–12% of ESIs attributable to *S. aureus* and *P. aeruginosa* are associated with a concomitant TI and subsequent peritonitis related to the catheter infection; in those cases, treatment of the catheter-related infection should be particularly aggressive, because the associated peritonitis episode can be resistant to treatment.[35,38] These particular organisms may also form a biofilm in the catheter, thereby precluding successful antibiotic management without catheter removal.[367]

Limitations: Evaluation of the PD catheter exit site remains subjective, is dependent on the observer and is often based on the use of a pediatric scoring system that has not been validated.

Table 8. Oral antibiotic recommendations for treatment of exit-site and tunnel infections.

Antimicrobial	Recommended dose	Dose frequency	Per-dose maximum
First choice			
Cephalexin	10 mg/kg/dose	Daily	500 mg
Dicloxacillin	6.25–12.5 mg/kg/dose	Four times per day	500 mg
Alternative choices:			
Amoxicillin/clavulanate	10–20 mg/kg/dose	Daily	875 mg
Ciprofloxacin	10–15 mg/kg/dose	Daily	500 mg
Clindamycin	10 mg/kg/dose	Three times daily	450 mg
Levofloxacin	10 mg/kg/dose	Every 48 h	500 mg
Linezolid[a]	10 mg/kg/dose	< 12 years: Three times daily ≥ 12 years: Twice daily	600 mg
Metronidazole	10 mg/kg/dose	Three times daily	500 mg
Rifampin[b]	5–10 mg/kg/dose	Twice daily	600 mg
Trimethoprim/Sulfamethoxazole	4–6 mg/kg/dose (based on Trimethoprim)	Daily	160mg
Fluconazole	6 mg/kg/dose	Every 24–48 h	400mg

[a]May consider reducing to 300 mg Q12hr after 72 hours if a prolonged duration (>10 days) is anticipated and patient is at risk for development of thrombocytopenia based on limited data.[410,411]
[b]Should not be used as monotherapy, or used routinely in areas in which tuberculosis is endemic.

Research Recommendations

● Studies should be conducted to assess the diagnostic accuracy of scoring systems in pediatric PD patients following targeted education of care providers.
● Strategies should be developed to improve the early detection of ESIs (i.e., by using automated image analysis and machine learning approaches).
● Prospective studies should assess the usefulness of ultrasonography to diagnose and follow catheter-related infections in pediatric patients.

Guideline 20 – Treatment of PD Catheter-Related Infection

20.1 We suggest empiric oral antibiotic treatment for PD catheter exit-site infection (ESI) with appropriate methicillin-susceptible *S. aureus* (MSSA) coverage, such as a first-generation cephalosporin or anti-staphylococcal penicillin, unless the patient has a prior history of infection or colonization with methicillin-resistant *S. aureus* (MRSA) or *Pseudomonas spp.*; in these cases we suggest the use of vancomycin (or clindamycin if prior isolates are susceptible) or an antipseudomonal antibiotic, respectively. Treatment should subsequently be modified as required based on culture results and susceptibilities **(Not Graded)**.

20.2 We suggest that in most cases, effective antibiotic treatment be continued for 7–14 days depending on the clinical response and microbiological results **(2D)**.

20.3 We suggest that an exit-site infection caused by *Pseudomonas* spp. be treated with at least 3 weeks of effective antibiotic therapy **(2C)**.

20.4 We suggest that an exit-site infection caused by Nontuberculous Mycobacteria (NTM) be treated in consultation with an infectious diseases specialist **(Not Graded)**.

20.5 We suggest that empiric oral antibiotic therapy with methicillin susceptible *S. aureus* (MSSA) coverage be initiated for treatment of a tunnel infection, unless the patient has a history of infection with MRSA or *Pseudomonas* spp., in which case empiric therapy should consist of IP vancomycin or an IP, oral or IV antipseudomonal antibiotic, respectively **(Not Graded)**.

20.6 We suggest that effective antibiotic therapy be administered for at least 3 weeks for any catheter tunnel infection **(2C)**.

20.7 Refractory catheter-related infection should be defined as an infection that has failed to resolve after 2 weeks of effective antibiotic therapy and intensified exit-site care **(Not Graded)**.

20.8 We suggest that surgical salvage interventions or catheter removal be conducted as part of the treatment for refractory catheter-related infections **(2D)**.

20.9 We recommend catheter removal if a catheter-related infection progresses to or occurs in conjunction with peritonitis due to the same organism **(1C)**.

Rationale

Guideline 20.1: Most ESIs are caused by methicillin-susceptible S. aureus (MSSA), followed by *P. aeruginosa*


Figure 6. Management algorithm for PD catheter exit-site and tunnel infections.
*add antifungal prophylaxis
**if nontuberculous mycobacteria, consult infectious diseases specialist for recommendations regarding antibiotic choice and duration of treatment

and methicillin-resistant S. aureus (MRSA).[35,368,369] Infections due to *Enterococcus spp.*, *E. coli*, *Klebsiella spp.*, and other gram-negative bacteria may also be seen. In patients with a colostomy, *Pseudomonas spp.* can be the leading isolated microorganism.[154]

Successful treatment of a catheter-related ESI is important because treatment failure may lead to catheter removal or peritonitis. In most cases, oral antibiotic therapy is effective (Table 8).[45,370,371] The ideal approach is to tailor the choice and duration of treatment based on susceptibility results and clinical response.

The empiric antibiotic regimen should primarily cover MSSA, favoring a first-generation cephalosporin or an antistaphylococcal penicillin. If the patient has a prior history of infection or colonization with MRSA, vancomycin (or clindamycin if known to be susceptible) can be used. To prevent development of resistance and vancomycin-associated adverse events, glycopeptides should be reserved for MRSA infections and not be used for routine treatment of ESIs secondary to other gram-positive bacteria. Despite the absence of high-quality evidence, oral rifampin may be added to the treatment of S. aureus infections that fail to improve or resolve promptly. Oral rifampin should never be given as monotherapy. In the case of a prior history of infection or colonization with *Pseudomonas* spp., antipseudomonal antibiotics are appropriate. Concomitant antifungal prophylaxis should be considered to mitigate the risk of fungal peritonitis.[27,45] (see Guideline 7)

Guideline 20.2: Clinical evaluation (inspection of drainage, tenderness and/or induration over the catheter pathway on palpation) and sometimes sonographic evaluation, is necessary to determine the intensity and the duration of treatment.[365]

Therapy should be continued until the exit site appears completely normal. The duration of antibiotic administration should balance the risk of recurrence due to incomplete bacterial eradication against the potential emergence of resistant strains from unnecessarily long antibiotic exposure. The recommended treatment duration should count from the day of initiation of effective antibiotic therapy based on susceptibility results. High quality data to guide optimal treatment durations are lacking. Consistent with IDSA guidelines for skin/soft tissue infections,[372] recent guidelines for management of ESIs in adults suggest adjusting the treatment duration based on clinical response; 7–10 days of effective antibiotic therapy is reasonable in most uncomplicated ESIs, except for those caused by *P. aeruginosa* and nontuberculous mycobacteria (NTM), if resolution of infection is confirmed by clinical evaluation at around 1 week following treatment initiation.[45,372] Data from a survey conducted by the Japanese Study Group of Pediatric Peritoneal Dialysis revealed that among 130 patients less than 15 years of age, the post-treatment relapse rate was 15%; the relapse rate was 40% among infections caused by MRSA.[373] Therefore, we suggest at

least 7 days of effective post-empiric antibiotic treatment in uncomplicated ESIs, if there is a good clinical response. If there is a lack of resolution after 7 days of therapy, administration of the effective antibiotic for 2 weeks is reasonable (Figure 6).

Treatment of an ESI will also likely benefit from an increased frequency of exit-site care and at least daily ESI inspection and cleansing as long as purulent discharge continues; however, there is no evidence-based data to support this practice. This approach does facilitate early recognition of worsening infection, including the development of a tunnel infection, and review of the need for additional therapeutic options. Granulomas over the exit site may require additional exit-site care because they are associated with exacerbated breakdown of the exit site.

Guideline 20.3: If there is a history of *P. aeruginosa,* empiric antibiotic therapy with antipseudomonal coverage should be started.[2,45] The formation of biofilm by this bacteria lowers the efficacy of antibiotic therapy, increasing the risk for relapse, progression to peritonitis, and the necessity of catheter removal.[2,45,374–377] An ESI or TI secondary to *P. aeruginosa* should be treated according to susceptibilities with either an IP antipseudomonal beta lactam or an oral fluoroquinolone. In patients with a satisfactory response, 3 weeks of antibiotic therapy is suggested (Figure 6). However, if complete clinical remission is not achieved by 3 weeks, the catheter should be removed and extended trials of antibiotic treatment should be avoided since there is no convincing evidence that a longer duration of therapy mitigates the risk of relapse and/or progression to peritonitis.[375,376] In an adult study in which 14 episodes of *P. aeruginosa* ESI were treated for at least 14 days with oral ciprofloxacin and/or intraperitoneal gentamicin or ceftazidime plus topical gentamicin, only 50% achieved resolution without recurrence or peritonitis, supporting a low threshold for catheter removal and replacement in refractory cases.[377]

Guideline 20.4: Diagnosis and management of NTM ESI is complex. When suspected, examination for acid-fast bacilli by Ziehl–Neelsen staining and culture on specific media should be requested. Antibiotic regimens usually require multiple agents and selection depends on the specific causative organism and its antimicrobial susceptibilities. The optimal duration of treatment is essentially unknown, but NTM skin/soft structure infections often require months of therapy. Consultation with an infectious diseases specialist for both antibiotic selection and treatment duration is recommended. In many cases, especially in patients failing to respond to therapy, management requires removal of the catheter.[45]

Guideline 20.5: The route of antibiotic administration for treatment of TIs can be oral, IP, or IV.[2,45] An empiric first-generation cephalosporin or an antistaphylococcal penicillin can initially be prescribed and subsequently adjusted based on culture and susceptibility results. For management of a TI in a patient with a history of MRSA,

we suggest empiric therapy with IP or IV vancomycin. For management of a TI in patients with history of *Pseudomonas* spp., we suggest empiric treatment with an IP, IV or oral antipseudomonal antibiotic. Tunnel ultrasonography is useful not only in detecting an occult TI in patients with clinical features of an isolated ESI, but also in evaluating the response to therapy. A treatment-refractory and persistent fluid collection around the catheter may support the need for surgical intervention.[365,378]

Guideline 20.6: There are no high-quality data identifying the optimal duration of therapy for TIs. Because of the increased severity of a TI relative to an ESI, and the presumed higher risk of peritonitis and subsequent catheter loss, these infections are generally treated with longer durations of antibiotics, at least 3 weeks, irrespective of the underlying organism.[365,378,379]

Guidelines 20.7, 20.8 and 20.9: A refractory catheter-related infection is defined as an infection that fails to respond after 2 weeks of effective antibiotic therapy and intensified exit-site care. Refractory catheter-related infections require surgical salvage interventions or catheter removal and should raise suspicion for atypical pathogens, including NTM.[45]

In cases without inner cuff involvement and without accompanying peritonitis, catheter salvage interventions can be attempted.[368] Adult studies have shown that simultaneous removal and reinsertion of the peritoneal dialysis catheter in the opposite quadrant is an acceptable surgical intervention with negligible recurrences rates when conducted for treatment of a refractory ESI or TI (see Guideline 18.6). The rate of ESI refractoriness to conservative treatment leading to catheter removal is highest in cases caused by Mycobacteria (up to 40%), *S. aureus* (35%), and *P. aeruginosa* (28%).[380] Patients with an ESI due to *P. aeruginosa* and those with tunnel

infections may benefit from being kept on antibiotics for 1–2 weeks post catheter salvage procedure to decrease the risk for a relapse.[354,357,381]

Catheter removal is suggested when catheter infection occurs simultaneously with peritonitis due to the same organism, with no attempted reinsertion of the PD catheter until at least 2 weeks after catheter removal and complete resolution of peritonitis. Catheter salvage procedures should not be attempted in these cases.

Limitations: There are no adequately conducted studies on the treatment duration of ESI and/or TI. There is also little data to help define the optimal timing of reinsertion of a PD catheter removed for treatment of infection.

Research Recommendations

● Adequately powered trials to better define the optimal treatment durations for exit-site and tunnel infections by specific microorganisms.
● Assessment of minimum waiting times for catheter reinsertion following removal due to a refractory exit-site or tunnel infection.
● Contribution of point-of-care ultrasound assessment for monitoring treatment response to antibiotic treatment of tunnel infection.

Guideline 21 – Evaluation of Primary Response

21.1 We suggest that in addition to visual inspection of the dialysis effluent for cloudiness, an objective standardized measure, such as the Disease Severity Score, be used to monitor clinical response at 72 hours after initiation of antibiotic therapy **(2D).**

Rationale

Guideline 21.1: Monitoring the clinical response to antibiotic therapy may provide important information to help guide therapy and further evaluation while culture results are awaited, or in the face of culture-negative peritonitis. Improvement in patient symptoms (e.g., a decline in pain and fever) and clearing of effluent cloudiness at 72 hours is, in most cases, evidence of successful therapy.

In some cases, use of objective, standardized response criteria can be helpful to avoid unnecessary premature changes of treatment and to rather promptly detect an insufficient treatment response. As noted in Guideline 8.2, a prospective randomized study of 168 episodes of peritonitis in 152 pediatric PD patients used a Disease Severity Score (DSS) to monitor clinical response.[183] The DSS was defined as the sum of points for pain and fever (Table 9) and the study demonstrated excellent agreement between improvement in the DSS score and final patient outcome. More recently, the IPPN has evaluated a modified DSS associated with

Table 9. Disease severity score.[183]

Score	Meaning
Pain (0–3)	
0	None
1	Moderate pain or nausea not requiring specific therapy
2	Severe pain, usually requiring analgesic therapy, or vomiting
3	Peritoneal pain with tense abdomen, or paralytic bowel, or both
Fever (0–2)	
0	< 37.5°C
1	37.5–38.9°C
2	> 38.9°C
Total (0–5)*	Sum of pain and fever

* Recent DSS calculations by IPPN based on 0–2 points for pain and 0–2 points for fever

1060 episodes of peritonitis at 3 days after treatment initiation, in which along with assessment of effluent cloudiness, 0–2 points could be given for abdominal pain and fever, respectively. A good clinical response was characterized by a DSS <=2 and clear effluent, while complete resolution was associated with a DSS = 0 with clear effluent. Full functional recovery, as defined by continuation of PD without functional impairment, occurred in 88.6% of episodes with a good 3-day response vs. 76% of those with a poor 3-day response (p < 0.0001).[168]

Limitations: The subjective assessment of abdominal pain can influence the reproducibility of the DSS.

Research Recommendation

● Data should be collected regarding the relationship between treatment modifications based on the 3-day DSS and patient outcome.

Guideline 22 – Monitoring of Infection Rates and Risk Factor Assessment

22.1 Every program should monitor the incidence and outcomes of peritonitis and exit-site infection on at least an annual basis to inform quality improvement activity **(Not Graded).**

22.2 The parameters monitored should include the PD-related peritonitis and exit-site infection rates, organism-specific peritonitis and exit-site infection rates, antimicrobial susceptibilities of the infecting organisms, and peritonitis outcomes **(Not Graded).**

22.3 The rate of peritonitis and exit-site infections should be reported as the number of episodes per patient-year **(Not Graded).**

22.4 Culture-negative peritonitis should be reported as a percentage of all peritonitis episodes per unit time **(Not Graded).**

22.5 An apparent cause analysis (ACA) should be conducted following each peritonitis episode **(Not Graded).**

22.6 We suggest that the overall peritonitis rate should be no more than 0.4 episodes per year, the proportion of culture-negative peritonitis episodes should be less than 15% of all peritonitis episodes and < 5% of PD catheter insertions should be followed by peritonitis within 30 days of catheter insertion **(Not Graded).**

Rationale

Guidelines 22.1 and 22.2: Programs should carefully monitor all PD related infections, both exit-site and peritonitis, as part of a continuous quality improvement program.[27,382–386] Causative organisms and their antibiotic susceptibilities and the patient outcomes should be reviewed by the entire dialysis team including physicians, nurses,

advanced practice nurses, infection prevention and infectious disease personnel and others involved in the provision and oversight of peritoneal dialysis care. The collection and sharing of these data can contribute to a better understanding of infection related morbidity in the program and help determine the optimal center specific empiric antibiotic therapy.

Guideline 22.3: The calculation of peritonitis and exit-site infection episodes per year at risk is conducted by totaling all the days on PD for the center's patient population, converting that total to years at risk starting from the time of PD commencement, and using the converted value as the denominator of the fraction.[2,27] In both the pediatric and adult guidelines, PD commencement is defined as the first day during which the first PD exchange was performed with the intention of continuing long-term PD therapy.[2,27] Relapsing episodes should be counted as a single episode of peritonitis when the rate is calculated, in contrast to recurrent and repeat episodes which should be counted as another episode.

Guideline 22.4: Culture-negative peritonitis accounts for a substantial percentage of the peritonitis episodes that occur in children. The SCOPE collaborative has demonstrated variable rates of culture-negative peritonitis in their participating sites, with 27% of 620 peritonitis episodes that occurred over 5.5 years being culture-negative .[185] Most notable was the finding that there was great variability in the culture technique and other laboratory procedures practiced at the center laboratories which may have contributed to a culture negative rate far greater than the desired benchmark rate of < 15%. Similar findings have been documented in adult programs.[188] Documentation of an elevated rate and the possible reasons for it, prompted attention to potential risk factors, and the development of a PD effluent culture bundle by SCOPE.

Guideline 22.5: The process by which the presumed cause for an episode of peritonitis is sought is important for the individual patient as well as for the center's quality improvement program. It is essential that a review of all potential risk factors be conducted, with contributions from physicians, nurses, advance practice nurses, infection prevention experts and infectious disease physicians, as well as the patient and family members. The dialysis team should conduct a formal review, or apparent cause analysis (ACA), of each infection in search for causation.[386,387] A tool to help carry out an ACA has been developed by the SCOPE collaborative (Figure S3). Identification will permit appropriate intervention for the patient who experienced an infection and potentially other patients cared for in the program.[27,385]

Guideline 22.6: The *ISPD peritonitis guideline recommendations: 2022 update on prevention and treatment for adult patients* recommend that in centers in which the culture-negative peritonitis rate exceeds 15% of peritonitis episodes, sampling and culture techniques should be reviewed with the dialysis staff and the laboratory.[27] Data collected by the IPPN and SCOPE reveal that 22% and 23% of pediatric dialysis programs, respectively achieve a

culture-negative peritonitis rate of less than 15%, which supports the establishment of 15% as the culture negative benchmark for pediatric PD programs as well.[388,389] The IPPN data is derived from the 50 largest IPPN participating centers, while the SCOPE data are based on those centers which have experienced >10 peritonitis episodes.

SCOPE has also determined overall annualized peritonitis rates by age and found them to be 0.40 based on 342 infections in children < 2 years, and 0.37 based on 1191 infections in children 2 years of age and greater. The IPPN found an annualized rate of 0.32 based on 2183 infections in children > 2 years of age. Thus, like the *ISPD peritonitis guideline recommendations: 2022 update on prevention and treatment for adult patients,* we suggest that the overall peritonitis rate be no more than 0.40 episodes per year at risk.[27]

The *ISPD Catheter-related Infection Recommendations: 2023 Update for adult patients* state that the proportion of PD catheter insertion related infections within 30 days of PD catheter insertion should be less than 5% of all catheters inserted.[45] When this frequency is exceeded, the surgical and medical teams should closely evaluate operative and post-operative management, ideally incorporating quality improvement principles. Data collected from SCOPE also revealed that less than 5% of PD catheter insertions were followed by peritonitis within 30 days, prompting a similar benchmark for pediatric PD programs, and the recommendation for similar actions should the benchmark be exceeded.[389]

Research Recommendations

● Further research should be conducted to better define risk factors for peritonitis and potential mitigation strategies through the assessment of ACAs.

Acknowledgements

Declaration of conflicting interests

Funding

ORCID iDs

Bradley A Warady https://orcid.org/0000-0003-1812-6587
Rebecca Same https://orcid.org/0000-0003-0337-1168
Peter Nourse https://orcid.org/0000-0002-5456-4456
Qian Shen https://orcid.org/0000-0003-3056-6737
Valerie Smith https://orcid.org/0009-0006-2711-6304

Supplemental material

Supplemental material for this article is available online.

References

1. Warady BA, Schaefer F, Holloway M, et al. Consensus guidelines for the treatment of peritonitis in pediatric patients receiving peritoneal dialysis. *Perit Dial int* 2000; 20: 610–624.
2. Warady BA, Bakkaloglu s, Newland j, et al. Consensus guidelines for the prevention and treatment of catheter-related infections and peritonitis in pediatric patients receiving peritoneal dialysis: 2012 update. *Perit Dial int* 2012; 32: S32–S86.
3. Guyatt GH, Oxman AD, Kunz R, et al. GRADE Guidelines: 2. Framing the question and deciding on important outcomes. *J Clin Epidemiol* 2011; 64: 395–400. 20101230.
4. Caring for Australians with Renal I. The Cari guidelines. Evidence for peritonitis treatment and prophylaxis: peritoneal dialysis-associated peritonitis in children. *Nephrology (Carlton)* 2004; 9: S45–S51.
5. Caring for Australians with Renal I. The Cari guidelines. Evidence for peritonitis treatment and prophylaxis: treatment of peritoneal dialysis-associated fungal peritonitis. *Nephrology (Carlton)* 2004; 9: S78–S81.
6. Chua A and Warady B. Chronic peritoneal dialysis in children, https://medilib.ir/uptodate/show/16400. 2023.
7. Ouzzani M, Hammady H, Fedorowicz Z, et al. Rayyan-a web and mobile app for systematic reviews. *Syst rev* 2016; 5: 20161205.
8. software Csr. Veritas Health Innovation. Melbourne. Australia. 2022.
9. Page MJ, McKenzie JE, Bossuyt PM, et al. The PRISMA 2020 statement: an updated guideline for reporting systematic reviews. *BMJ* 2021; 372: n71. 20210329.
10. Sterne JA, Hernan MA, Reeves BC, et al. ROBINS-I: a tool for assessing risk of bias in non-randomised studies of interventions. *BMJ* 2016; 355: i4919. 20161012.
11. Murad MH, Sultan S, Haffar S, et al. Methodological quality and synthesis of case series and case reports. *BMJ Evid Based Med* 2018; 23: 60–63. 20180202.
12. Schunemann HJ, Mustafa RA, Brozek J, et al. GRADE Guidelines: 21 part 1. Study design, risk of bias, and indirectness in rating the certainty across a body of evidence for test accuracy. *J Clin Epidemiol* 2020; 122: 129–141. 20200212.
13. Schunemann HJ, Mustafa RA, Brozek J, et al. GRADE Guidelines: 21 part 2. Test accuracy: inconsistency, imprecision, publication bias, and other domains for rating the certainty of evidence and presenting it in evidence profiles and summary of findings tables. *J Clin Epidemiol* 2020; 122: 142–152. 20200210.
14. Evidence Prime IIUM, editor. GRADEpro GDT. GRADEpro Guideline Development Tool [Software], 2015.
15. Beagley L. Educating patients: understanding barriers, learning styles, and teaching techniques. *J Perianesth Nurs* 2011; 26: 331–337.
16. Bernardini J, Price V, Figueiredo A, et al. Peritoneal dialysis patient training, 2006. *Perit Dial int* 2006; 26: 625–632.
17. Figueiredo AE, Bernardini J, Bowes E, et al. A syllabus for teaching peritoneal dialysis to patients and caregivers. *Perit Dial int* 2016; 36: 592–605. 20160225.
18. Administration HRS. Health Literacy. 2022.

19. Auguste BL, Girsberger M, Kennedy C, et al. Are adverse events in newly trained home dialysis patients related to learning styles? A single-centre retrospective study from Toronto, Canada. *BMJ Open* 2020; 10: e033315. 20200120.

20. Holloway M, Mujais S, Kandert M, et al. Pediatric peritoneal dialysis training: characteristics and impact on peritonitis rates. *Perit Dial Int* 2001; 21: 401–404.

21. Begin B, Richardson T, Ehrlich J, et al. Training practices and peritonitis rates in children on maintenance peritoneal dialysis: results from the Standardizing Care to Improve Outcomes in Pediatric End Stage Kidney Disease (SCOPE) collaborative. *Pediatr Nephrol* 2023; 38: 3401–3406. 20230425.

22. Kamath N, Borzych-Duzalka D, Kaur A, et al. Pediatric peritoneal dialysis training program and its relationship to peritonitis: a study of the International Pediatric Peritoneal Dialysis Network. *Pediatr Nephrol* 2023; 38: 4111–4118. 20230705.

23. Neu AM, Miller MR, Stuart J, et al. Design of the standardizing care to improve outcomes in pediatric end stage renal disease collaborative. *Pediatr Nephrol* 2014; 29: 1477–1484. 20140724.

24. Sethna CB, Bryant K, Munshi R, et al. Risk factors for and outcomes of catheter-associated peritonitis in children: The SCOPE collaborative. *Clin J Am Soc Nephrol* 2016; 11: 1590–1596. 20160623.

25. Ellis EN, Blaszak C, Wright S, et al. Effectiveness of home visits to pediatric peritoneal dialysis patients. *Perit Dial Int* 2012; 32: 419–423. 20110930.

26. Alhameedi RS CJ. How are families taught to look after their children on peritoneal dialysis? *Saudi J Kidney Dis Transpl* 2016; 27: 29–36.

27. Li PK, Chow KM, Cho Y, et al. ISPD peritonitis guideline recommendations: 2022 update on prevention and treatment. *Perit Dial Int* 2022; 42: 110–153.

28. Teo S, Yuen TW, Cheong CW, et al. Structured re-training to reduce peritonitis in a pediatric peritoneal dialysis program: a quality improvement intervention. *Pediatr Nephrol* 2021; 36: 3191–3200. 20210402.

29. NAPRTCS. Annual Dialysis Report https://naprtcs.org, 2011.

30. Keswani M, Redpath Mahon AC, Richardson T, et al. Risk factors for early onset peritonitis: the SCOPE collaborative. *Pediatr Nephrol* 2019; 34: 1387–1394. 20190409.

31. Borzych-Duzalka D, Aki TF, Azocar M, et al. Peritoneal dialysis access revision in children: Causes, interventions, and outcomes. *Clin J Am Soc Nephrol* 2017; 12: 105–112. 20161129.

32. Furth SL, Donaldson LA, Sullivan EK, et al. Peritoneal dialysis catheter infections and peritonitis in children: a report of the North American Pediatric Renal Transplant Cooperative Study. *Pediatr Nephrol* 2000; 15: 179–182.

33. Jones LL, Tweedy L and Warady BA. The impact of exit-site care and catheter design on the incidence of catheter-related infections. *Adv Perit Dial* 1995; 11: 302–305.

34. Zaritsky JJ, Hanevold C, Quigley R, et al. Epidemiology of peritonitis following maintenance peritoneal dialysis catheter placement during infancy: a report of the SCOPE collaborative. *Pediatr Nephrol* 2018; 33: 713–722. 20171117.

35. Swartz SJ, Neu A, Skversky Mason A, et al. Exit site and tunnel infections in children on chronic peritoneal dialysis: findings from the Standardizing Care to Improve Outcomes in Pediatric End Stage Renal Disease (SCOPE) Collaborative. *Pediatr Nephrol* 2018; 33: 1029–1035. 20180226.

36. Macchini F, Valade A, Ardissino G, et al. Chronic peritoneal dialysis in children: catheter related complications. A single centre experience. *Pediatr Surg Int* 2006; 22: 524–528. 20060516.

37. Lane JC, Warady BA, Feneberg R, et al. Relapsing peritonitis in children who undergo chronic peritoneal dialysis: a prospective study of the international pediatric peritonitis registry. *Clin J Am Soc Nephrol* 2010; 5: 1041–1046. 20100429.

38. Zurowska A, Feneberg R, Warady BA, et al. Gram-negative peritonitis in children undergoing long-term peritoneal dialysis. *Am J Kidney Dis* 2008; 51: 455–462.

39. Rinaldi S, Sera F, Verrina E, et al. The Italian registry of pediatric chronic peritoneal dialysis: a ten-year experience with chronic peritoneal dialysis catheters. *Perit Dial Int* 1998; 18: 71–74.

40. Debowski JA, Waerp C, Kjellevold SA, et al. Cuff extrusion in peritoneal dialysis: single-centre experience with the cuff-shaving procedure in five patients over a 4-year period. *Clin Kidney J* 2017; 10: 131–134. 20160916.

41. Crabtree JH, Shrestha BM, Chow KM, et al. Creating and maintaining optimal peritoneal dialysis access in the adult patient: 2019 Update. *Perit Dial Int* 2019; 39: 414–436. 20190426.

42. Gokal R, Alexander S, Ash S, et al. Peritoneal catheters and exit-site practices toward optimum peritoneal access: 1998 update. Official report from the International Society for Peritoneal Dialysis). *Perit Dial Int* 1998; 18: 11–33.

43. Eklund B, Honkanen E, Kyllonen L, et al. Peritoneal dialysis access: prospective randomized comparison of single-cuff and double-cuff straight Tenckhoff catheters. *Nephrol Dial Transplant* 1997; 12: 2664–2666.

44. Nessim SJ, Bargman JM and Jassal SV. Relationship between double-cuff versus single-cuff peritoneal dialysis catheters and risk of peritonitis. *Nephrol Dial Transplant* 2010; 25: 2310–2314. 20100126.

45. Chow KM, Li PK, Cho Y, et al. ISPD Catheter-related Infection Recommendations: 2023 Update. *Perit Dial Int* 2023; 43: 201–219. 20230526.

46. Gadallah MF, Mignone J, Torres C, et al. The role of peritoneal dialysis catheter configuration in preventing catheter tip migration. *Adv Perit Dial* 2000; 16: 47–50.

47. Lye WC, Kour NW, van der Straaten JC, et al. A prospective randomized comparison of the Swan neck, coiled, and straight Tenckhoff catheters in patients on CAPD. *Perit Dial Int* 1996; 16(Suppl 1): S333–335.

48. Schaefer F, Feneberg R, Aksu N, et al. Worldwide variation of dialysis-associated peritonitis in children. *Kidney Int* 2007; 72: 1374–1379. 20070919.

49. Popovich RP, Moncrief JW and Nolph KD. Continuous ambulatory peritoneal dialysis. *Artif Organs* 1978; 2: 84–86.

50. Daschner M, Gfrorer S, Zachariou Z, et al. Laparoscopic Tenckhoff catheter implantation in children. *Perit Dial Int* 2002; 22: 22–26.

51. Wasik HL, Keswani M, Munshi R, et al. Assessment of potential peritonitis risk factors in pediatric patients receiving maintenance peritoneal dialysis. *Pediatr Nephrol* 2023; 38: 4119–4125.

52. Lindley RM, Williams AR, Fraser N, et al. Synchronous laparoscopic-assisted percutaneous endoscopic gastrostomy and peritoneal dialysis catheter placement is a valid alternative to open surgery. *J Pediatr Urol* 2012; 8: 527–530. 20111022.

53. Wright MJ, Bel'eed K, Johnson BF, et al. Randomized prospective comparison of laparoscopic and open peritoneal dialysis catheter insertion. *Perit Dial Int* 1999; 19: 372–375.

54. Medani S, Hussein W, Shantier M, et al. Comparison of percutaneous and open surgical techniques for first-time peritoneal dialysis catheter placement in the unbreached peritoneum. *Perit Dial Int* 2015; 35: 576–585. 20140731.

55. Jwo SC, Chen KS, Lee CC, et al. Prospective randomized study for comparison of open surgery with laparoscopic-assisted placement of Tenckhoff peritoneal dialysis catheter–a single center experience and literature review. *J Surg Res* 2010; 159: 489–496. 20081009.

56. Ozener C, Bihorac A and Akoglu E. Technical survival of CAPD catheters: comparison between percutaneous and conventional surgical placement techniques. *Nephrol Dial Transplant* 2001; 16: 1893–1899.

57. Voss D, Hawkins S, Poole G, et al. Radiological versus surgical implantation of first catheter for peritoneal dialysis: a randomized non-inferiority trial. *Nephrol Dial Transplant* 2012; 27: 4196–4204. 20120718.

58. van Laanen JHH, Cornelis T, Mees BM, et al. Randomized controlled trial comparing open versus laparoscopic placement of a peritoneal dialysis catheter and outcomes: The CAPD I trial. *Perit Dial Int* 2018; 38: 104–112. 20180131.

59. Xie H, Zhang W, Cheng J, et al. Laparoscopic versus open catheter placement in peritoneal dialysis patients: a systematic review and meta-analysis. *BMC Nephrol* 2012; 13: 69. 20120727.

60. Hagen SM, Lafranca JA, Steyerberg EW, et al. Laparoscopic versus open peritoneal dialysis catheter insertion: a meta-analysis. *PLoS One* 2013; 8(e56351): 20130215.

61. Strippoli GF, Tong A, Johnson D, et al. Catheter-related interventions to prevent peritonitis in peritoneal dialysis: a systematic review of randomized, controlled trials. *J Am Soc Nephrol* 2004; 15: 2735–2746.

62. Htay H, Johnson DW, Craig JC, et al. Catheter type, placement and insertion techniques for preventing catheter-related infections in chronic peritoneal dialysis patients. *Cochrane Database Syst Rev* 2019; 5: CD004680. 20190531.

63. Agarwal A, Whitlock RH, Bamforth RJ, et al. Percutaneous versus surgical insertion of peritoneal dialysis catheters: A systematic review and meta-analysis. *Can J Kidney Health Dis* 2021; 8.

64. Shrestha BM, Shrestha D, Kumar A, et al. Advanced laparoscopic peritoneal dialysis catheter insertion: systematic review and meta-analysis. *Perit Dial Int* 2018; 38: 163–171.

65. Crabtree JH and Fishman A. A laparoscopic method for optimal peritoneal dialysis access. *Am Surg* 2005; 71: 135–143.

66. Flanigan M and Gokal R. Peritoneal catheters and exit-site practices toward optimum peritoneal access: a review of current developments. *Perit Dial Int* 2005; 25: 132–139.

67. Rinaldi S, Sera F, Verrina E, et al. Chronic peritoneal dialysis catheters in children: a fifteen-year experience of the Italian registry of pediatric chronic peritoneal dialysis. *Perit Dial Int* 2004; 24: 481–486.

68. Schuh MP, Nehus E, Liu C, et al. Omentectomy reduces the need for peritoneal dialysis catheter revision in children: a study from the Pediatric Nephrology Research Consortium. *Pediatr Nephrol* 2021; 36: 3953–3959. 20210614.

69. Sojo ET, Grosman MD, Monteverde ML, et al. Fibrin glue is useful in preventing early dialysate leakage in children on chronic peritoneal dialysis. *Perit Dial Int* 2004; 24: 186–190.

70. Htay H, Johnson DW, Craig JC, et al. Urgent-start peritoneal dialysis versus haemodialysis for people with chronic kidney disease. *Cochrane Database Syst Rev* 2021; 1: CD012899. 20210127.

71. Sardegna KM, Beck AM and Strife CF. Evaluation of perioperative antibiotics at the time of dialysis catheter placement. *Pediatr Nephrol* 1998; 12: 149–152.

72. Bennet-Jones D MJ, Barratt AJ, DuDy J, Naish PF and Aber GM. Prophylactic gentamicin in the prevention of early exit-site infections and peritonitis in CAPD. *Advances in Peritoneal Dialysis* 1988; 4: 147–150.

73. Wikdahl AM, Engman U, Stegmayr BG, et al. One-dose cefuroxime i.v. and i.p. reduces microbial growth in PD patients after catheter insertion. *Nephrol Dial Transplant* 1997; 12: 157–160.

74. Lye WC, Lee EJ and Tan CC. Prophylactic antibiotics in the insertion of Tenckhoff catheters. *Scand J Urol Nephrol* 1992; 26: 177–180.

75. Gadallah MF, Ramdeen G, Mignone J, et al. Role of preoperative antibiotic prophylaxis in preventing postoperative peritonitis in newly placed peritoneal dialysis catheters. *Am J Kidney Dis* 2000; 36: 1014–1019.

76. Campbell D, Mudge DW, Craig JC, et al. Antimicrobial agents for preventing peritonitis in peritoneal dialysis patients. *Cochrane Database Syst Rev* 2017; 4: CD004679. 20170408.

77. Harel Z, Wald R, Bell C, et al. Outcome of patients who develop early-onset peritonitis. *Adv Perit Dial* 2006; 22: 46–49.

78. Feng S, Wang Y, Qiu B, et al. Impact of early-onset peritonitis on mortality and technique survival in peritoneal dialysis patients. *Springerplus* 2016; 5: 1676. 20160929.

79. Twardowski ZJ and Prowant BF. Exit-site healing post catheter implantation. *Perit Dial Int* 1996; 16(Suppl 3): S51–S70.

80. Dombros N, Dratwa M, Feriani M, et al. European best practice guidelines for peritoneal dialysis. 3 Peritoneal access. *Nephrol Dial Transplant* 2005; 20(Suppl 9): ix8–ix12.

81. Prowant BF, Warady BA and Nolph KD. Peritoneal dialysis catheter exit-site care: results of an international survey. *Perit Dial Int* 1993; 13: 149–154.

82. Kopriva-Altfahrt G, Konig P, Mundle M, et al. Exit-site care in Austrian peritoneal dialysis centers – a nationwide survey. *Perit Dial Int* 2009; 29: 330–339.

83. Ding XR, Huang HE, Liao YM, et al. Daily self-care practices influence exit-site condition in patients having peritoneal dialysis: A multicenter cross-sectional survey. *J Adv Nurs* 2021; 77: 2293–2306. 20210111.

84. Chua AN, Goldstein SL, Bell D, et al. Topical mupirocin/sodium hypochlorite reduces peritonitis and exit-site infection rates in children. *Clin J Am Soc Nephrol* 2009; 4: 1939–1943. 20091009.

85. Szeto CC, Li PK, Johnson DW, et al. ISPD catheter-related infection recommendations: 2017 update. *Perit Dial Int* 2017; 37: 141–154.

86. Luzar MA, Brown CB, Balf D, et al. Exit-site care and exit-site infection in continuous ambulatory peritoneal dialysis (CAPD): results of a randomized multicenter trial. *Perit Dial Int* 1990; 10: 25–29.

87. Waite NM, Webster N, Laurel M, et al. The efficacy of exit site povidone-iodine ointment in the prevention of early peritoneal dialysis-related infections. *Am J Kidney Dis* 1997; 29: 763–768.

88. Wilson AP, Lewis C, O'Sullivan H, et al. The use of povidone iodine in exit site care for patients undergoing continuous peritoneal dialysis (CAPD). *J Hosp Infect* 1997; 35: 287–293.

89. Wang JLHSY, Chang MY, Wu YH and Wang HH. Daily chlorhexidine care at exit site in patients with peritoneal dialysis: a randomized control trial. *J Microbiol Imm Inf* 2015; 48: S57–58.

90. Mendoza-Guevara L, Castro-Vazquez F, Aguilar-Kitsu A, et al. Amuchina 10&per; solution, safe antiseptic for preventing infections of exit-site of Tenckhoff catheters, in the pediatric population of a dialysis program. *Contrib Nephrol* 2007; 154: 139–144.

91. Wadhwa NK, Cabralda T, Stratos J, Cascio C, Irwin C, et al. A randomized trial of Amuchina 10&per; versus povidone-iodine 10&per; solution for exit-site care/infection in peritoneal dialysis patients. *Perit Dial Int* 1995; 15: S1–64.

92. Wadhwa NKSH and Cabralda T. Amuchina 5&per; versus povidone-iodine 10&per; solution for exit-site care/infection in peritoneal dialysis patients. *Perit Dial Int* 1997; 17: S1–46.

93. Fuchs JGE, Jackson-Bey D, Krawtz D and Schreiber MJ. A prospective randomized study of peritoneal catheter exit-site care. *Nephrol Hypertens* 1990; 19: 81–84.

94. Piraino B. Staphylococcus aureus infections in dialysis patients: focus on prevention. *ASAIO J* 2000; 46: S13–17.

95. Blowey DL, Warady BA and McFarland KS. The treatment of Staphylococcus aureus nasal carriage in pediatric peritoneal dialysis patients. *Adv Perit Dial* 1994; 10: 297–299.

96. Kingwatanakul P and Warady BA. Staphylococcus aureus nasal carriage in children receiving long-term peritoneal dialysis. *Adv Perit Dial* 1997; 13: 281–284.

97. Gupta B, Bernardini J and Piraino B. Peritonitis associated with exit site and tunnel infections. *Am J Kidney Dis* 1996; 28: 415–419.

98. Swartz R, Messana J, Starmann B, et al. Preventing Staphylococcus aureus infection during chronic peritoneal dialysis. *J Am Soc Nephrol* 1991; 2: 1085–1091.

99. Bernardini J, Piraino B, Holley J, et al. A randomized trial of Staphylococcus aureus prophylaxis in peritoneal dialysis patients: mupirocin calcium ointment 2&per; applied to the exit site versus cyclic oral rifampin. *Am J Kidney Dis* 1996; 27: 695–700.

100. Bernardini J, Bender F, Florio T, et al. Randomized, double-blind trial of antibiotic exit site cream for prevention of exit site infection in peritoneal dialysis patients. *J Am Soc Nephrol* 2005; 16: 539–545. 20041229.

101. Chu KH, Choy WY, Cheung CC, et al. A prospective study of the efficacy of local application of gentamicin versus mupirocin in the prevention of peritoneal dialysis catheter-related infections. *Perit Dial Int* 2008; 28: 505–508.

102. Xu G, Tu W and Xu C. Mupirocin for preventing exit-site infection and peritonitis in patients undergoing peritoneal dialysis. *Nephrol Dial Transplant* 2010; 25: 587–592. 20090813.

103. Mahajan S, Tiwari SC, Kalra V, et al. Effect of local mupirocin application on exit-site infection and peritonitis in an Indian peritoneal dialysis population. *Perit Dial Int* 2005; 25: 473–477.

104. Lim CT, Wong KS and Foo MW. The impact of topical mupirocin on peritoneal dialysis infection in Singapore General Hospital. *Nephrol Dial Transplant* 2005; 20: 2202–2206. 20050726.

105. Obata Y, Murashima M, Toda N, et al. Topical application of mupirocin to exit sites in patients on peritoneal dialysis: a systematic review and meta-analysis of randomized controlled trials. *Ren Replace Ther* 2020; 6.

106. Piraino B, Bernardini J, Florio T, et al. Staphylococcus aureus prophylaxis and trends in gram-negative infections in peritoneal dialysis patients. *Perit Dial Int* 2003; 23: 456–459.

107. Mahaldar A, Weisz M and Kathuria P. Comparison of gentamicin and mupirocin in the prevention of exit-site infection and peritonitis in peritoneal dialysis. *Adv Perit Dial* 2009; 25: 56–59.

108. Pierce DA, Williamson JC, Mauck VS, et al. The effect on peritoneal dialysis pathogens of changing topical antibiotic prophylaxis. *Perit Dial Int* 2012; 32: 525–530. 20120201.

109. Wong PN, Tong GM, Wong YY, et al. Alternating mupirocin/gentamicin is associated with increased risk of fungal peritonitis as compared with gentamicin alone—results of a randomized open-label controlled trial. *Perit Dial Int* 2016; 36(3): 340–346.

110. Johnson DW, Badve SV, Pascoe EM, et al. Antibacterial honey for the prevention of peritoneal-dialysis-related infections (HONEYPOT): a randomised trial. *Lancet Infect Dis* 2014; 14: 23–30. 20131010.

111. Khandelwal M, Bailey S, Izatt S, et al. Structural changes in silicon rubber peritoneal dialysis catheters in patients using mupirocin at the exit site. *Int J Artif Organs* 2003; 26: 913–917.

112. Gardezi AI, Schlageter KW, Foster DM, et al. Erosion of the Silicone Peritoneal Dialysis Catheter with the Use of Gentamicin Cream at the Exit Site. *Adv Perit Dial* 2016; 32: 15–18.

113. Riu S, Ruiz CG, Martinez-Vea A, et al. Spontaneous rupture of polyurethane peritoneal catheter. A possible deleterious effect of mupirocin ointment. *Nephrol Dial Transplant* 1998; 13: 1870–1871.

114. Wong C, Luk IW, Ip M, et al. Prevention of gram-positive infections in peritoneal dialysis patients in Hong Kong: a cost-effectiveness analysis. *Am J Infect Control* 2014; 42: 412–416.

115. Forbes TA, Shaw L and Quinlan C. Topical Honey in the Management of Pediatric Peritoneal Dialysis Exit Sites. *Perit Dial Int* 2016; 36: 684–687.

116. Luzar MA. Peritonitis prevention in continuous ambulatory peritoneal dialysis. *Nephrologie* 1992; 13: 171–177.

117. Warady BA, Ellis EN, Fivush BA, et al. "Flush before fill" in children receiving automated peritoneal dialysis. *Perit Dial Int* 2003; 23: 493–498.

118. Garcia-Lopez E, Mendoza-Guevara L, Morales A, et al. Comparison of peritonitis rates in children on CAPD with spike connector versus two disconnect systems. *Adv Perit Dial* 1994; 10: 300–303.

119. Daly C, Cody JD, Khan I, et al. Double bag or Y-set versus standard transfer systems for continuous ambulatory peritoneal dialysis in end-stage kidney disease. *Cochrane Database Syst Rev* 2014; 2014: CD003078. 20140813.

120. Burkart JM, Hylander B, Durnell-Figel T, et al. Comparison of peritonitis rates during long-term use of standard spike versus Ultraset in continuous ambulatory peritoneal dialysis (CAPD). *Perit Dial Int* 1990; 10: 41–43.

121. Maiorca R, Cantaluppi A, Cancarini GC, et al. Prospective controlled trial of a Y-connector and disinfectant to prevent peritonitis in continuous ambulatory peritoneal dialysis. *Lancet* 1983; 2: 642–644.

122. wScalamognaA,DeVecchiA,CastelnovoC,etal.Long-termincidenceofperitonitisinCAPDpatientstreatedbytheYsettechnique: experienceinasinglecenter.*Nephron*1990;55:24–27.

123. Harris DC, Yuill EJ, Byth K, et al. Twin- versus single-bag disconnect systems: infection rates and cost of continuous ambulatory peritoneal dialysis. *J Am Soc Nephrol* 1996; 7: 2392–2398.

124. Kiernan L, Kliger A, Gorban-Brennan N, et al. Comparison of continuous ambulatory peritoneal dialysis-related infections with different "Y-tubing" exchange systems. *J Am Soc Nephrol* 1995; 5: 1835–1838.

125. Li PK, Szeto CC, Law MC, et al. Comparison of double-bag and Y-set disconnect systems in continuous ambulatory peritoneal dialysis: a randomized prospective multicenter study. *Am J Kidney Dis* 1999; 33: 535–540.

126. Monteon F, Correa-Rotter R, Paniagua R, et al. Prevention of peritonitis with disconnect systems in CAPD: a randomized controlled trial. The Mexican Nephrology Collaborative Study Group. *Kidney Int* 1998; 54: 2123–2128.

127. Cheng IK, Chan CY, Cheng SW, et al. A randomized prospective study of the cost-effectiveness of the conventional spike, O-set, and UVXD techniques in continuous ambulatory peritoneal dialysis. *Perit Dial Int* 1994; 14: 255–260.

128. Group CCCT. Peritonitis in continuous ambulatory peritoneal dialysis (CAPD): a multi-centre randomized clinical trial comparing the Y connector disinfectant system to standard systems. Canadian CAPD Clinical Trials Group. *Perit Dial Int* 1989; 9: 159–163.

129. Dryden MS, McCann M, Wing AJ, et al. Controlled trial of a Y-set dialysis delivery system to prevent peritonitis in patients receiving continuous ambulatory peritoneal dialysis. *J Hosp Infect* 1992; 20: 185–192.

130. Li PK, Chan TH, So WY, et al. Comparisons of Y-set disconnect system (Ultraset) versus conventional spike system in uremic patients on CAPD: outcome and cost analysis. *Perit Dial Int* 1996; 16(Suppl 1): S368–370.

131. Owen JE, Walker RG, Lemon J, et al. Randomized study of peritonitis with conventional versus O-set techniques in continuous ambulatory peritoneal dialysis. *Perit Dial Int* 1992; 12: 216–220.

132. Viglino G, Colombo A, Scalamogna A, et al. Prospected randomized study of two Y devices in continuous ambulatory peritoneal dialysis (CAPD). *Perit Dial Int* 1989; 9: 165–168.

133. Viglino G, Colombo A, Cantu P, et al. In vitro and in vivo efficacy of a new connector device for continuous ambulatory peritoneal dialysis. *Perit Dial Int* 1993; 13(Suppl 2): S148–151.

134. Rottembourg J BR, Issad B, Allouache M and Jacobs C. Prospective randomized study about Y-connectors in CAPD patients. *Adv Perit Dial* 1987; 3: 107–113.

135. Lindholm T SO and Krutzen L. Evaluation of a new take-off system (Ultraset) versus conventional spike system in uremic patients on CAPD: outcome and cost-analysis. *Adv Perit Dial* 1988; 4: 262–265.

136. Shaw V, Anderson C, Desloovere A, et al. Nutritional management of the infant with chronic kidney disease stages 2-5 and on dialysis. *Pediatr Nephrol* 2023; 38: 87–103. 20220405.

137. Murugasu B, Conley SB, Lemire JM, et al. Fungal peritonitis in children treated with peritoneal dialysis and gastrostomy feeding. *Pediatr Nephrol* 1991; 5: 620–621.

138. Phan J, Stanford S, Zaritsky JJ, et al. Risk factors for morbidity and mortality in pediatric patients with peritoneal dialysis catheters. *J Pediatr Surg* 2013; 48: 197–202.

139. Rahim KA, Seidel K and McDonald RA. Risk factors for catheter-related complications in pediatric peritoneal dialysis. *Pediatr Nephrol* 2004; 19: 1021–1028. 20040617.

140. Ramage IJ, Harvey E, Geary DF, et al. Complications of gastrostomy feeding in children receiving peritoneal dialysis. *Pediatr Nephrol* 1999; 13: 249–252.

141. Warady BA and Bunchman T. Dialysis therapy for children with acute renal failure: survey results. *Pediatr Nephrol* 2000; 15: 11–13.

142. Borzych-Duzalka D, Schaefer F and Warady BA. Targeting optimal PD management in children: what have we learned from the IPPN registry? *Pediatr Nephrol* 2021; 36: 1053–1063. 20200527.

143. Ledermann SE, Spitz L, Moloney J, et al. Gastrostomy feeding in infants and children on peritoneal dialysis. *Pediatr Nephrol* 2002; 17: 246–250.

144. von Schnakenburg C, Feneberg R, Plank C, et al. Percutaneous endoscopic gastrostomy in children on peritoneal dialysis. *Perit Dial Int* 2006; 26: 69–77.

145. Kempf C, Holle J, Berns S, et al. Feasibility of percutaneous endoscopic gastrostomy insertion in children receiving peritoneal dialysis. *Perit Dial Int* 2022; 42: 482–488. 20211117.

146. Fox D, Campagna EJ, Friedlander J, et al. National trends and outcomes of pediatric gastrostomy tube placement. *J Pediatr Gastroenterol Nutr* 2014; 59: 582–588.

147. Jones VS, La Hei ER and Shun A. Laparoscopic gastrostomy: the preferred method of gastrostomy in children. *Pediatr Surg Int* 2007; 23: 1085–1089. 20070908.

148. Dorman RM, Benedict LA, Sujka J, et al. Safety of laparoscopic gastrostomy in children receiving peritoneal dialysis. *J Surg Res* 2019; 244: 460–467. 20190719.

149. Prestidge C, Ronaldson J, Wong W, et al. Infectious outcomes following gastrostomy in children receiving peritoneal dialysis. *Pediatr Nephrol* 2015; 30: 849–854. 20141204.

150. Adachi Y, Akino K, Mita H, et al. Systemic prophylactic antibiotics for the modified introducer method for percutaneous endoscopic gastrostomy: A prospective, randomized, double-blind study. *J Clin Gastroenterol* 2016; 50: 727–732.

151. Ingraham CR, Johnson GE, Albrecht EL, et al. Value of antibiotic prophylaxis for percutaneous gastrostomy: A double-blind randomized trial. *J Vasc Interv Radiol* 2018; 29: 55–61 e52. 20171101.

152. Lipp A and Lusardi G. Systemic antimicrobial prophylaxis for percutaneous endoscopic gastrostomy. *Cochrane Database Syst Rev* 2013; 2013: CD005571. 20131114.

153. Alessandri F, Strisciuglio C, Borrazzo C, et al. Antibiotic prophylaxis for percutaneous endoscopic gastrostomy in

children: A randomised controlled trial. *J Pediatr Gastroenterol Nutr* 2021; 72: 366–371.

154. Chan EYH, Borzych-Duzalka D, Alparslan C, et al. Colostomy in children on chronic peritoneal dialysis. *Pediatr Nephrol* 2020; 35: 119–126. 20191030.

155. Warady BA, Bashir M and Donaldson LA. Fungal peritonitis in children receiving peritoneal dialysis: a report of the NAPRTCS. *Kidney Int* 2000; 58: 384–389.

156. Lee KO, Park SJ, Kim JH, et al. Outcomes of peritonitis in children on peritoneal dialysis: a 25-year experience at Severance Hospital. *Yonsei Med J* 2013; 54: 983–989.

157. Bordador EB, Johnson DW, Henning P, et al. Epidemiology and outcomes of peritonitis in children on peritoneal dialysis in Australasia. *Pediatr Nephrol* 2010; 25: 1739–1745.

158. Munshi R, Sethna CB, Richardson T, et al. Fungal peritonitis in the Standardizing Care to Improve Outcomes in Pediatric End Stage Renal Disease (SCOPE) Collaborative. *Pediatr Nephrol* 2018; 33: 873–880. 20180108.

159. Raaijmakers R, Schroder C, Monnens L, et al. Fungal peritonitis in children on peritoneal dialysis. *Pediatr Nephrol* 2007; 22: 288–293. 20061117.

160. Robitaille P, Merouani A, Clermont MJ, et al. Successful antifungal prophylaxis in chronic peritoneal dialysis: a pediatric experience. *Perit Dial Int* 1995; 15: 77–79.

161. Zaruba K, Peters J and Jungbluth H. Successful prophylaxis for fungal peritonitis in patients on continuous ambulatory peritoneal dialysis: six years' experience. *Am J Kidney Dis* 1991; 17: 43–46.

162. Wadhwa NK, Suh H and Cabralda T. Antifungal prophylaxis for secondary fungal peritonitis in peritoneal dialysis patients. *Adv Perit Dial* 1996; 12: 189–191.

163. Moreiras-Plaza M, Vello-Roman A, Samprom-Rodriguez M, et al. Ten years without fungal peritonitis: a single center's experience. *Perit Dial Int* 2007; 27: 460–463.

164. Wong PN, Lo KY, Tong GM, et al. Prevention of fungal peritonitis with nystatin prophylaxis in patients receiving CAPD. *Perit Dial Int* 2007; 27: 531–536.

165. Lo WK, Chan CY, Cheng SW, et al. A prospective randomized control study of oral nystatin prophylaxis for Candida peritonitis complicating continuous ambulatory peritoneal dialysis. *Am J Kidney Dis* 1996; 28: 549–552.

166. Restrepo C, Chacon J and Manjarres G. Fungal peritonitis in peritoneal dialysis patients: successful prophylaxis with fluconazole, as demonstrated by prospective randomized control trial. *Perit Dial Int* 2010; 30: 619–625. 20100715.

167. Neu A. Personal Communication.

168. Borzych-Duzałka D, Same R, Neu A, et al. Best Practice of peritoneal dialysis-associated gram-negative peritonitis in children: Insights from the international pediatric peritoneal dialysis network registry. *Kidney Int Rep* 2024; 9: 1654–1663. Personal Commication

169. Wilson WR, Gewitz M, Lockhart PB, et al. Prevention of Viridans group streptococcal infective endocarditis: A scientific statement from the american heart association. *Circulation* 2021; 143: e963–e978. 20210415.

170. Privitera G, Scarpellini P, Ortisi G, et al. Prospective study of Clostridium difficile intestinal colonization and disease following single-dose antibiotic prophylaxis in surgery. *Antimicrob Agents Chemother* 1991; 35: 208–210.

171. Crotty MP, Meyers S, Hampton N, et al. Impact of antibacterials on subsequent resistance and clinical outcomes in adult patients with viral pneumonia: an opportunity for stewardship. *Crit Care* 2015; 19(404): 20151118.

172. Yap DY, Chu WL, Ng F, et al. Risk factors and outcome of contamination in patients on peritoneal dialysis–a single-center experience of 15 years. *Perit Dial Int* 2012; 32: 612–616. 20120601.

173. Quinlan C, Cantwell M and Rees L. Eosinophilic peritonitis in children on chronic peritoneal dialysis. *Pediatr Nephrol* 2010; 25: 517–522. 20091202.

174. Kenan BU, Buyukkaragoz B, Leventoglu E, et al. Eosinophilic peritonitis in children undergoing maintenance peritoneal dialysis: A case report and literature review. *Semin Dial* 2022; 35: 548–555. 20220704.

175. Akman S, Uygun V and Guven AG. Value of the urine strip test in the early diagnosis of bacterial peritonitis. *Pediatr Int* 2005; 47: 523–527.

176. Park SJ, Lee JY, Tak WT, et al. Using reagent strips for rapid diagnosis of peritonitis in peritoneal dialysis patients. *Adv Perit Dial* 2005; 21: 69–71.

177. Miller JM, Binnicker MJ, Campbell S, et al. A Guide to utilization of the microbiology laboratory for diagnosis of infectious diseases: 2018 Update by the infectious diseases society of America and the American Society for microbiology. *Clin Infect Dis* 2018; 67: 813–816.

178. Leber AL. (Ed) C-ADBE. *Clinical Microbiology Procedure handbook, Multi-Volume (ASM Books)*. Washington, DC: ASM Press, 2023.

179. Flanigan MJ, Freeman RM and Lim VS. Cellular response to peritonitis among peritoneal dialysis patients. *Am J Kidney Dis* 1985; 6: 420–424.

180. Rocklin MA and Teitelbaum I. Noninfectious causes of cloudy peritoneal dialysate. *Semin Dial* 2001; 14: 37–40.

181. Warady BA, Feneberg R, Verrina E, et al. Peritonitis in children who receive long-term peritoneal dialysis: a prospective evaluation of therapeutic guidelines. *J Am Soc Nephrol* 2007; 18: 2172–2179. 20070620.

182. Chadha V, Schaefer FS and Warady BA. Dialysis-associated peritonitis in children. *Pediatr Nephrol* 2010; 25: 425–440. 20090204.

183. Schaefer F, Klaus G, Muller-Wiefel DE, et al. Intermittent versus continuous intraperitoneal glycopeptide/ceftazidime treatment in children with peritoneal dialysis-associated peritonitis. The Mid-European Pediatric Peritoneal Dialysis Study Group (MEPPS). *J Am Soc Nephrol* 1999; 10: 136–145.

184. Piraino B, Bailie GR, Bernardini J, et al. Peritoneal dialysis-related infections recommendations: 2005 update. *Perit Dial Int* 2005; 25: 107–131.

185. Davis TK, Bryant KA, Rodean J, et al. Variability in culture-negative peritonitis rates in pediatric peritoneal dialysis programs in the United States. *Clin J Am Soc Nephrol* 2021; 16: 233–240. 20210118.

186. von Graevenitz A and Amsterdam D. Microbiological aspects of peritonitis associated with continuous ambulatory peritoneal dialysis. *Clin Microbiol Rev* 1992; 5: 36–48.

187. Tanratananon D, Deekae S, Raksasuk S, et al. Evaluation of different methods to improve culture-negative peritoneal dialysis-related peritonitis: A single-center study. *Ann Med Surg (Lond)* 2021; 63: 102139. 20210213.

188. Sewell DL, Golper TA, Hulman PB, et al. Comparison of large volume culture to other methods for isolation of microorganisms from dialysate. *Perit Dial Int* 1990; 10: 49–52.

189. Lye WC, Wong PL, Leong SO, et al. Isolation of organisms in CAPD peritonitis: a comparison of two techniques. *Adv Perit Dial* 1994; 10: 166–168.

190. Blondeau JM, Pylypchuk GB, Kappel JE, et al. Comparison of bedside- and laboratory-inoculated Bactec high- and low-volume resin bottles for the recovery of microorganisms causing peritonitis in CAPD patients. *Diagn Microbiol Infect Dis* 1998; 31: 281–287.

191. Yoo TH, Chang KH, Ryu DR, et al. Usefulness of 23S rRNA amplification by PCR in the detection of bacteria in CAPD peritonitis. *Am J Nephrol* 2006; 26: 115–120. 20060314.

192. Johnson G, Wilks M, Warwick S, et al. Comparative study of diagnosis of PD peritonitis by quantitative polymerase chain reaction for bacterial DNA vs culture methods. *J Nephrol* 2006; 19: 45–49.

193. Muthucumarana K, Howson P, Crawford D, et al. The relationship between presentation and the time of initial administration of antibiotics with outcomes of peritonitis in peritoneal dialysis patients: The PROMPT study. *Kidney Int Rep* 2016; 1: 65–72. 20160611.

194. Oki R, Tsuji S, Hamasaki Y, et al. Time until treatment initiation is associated with catheter survival in peritoneal dialysis-related peritonitis. *Sci Rep* 2021; 11: 6547. 20210322.

195. Wong KM, Chan YH, Cheung CY, et al. Cefepime versus vancomycin plus netilmicin therapy for continuous ambulatory peritoneal dialysis-associated peritonitis. *Am J Kidney Dis* 2001; 38: 127–131.

196. Li PK, Ip M, Law MC, et al. Use of intraperitoneal cefepime as monotherapy in treatment of CAPD peritonitis. *Perit Dial Int* 2000; 20: 232–234.

197. Kitrungphaiboon T, Puapatanakul P, Chuengsaman P, et al. Intraperitoneal cefepime monotherapy versus combination therapy of cefazolin plus ceftazidime for empirical treatment of CAPD-associated peritonitis: A multicenter, open-label, noninferiority, randomized, controlled trial. *Am J Kidney Dis* 2019; 74: 601–609. 20190719.

198. Badve SV, Hawley CM, McDonald SP, et al. Use of aminoglycosides for peritoneal dialysis-associated peritonitis does not affect residual renal function. *Nephrol Dial Transplant* 2012; 27: 381–387. 20110601.

199. Baker RJ, Senior H, Clemenger M, et al. Empirical aminoglycosides for peritonitis do not affect residual renal function. *Am J Kidney Dis* 2003; 41: 670–675.

200. Lui SL, Cheng SW, Ng F, et al. Cefazolin plus netilmicin versus cefazolin plus ceftazidime for treating CAPD peritonitis: effect on residual renal function. *Kidney Int* 2005; 68: 2375–2380.

201. Kranzer K, Elamin WF, Cox H, et al. A systematic review and meta-analysis of the efficacy and safety of N-acetylcysteine in preventing aminoglycoside-induced ototoxicity: implications for the treatment of multidrug-resistant TB. *Thorax* 2015; 70: 1070–1077. 20150907.

202. Feldman L, Efrati S, Eviatar E, et al. Gentamicin-induced ototoxicity in hemodialysis patients is ameliorated by N-acetylcysteine. *Kidney Int* 2007; 72: 359–363. 20070425.

203. Kocyigit I, Vural A, Unal A, et al. Preventing amikacin related ototoxicity with N-acetylcysteine in patients undergoing peritoneal dialysis. *Eur Arch Otorhinolaryngol* 2015; 272: 2611–2620. 20140730.

204. Vural A, Kocyigit I, San F, et al. Long-term protective effect of N-acetylcysteine against amikacin-induced ototoxicity in end-stage renal disease: A randomized trial. *Perit Dial Int* 2018; 38: 57–62. 20171102.

205. Tokgoz B, Ucar C, Kocyigit I, et al. Protective effect of N-acetylcysteine from drug-induced ototoxicity in uraemic patients with CAPD peritonitis. *Nephrol Dial Transplant* 2011; 26: 4073–4078. 20110506.

206. McDermott JH, Wolf J, Hoshitsuki K, et al. Clinical Pharmacogenetics implementation consortium guideline for the use of aminoglycosides based on MT-RNR1 genotype. *Clin Pharmacol Ther* 2022; 111: 366–372. 20210620.

207. Institute CaLS. *Performance Standards for Antimicrobial Susceptibility Testing*. 33rd ed. 2023.

208. Testing ECoAS. *Breakpoint tables for interpretation of MICs and zone diameters*. Version 10.0 ed. 2020.

209. Payne LE, Gagnon DJ, Riker RR, et al. Cefepime-induced neurotoxicity: a systematic review. *Crit Care* 2017; 21(276): 20171114.

210. Yuen S-K, Yong S-P and Tsui H-S. Neurotoxicity secondary to intraperitoneally administered cefepime: Report of Two Cases. *Hong Kong J Nephrol* 2004; 6: 106–108.

211. Gerber JS, Ross RK, Bryan M, et al. Association of Broad- vs Narrow-spectrum antibiotics with treatment failure, adverse events, and quality of life in children with acute respiratory tract infections. *JAMA* 2017; 318: 2325–2336.

212. Joerger T, Taylor MG, Li Y, et al. Impact of penicillin allergy labels on children treated for outpatient respiratory infections. *J Pediatric Infect Dis Soc* 2023; 12: 92–98.

213. Board A. Measurement of specific and nonspecific IgG4 levels as diagnostic and prognostic tests for clinical allergy. AAAI Board of Directors. *J Allergy Clin Immunol* 1995; 95: 652–654.

214. Barlam TF, Cosgrove SE, Abbo LM, et al. Implementing an antibiotic stewardship program: guidelines by the infectious diseases Society of America and the society for healthcare epidemiology of America. *Clin Infect Dis* 2016; 62: e51–77. 20160413.

215. Ahmed KA, Fox SJ, Frigas E, et al. Clinical outcome in the use of cephalosporins in pediatric patients with a history of penicillin allergy. *Int Arch Allergy Immunol* 2012; 158: 405–410. 20120405.

216. Chiron A, Gaouar H, Autegarden JE, et al. Allergy to third- and second-generation cephalosporins in confirmed penicillin-allergic patients. *J Allergy Clin Immunol Pract* 2020; 8: 2409–2411 e2403. 20200405.

217. Khan DA, Banerji A, Blumenthal KG, et al. Drug allergy: A 2022 practice parameter update. *J Allergy Clin Immunol* 2022; 150: 1333–1393. 20220917.

218. Same RG, Hsu AJ, Cosgrove SE, et al. Antibiotic-Associated Adverse Events in Hospitalized Children. *J Pediatric Infect Dis Soc* 2021; 10: 622–628.

219. Same RG, Hsu AJ and Tamma PD. Optimizing the management of uncomplicated gram-negative bloodstream infections in children: Translating evidence from adults into pediatric practice. *J Pediatric Infect Dis Soc* 2019; 8: 485–488.

220. Kovacich A, Tamma PD, Advani S, et al. Peripherally inserted central venous catheter complications in children receiving Outpatient Parenteral Antibiotic Therapy (OPAT). *Infect Control Hosp Epidemiol* 2016; 37: 420–424. 20160112.

221. Greencorn DJ, Kuhle S, Ye L, et al. Risk factors for mechanical complications of peripherally inserted central catheters in children. *Infect Control Hosp Epidemiol* 2023; 44: 885–890. 20221020.

222. AAP. *Red Book 2021: Report of the Committee on Infectious Diseases.* 32nd ed.: American Academy of Pediatrics, 2021–2024.

223. McMullan BJ, Bowen A, Blyth CC, et al. Epidemiology and Mortality of Staphylococcus aureus Bacteremia in Australian and New Zealand Children. *JAMA Pediatr* 2016; 170: 979–986.

224. Tobudic S, Kern S, Kussmann M, et al. Effect of Peritoneal Dialysis Fluids on Activity of Teicoplanin Against Methicillin-Resistant Staphylococcus aureus Biofilm. *Perit Dial Int* 2019; 39: 293–294.

225. Hennessy K, Capparelli EV, Romanowski G, et al. Intraperitoneal vancomycin for peritoneal dialysis-associated peritonitis in children: Evaluation of loading dose guidelines. *PeritDialInt* 2021;41:202–208.20200831.

226. Blowey DL, Warady BA, Abdel-Rahman S, et al. Vancomycin disposition following intraperitoneal administration in children receiving peritoneal dialysis. *Perit Dial Int* 2007; 27: 79–85.

227. Szeto CC, Chow KM, Kwan BC, et al. Staphylococcus aureus peritonitis complicates peritoneal dialysis: review of 245 consecutive cases. *Clin J Am Soc Nephrol* 2007; 2: 245–251. 20070103.

228. Govindarajulu S, Hawley CM, McDonald SP, et al. Staphylococcus aureus peritonitis in Australian peritoneal dialysis patients: predictors, treatment, and outcomes in 503 cases. *Perit Dial Int* 2010; 30: 311–319. 20100226.

229. Wang HH, Huang CH, Kuo MC, et al. Microbiology of peritoneal dialysis-related infection and factors of refractory peritoneal dialysis related peritonitis: A ten-year single-center study in Taiwan. *J Microbiol Immunol Infect* 2019; 52: 752–759. 20190108.

230. Chen HC, Shieh CC and Sung JM. Increasing staphylococcus species resistance in peritoneal dialysis-related peritonitis over a 10-Year period in a single taiwanese center. *Perit Dial Int* 2018; 38: 266–270.

231. Camargo CH, Cunha Mde L, Caramori JC, et al. Peritoneal dialysis-related peritonitis due to coagulase-negative Staphylococcus: a review of 115 cases in a Brazilian center. *Clin J Am Soc Nephrol* 2014; 9: 1074–1081. 20140327.

232. Szeto CC, Kwan BC, Chow KM, et al. Coagulase negative staphylococcal peritonitis in peritoneal dialysis patients: review of 232 consecutive cases. *Clin J Am Soc Nephrol* 2008; 3: 91–97. 20071121.

233. Heywood A and Bargman JM. Coagulase-negative staphylococcal peritonitis: outcomes of cephalosporin-resistant strains. *Adv Perit Dial* 2010; 26: 34–36.

234. Edey M, Hawley CM, McDonald SP, et al. Enterococcal peritonitis in Australian peritoneal dialysis patients: predictors, treatment and outcomes in 116 cases. *Nephrol Dial Transplant* 2010; 25: 1272–1278. 20091130.

235. Szeto CC, Ng JK, Chow KM, et al. Treatment of enterococcal peritonitis in peritoneal dialysis patients by oral amoxicillin or intra-peritoneal vancomcyin: a retrospective study. *Kidney Blood Press Res* 2017; 42: 837–843. 20171027.

236. Yip T, Tse KC, Ng F, et al. Clinical course and outcomes of single-organism Enterococcus peritonitis in peritoneal dialysis patients. *Perit Dial Int* 2011; 31: 522–528. 20110430.

237. Sutherland SM, Alexander SR, Feneberg R, et al. Enterococcal peritonitis in children receiving chronic peritoneal dialysis. *Nephrol Dial Transplant* 2010; 25: 4048–4054. 20100525.

238. Kussmann M, Schuster L, Wrenger S, et al. Influence of different peritoneal dialysis fluids on the in vitro activity of cefepime, ciprofloxacin, ertapenem, meropenem and tobramycin against escherichia coli. *Perit Dial Int* 2016; 36: 662–668. 20160928.

239. Paul LP S, Ficheux M, Debruyne D, et al. Pharmacokinetics of 300 mg/d Intraperitoneal Daptomycin: New Insight from the DaptoDP Study. *Perit Dial Int* 2018; 38: 463–466.

240. Unal A, Agkus C, Kocyigit I, et al. Peritoneal dialysis-related peritonitis caused by vancomycin-resistant Enterococcus faecium. *Ther Apher Dial* 2011; 15: 115–116. 20100831.

241. Bailey EM, Faber MD and Nafziger DA. Linezolid for treatment of vancomycin-resistant enterococcal peritonitis. *Am J Kidney Dis* 2001; 38: E20.

242. Song IJ, Seo JW, Kwon YE, et al. Successful treatment of vancomycin-resistant enterococcus peritonitis using linezolid without catheter removal in a peritoneal dialysis patient. *Perit Dial Int* 2014; 34: 235–239.

243. Kussmann M, Schuster L, Zeitlinger M, et al. The influence of different peritoneal dialysis fluids on the in vitro activity of ampicillin, daptomycin, and linezolid against Enterococcus faecalis. *Eur J Clin Microbiol Infect Dis* 2015; 34: 2257–2263. 20150904.

244. Tamma PD, Aitken SL, Bonomo RA, et al. Infectious diseases society of America 2023 guidance on the treatment of antimicrobial resistant gram-negative infections. *Clin Infect Dis*. Epub ahead of print 18 July 2023. DOI: 10.1093/cid/ciad428.

245. Yip T, Tse KC, Lam MF, et al. Risk factors and outcomes of extended-spectrum beta-lactamase-producing E. coli peritonitis in CAPD patients. *Perit Dial Int* 2006; 26: 191–197.

246. Heil EL, Bork JT, Abbo LM, et al. Optimizing the management of uncomplicated gram-negative bloodstream infections: consensus guidance using a modified delphi process. *Open Forum Infect Dis* 2021; 8: ofab434. 20211011.

247. Kaye KS, Gupta V, Mulgirigama A, et al. Antimicrobial resistance trends in urine escherichia coli isolates from adult and adolescent females in the United States From 2011 to 2019: Rising ESBL Strains and Impact on Patient Management. *Clin Infect Dis* 2021; 73: 1992–1999.

248. Collingwood JD, Yarbrough AH, Boppana SB, et al. Increasing prevalence of pediatric community-acquired UTI by extended spectrum beta-lactamase-producing E. coli: Cause for doncern. *Pediatr Infect Dis J* 2023; 42: 106–109. 20221115.

249. Cassini A, Hogberg LD, Plachouras D, et al. Attributable deaths and disability-adjusted life-years caused by infections with antibiotic-resistant bacteria in the EU and the European Economic Area in 2015: a population-level modelling analysis. *Lancet Infect Dis* 2019; 19: 56–66. 20181105.

250. Harris PNA, Tambyah PA, Lye DC, et al. Effect of Piperacillin-Tazobactam vs Meropenem on 30-Day

Mortality for Patients With E coli or Klebsiella pneumoniae Bloodstream Infection and Ceftriaxone Resistance: A Randomized Clinical Trial. *JAMA* 2018; 320: 984–994.

251. Tamma PD, Conley AT, Cosgrove SE, et al. Association of 30-Day Mortality With Oral Step-Down vs Continued Intravenous Therapy in Patients Hospitalized With Enterobacteriaceae Bacteremia. *JAMA Intern Med* 2019; 179: 316–323.

252. Punjabi C, Tien V, Meng L, et al. Oral Fluoroquinolone or Trimethoprim-sulfamethoxazole vs. ss-lactams as Step-Down Therapy for Enterobacteriaceae Bacteremia: Systematic Review and Meta-analysis. *Open Forum Infect Dis* 2019; 6. 20190814.

253. Kussmann M, Ferth A, Obermuller M, et al. Compatibility of ciprofloxacin with commercial peritoneal dialysis solutions. *Sci Rep* 2019; 9: 6512. 20190424.

254. Fernandez-Varon E, Marin P, Espuny A, et al. Stability of moxifloxacin injection in peritoneal dialysis solution bags (Dianeal PD1 1.36&per; and Dianeal PD1 3.86&per;). *J Clin Pharm Ther* 2006; 31: 641–643.

255. Skalioti C, Tsaganos T, Stamatiadis D, et al. Pharmacokinetics of moxifloxacin in patients undergoing continuous ambulatory peritoneal dialysis. *Perit Dial Int* 2009; 29: 575–579.

256. Lee C, Walker SAN, Palmay L, et al. Steady-state pharmacokinetics of oral ciprofloxacin in continuous cycling peritoneal dialysis patients: Brief report. *Perit Dial Int* 2018; 38: 73–76.

257. Adefurin A, Sammons H, Jacqz-Aigrain E, et al. Ciprofloxacin safety in paediatrics: a systematic review. *Arch Dis Child* 2011; 96: 874–880. 20110723.

258. Li S, Chen Z, Huang L, et al. Safety of quinolones in children: A systematic review and meta-analysis. *Paediatr Drugs* 2022; 24: 447–464. 20220630.

259. Ross RK, Kinlaw AC, Herzog MM, et al. Fluoroquinolone Antibiotics and Tendon Injury in Adolescents. *Pediatrics* 2021; 147: 20210514.

260. Daneman N, Lu H and Redelmeier DA. Fluoroquinolones and collagen associated severe adverse events: a longitudinal cohort study. *BMJ Open* 2015; 5: e010077. 20151118.

261. Lee CC, Lee MT, Chen YS, et al. Risk of aortic dissection and aortic aneurysm in patients taking oral fluoroquinolone. *JAMA Intern Med* 2015; 175: 1839–1847.

262. Singh S and Nautiyal A. Aortic dissection and aortic aneurysms associated with fluoroquinolones: A systematic review and meta-analysis. *Am J Med* 2017; 130: 1449–1457 e1449. 20170721.

263. Pasternak B, Inghammar M and Svanstrom H. Fluoroquinolone use and risk of aortic aneurysm and dissection: nationwide cohort study. *BMJ* 2018; 360: k678. 20180308.

264. Lee CC, Lee MG, Hsieh R, et al. Oral fluoroquinolone and the risk of aortic dissection. *J Am Coll Cardiol* 2018; 72: 1369–1378.

265. Communication FDS. FDA warns about increased risk of ruptures or tears in the aorta blood vessel with fluoroquinolone antibiotics in certain patients. 2018.

266. Tamma PD, Doi Y, Bonomo RA, et al. A Primer on AmpC beta-Lactamases: Necessary knowledge for an increasingly multidrug-resistant world. *Clin Infect Dis* 2019; 69: 1446–1455.

267. Jacoby GA. AmpC beta-lactamases. *Clin Microbiol Rev* 2009; 22: 161–182. Table of Contents 2009.

268. Jacobson KL, Cohen SH, Inciardi JF, et al. The relationship between antecedent antibiotic use and resistance to extended-spectrum cephalosporins in group I beta-lactamase-producing organisms. *Clin Infect Dis* 1995; 21: 1107–1113.

269. Chow JW, Fine MJ, Shlaes DM, et al. Enterobacter bacteremia: clinical features and emergence of antibiotic resistance during therapy. *Ann Intern Med* 1991; 115: 585–590.

270. Kaye KS, Cosgrove S, Harris A, et al. Risk factors for emergence of resistance to broad-spectrum cephalosporins among Enterobacter spp. *Antimicrob Agents Chemother* 2001; 45: 2628–2630.

271. Hilty M, Sendi P, Seiffert SN, et al. Characterisation and clinical features of Enterobacter cloacae bloodstream infections occurring at a tertiary care university hospital in Switzerland: is cefepime adequate therapy? *Int J Antimicrob Agents* 2013; 41: 236–249. 20130110.

272. Tamma PD, Girdwood SC, Gopaul R, et al. The use of cefepime for treating AmpC beta-lactamase-producing Enterobacteriaceae. *Clin Infect Dis* 2013; 57: 781–788. 20130611.

273. Kohlmann R, Bahr T and Gatermann SG. Species-specific mutation rates for ampC derepression in Enterobacterales with chromosomally encoded inducible AmpC beta-lactamase. *J Antimicrob Chemother* 2018; 73: 1530–1536.

274. Choi SH, Lee JE, Park SJ, et al. Emergence of antibiotic resistance during therapy for infections caused by Enterobacteriaceae producing AmpC beta-lactamase: implications for antibiotic use. *Antimicrob Agents Chemother* 2008; 52: 995–1000. 20071217.

275. Logan LK and Weinstein RA. The epidemiology of carbapenem-resistant enterobacteriaceae: the impact and evolution of a global menace. *J Infect Dis* 2017; 215: S28–S36.

276. Nadarajah L, Yaqoob MM and Fan S. Persistent colonization of exit site is associated with modality failure in peritoneal dialysis. *Perit Dial Int* 2022; 42: 96–99. 20201123.

277. Szeto CC, Chow KM, Leung CB, et al. Clinical course of peritonitis due to Pseudomonas species complicating peritoneal dialysis: a review of 104 cases. *Kidney Int* 2001; 59: 2309–2315.

278. Siva B, Hawley CM, McDonald SP, et al. Pseudomonas peritonitis in Australia: predictors, treatment, and outcomes in 191 cases. *Clin J Am Soc Nephrol* 2009; 4: 957–964. 20090430.

279. Tamma PD, Cosgrove SE and Maragakis LL. Combination therapy for treatment of infections with gram-negative bacteria. *Clin Microbiol Rev* 2012; 25: 450–470.

280. Romney M. Humphries VUMC, Nashville, Tennessee. CLSI M100-Ed33: Updated Aminoglycoside Breakpoints for Enterobacterales and Pseudomonas aeruginosa. 2023.

281. Chang YT, Lin CY, Chen YH, et al. Update on infections caused by Stenotrophomonas maltophilia with particular attention to resistance mechanisms and therapeutic options. *Front Microbiol* 2015; 6(893): 20150902.

282. Cai B, Tillotson G, Benjumea D, et al. The burden of bloodstream infections due to stenotrophomonas maltophilia in the United States: A large, retrospective database study. *Open Forum Infect Dis* 2020; 7: ofaa141. 20200422.

283. Sarzynski SH, Warner S, Sun J, et al. Trimethoprim-sulfamethoxazole versus levofloxacin for stenotrophomonas maltophilia infections: A retrospective comparative

effectiveness study of electronic health records from 154 US hospitals. *Open Forum Infect Dis* 2022; 9: ofab644. 20220117.

284. Ko JH, Kang CI, Cornejo-Juarez P, et al. Fluoroquinolones versus trimethoprim-sulfamethoxazole for the treatment of Stenotrophomonas maltophilia infections: a systematic review and meta-analysis. *Clin Microbiol Infect* 2019; 25: 546–554. 20181116.

285. Shah MD, Coe KE, El Boghdadly Z, et al. Efficacy of combination therapy versus monotherapy in the treatment of Stenotrophomonas maltophilia pneumonia. *J Antimicrob Chemother* 2019; 74: 2055–2059.

286. Hand E, Davis H, Kim T, et al. Monotherapy with minocycline or trimethoprim/sulfamethoxazole for treatment of Stenotrophomonas maltophilia infections. *J Antimicrob Chemother* 2016; 71: 1071–1075. 20160121.

287. Htay H, Cho Y, Pascoe EM, et al. Multicentre registry data analysis comparing outcomes of culture-negative peritonitis and different subtypes of culture-positive peritonitis in peritoneal dialysis patients. *Perit Dial Int* 2020; 40: 47–56.

288. Kovitangkoon K, Lukkanalikitkul E, Wiangnon P, et al. Cefazolin plus ceftazidime versus cefazolin monotherapy in the treatment of culture-negative peritonitis: A retrospective cohort study. *Int J Nephrol Renovasc Dis* 2022; 15: 17–25. 20220211.

289. Miles R, Hawley CM, McDonald SP, et al. Predictors and outcomes of fungal peritonitis in peritoneal dialysis patients. *Kidney Int* 2009; 76: 622–628. 20090610.

290. Chang TI, Kim HW, Park JT, et al. Early catheter removal improves patient survival in peritoneal dialysis patients with fungal peritonitis: results of ninety-four episodes of fungal peritonitis at a single center. *Perit Dial Int* 2011; 31: 60–66. 20100526.

291. Nadeau-Fredette AC and Bargman JM. Characteristics and outcomes of fungal peritonitis in a modern North American cohort. *Perit Dial Int* 2015; 35: 78–84. 20140204.

292. Wang AY, Yu AW, Li PK, et al. Factors predicting outcome of fungal peritonitis in peritoneal dialysis: analysis of a 9-year experience of fungal peritonitis in a single center. *Am J Kidney Dis* 2000; 36: 1183–1192.

293. Goldie SJ, Kiernan-Tridle L, Torres C, et al. Fungal peritonitis in a large chronic peritoneal dialysis population: a report of 55 episodes. *Am J Kidney Dis* 1996; 28: 86–91.

294. Blowey DL, Garg UC, Kearns GL, et al. Peritoneal penetration of amphotericin B lipid complex and fluconazole in a pediatric patient with fungal peritonitis. *Adv Perit Dial* 1998; 14: 247–250.

295. Peng LW and Lien YH. Pharmacokinetics of single, oral-dose voriconazole in peritoneal dialysis patients. *Am J Kidney Dis* 2005; 45: 162–166.

296. Tobudic S, Harrison N, Forstner C, et al. Effect of peritoneal dialysis fluids on activity of echinocandins against Candida spp. biofilm. *Med Mycol* 2017; 55: 790–793.

297. Gioia F, Gomez-Lopez A, Alvarez ME, et al. Pharmacokinetics of echinocandins in suspected candida peritonitis: A potential risk for resistance. *Int J Infect Dis* 2020; 101: 24–28. 20200913.

298. Akpolat T. Tuberculous peritonitis. *Perit Dial Int* 2009; 29(Suppl 2): S166–169.

299. Ram R, Swarnalatha G, Akpolat T, et al. Mycobacterium tuberculous peritonitis in CAPD patients: a report of 11 patients and review of literature. *Int Urol Nephrol* 2013; 45: 1129–1135. 20121110.

300. Tamayo-Isla RA, de la Cruz MC and Okpechi IG. Mycobacterial Peritonitis in CAPD Patients in Limpopo: A 6-Year Cumulative Report from a Single Center in South Africa. *Perit Dial Int* 2016; 36: 218–222.

301. Thomson BKA, Vaughan S and Momciu B. Mycobacterium tuberculosis peritonitis in peritoneal dialysis patients: A scoping review. *Nephrology (Carlton)* 2022; 27: 133–144. 20211206.

302. Song Y, Wu J, Yan H, et al. Peritoneal dialysis-associated nontuberculous mycobacterium peritonitis: a systematic review of reported cases. *Nephrol Dial Transplant* 2012; 27: 1639–1644. 20110902.

303. Bnaya A, Wiener-Well Y, Soetendorp H, et al. Nontuberculous mycobacteria infections of peritoneal dialysis patients: A multicenter study. *Perit Dial Int* 2021; 41: 284–291. 20200513.

304. Fung WW, Chow KM, Li PK, et al. Clinical course of peritoneal dialysis-related peritonitis due to non-tuberculosis mycobacterium - A single centre experience spanning 20 years. *Perit Dial Int* 2022; 42: 204–211. 20210903.

305. Haubrich K, Mammen C, Sekirov I, et al. Mycobacterium fortuitum peritoneal dialysis-related peritonitis in a child: A case report and review of the literature. *J Assoc Med Microbiol Infect Dis Can* 2022; 7: 125–130. 20220603.

306. Washida N and Itoh H. The Role of Non-Tuberculous Mycobacteria in Peritoneal Dialysis-Related Infections: A Literature Review. *Contrib Nephrol* 2018; 196: 155–161. 20180724.

307. Renaud CJ, Subramanian S, Tambyah PA, et al. The clinical course of rapidly growing nontuberculous mycobacterial peritoneal dialysis infections in Asians: A case series and literature review. *Nephrology (Carlton)* 2011; 16: 174–179.

308. Jiang SH, Roberts DM, Dawson AH, et al. Mycobacterium fortuitum as a cause of peritoneal dialysis-associated peritonitis: case report and review of the literature. *BMC Nephrol* 2012; 13(35): 20120608.

309. Jiang SH, Roberts DM, Clayton PA, et al. Non-tuberculous mycobacterial PD peritonitis in Australia. *Int Urol Nephrol* 2013; 45: 1423–1428. 20121118.

310. Li PK, Szeto CC, Piraino B, et al. ISPD Peritonitis Recommendations: 2016 Update on Prevention and Treatment. *Perit Dial Int* 2016; 36: 481–508. 20160609.

311. Yamada T, Ushijima K and Uemura O. A hospital-acquired outbreak of catheter-related nontuberculous mycobacterial infection in children on peritoneal dialysis. *CEN Case Rep* 2015; 4: 43–47. 20140720.

312. Griffith DE, Aksamit T, Brown-Elliott BA, et al. An official ATS/IDSA statement: diagnosis, treatment, and prevention of nontuberculous mycobacterial diseases. *Am J Respir Crit Care Med* 2007; 175: 367–416.

313. Lo MW, Mak SK, Wong YY, et al. Atypical mycobacterial exit-site infection and peritonitis in peritoneal dialysis patients on prophylactic exit-site gentamicin cream. *Perit Dial Int* 2013; 33: 267–272. 20121002.

314. Burke M, Hawley CM, Badve SV, et al. Relapsing and recurrent peritoneal dialysis-associated peritonitis: a multicenter registry study. *Am J Kidney Dis* 2011; 58: 429–436. 20110520.

315. Szeto CC, Kwan BC, Chow KM, et al. Recurrent and relapsing peritonitis: causative organisms and response to treatment. *Am J Kidney Dis* 2009; 54: 702–710. 20090704.

316. Szeto CC, Kwan BC, Chow KM, et al. Repeat peritonitis in peritoneal dialysis: retrospective review of 181 consecutive cases. *Clin J Am Soc Nephrol* 2011; 6: 827–833. 20101223.

317. Thirugnanasambathan T, Hawley CM, Badve SV, et al. Repeated peritoneal dialysis-associated peritonitis: a multi-center registry study. *Am J Kidney Dis* 2012; 59: 84–91. 20110816.

318. Reis M, Ribeiro C, Gomes AM, et al. Repeat and relapsing peritonitis microbiological trends and outcomes: A 21-year single-center experience. *Int J Nephrol* 2021; 2021: 6662488. 20210130.

319. Whitty R, Bargman JM, Kiss A, et al. Residual kidney function and peritoneal dialysis-associated peritonitis treatment outcomes. *Clin J Am Soc Nephrol* 2017; 12: 2016–2022. 20171107.

320. Szeto CC, Ng JK, Wing-Shing Fung W, et al. Extended antibiotic therapy for the prevention of relapsing and recurrent peritonitis in peritoneal dialysis patients: a randomized controlled trial. *Clin Kidney J* 2021; 14: 991–997. 20210117.

321. Szeto CC, Lai KB, Kwan BC, et al. Bacteria-derived DNA fragment in peritoneal dialysis effluent as a predictor of relapsing peritonitis. *Clin J Am Soc Nephrol* 2013; 8: 1935–1941. 20131003.

322. Williams AJ, Boletis I, Johnson BF, et al. Tenckhoff catheter replacement or intraperitoneal urokinase: a randomised trial in the management of recurrent continuous ambulatory peritoneal dialysis (CAPD) peritonitis. *Perit Dial Int* 1989; 9: 65–67.

323. Ballinger AE, Palmer SC, Wiggins KJ, et al. Treatment for peritoneal dialysis-associated peritonitis. *Cochrane Database Syst Rev* 2014; 2014: CD005284.

324. Poyrazoglu HM, Dusunsel R, Patiroglu T, et al. Humoral immunity and frequency of peritonitis in chronic peritoneal dialysis patients. *Pediatr Nephrol* 2002; 17: 85–90.

325. Neu AM, Warady BA, Lederman HM, et al. Hypogammaglobulinemia in infants and young children maintained on peritoneal dialysis. Pediatric Dialysis Study Consortium. *Perit Dial Int* 1998; 18: 440–443.

326. Bouts AH, Davin JC, Krediet RT, et al. Immunoglobulins in chronic renal failure of childhood: effects of dialysis modalities. *Kidney Int* 2000; 58: 629–637.

327. Lalan S, Dai H and Warady BA. Hypogammaglobulinemia in infants receiving chronic peritoneal dialysis. *Pediatr Nephrol* 2017; 32: 503–509. 20161007.

328. Courivaud C, Bardonnet K, Crepin T, et al. Serum immunoglobulin G levels and peritonitis in peritoneal dialysis patients. *J Nephrol* 2015; 28: 511–515. 20150311.

329. Ceri H, Olson ME, Stremick C, et al. The Calgary Biofilm Device: new technology for rapid determination of antibiotic susceptibilities of bacterial biofilms. *J Clin Microbiol* 1999; 37: 1771–1776.

330. Tong MK, Leung KT, Siu YP, et al. Use of intraperitoneal urokinase for resistant bacterial peritonitis in continuous ambulatory peritoneal dialysis. *J Nephrol* 2005; 18: 204–208.

331. Gadallah MF, Tamayo A, Sandborn M, et al. Role of intra-peritoneal urokinase in acute peritonitis and prevention of catheter loss in peritoneal dialysis patients. *Adv Perit Dial* 2000; 16: 233–236.

332. Innes A, Burden RP, Finch RG, et al. Treatment of resistant peritonitis in continuous ambulatory peritoneal dialysis with intraperitoneal urokinase: a double-blind clinical trial. *Nephrol Dial Transplant* 1994; 9: 797–799.

333. Klaus G, Schafer F, Querfeld U, et al. Treatment of relapsing peritonitis in pediatric patients on peritoneal dialysis. *Adv Perit Dial* 1992; 8: 302–305.

334. Demoulin N and Goffin E. Intraperitoneal urokinase and oral rifampicin for persisting asymptomatic dialysate infection following acute coagulase-negative staphylococcus peritonitis. *Perit Dial Int* 2009; 29: 548–553.

335. Haivas CD and Teitelbaum I. Eradication of repeated episodes of coagulase-negative Staphylococcus peritonitis: a multipronged approach. *Perit Dial Int* 2019; 39: 568–570.

336. Margetts P. Heparin and the peritoneal membrane. *Perit Dial Int* 2009; 29: 16–19.

337. de Boer AW, Levi M, Reddingius RE, et al. Intraperitoneal hypercoagulation and hypofibrinolysis is present in childhood peritonitis. *Pediatr Nephrol* 1999; 13: 284–287.

338. Nadig C, Binswanger U and von Felten A. Is heparin therapy necessary in CAPD peritonitis? *Perit Dial Int* 1997; 17: 493–496.

339. Chow KM, Szeto CC, Kwan BC, et al. Randomized controlled study of icodextrin on the treatment of peritoneal dialysis patients during acute peritonitis. *Nephrol Dial Transplant* 2014; 29: 1438–1443. 20140226.

340. Hui YH, So WK, Ng MS, et al. Treating peritoneal dialysis catheter exit-site granulomas with chlorhexidine swabstick: a pilot study. *J Ren Care* 2021; 47: 103–112. 20201218.

341. Matinfar M, Taheri S, Karimi S, et al. Successful treatment of peritoneal dialysis catheter exit-site granuloma with silver ion-based dressing. *J Vasc Access* 2021; 22: 685–686. 20200720.

342. Piraino B. Peritoneal dialysis catheter replacement: "save the patient and not the catheter". *Semin Dial* 2003; 16: 72–75.

343. Choi P, Nemati E, Banerjee A, et al. Peritoneal dialysis catheter removal for acute peritonitis: a retrospective analysis of factors associated with catheter removal and prolonged postoperative hospitalization. *Am J Kidney Dis* 2004; 43: 103–111.

344. Lu W, Kwan BC, Chow KM, et al. Peritoneal dialysis-related peritonitis caused by Pseudomonas species: insight from a post-millennial case series. *PLoS One* 2018; 13: e0196499. 20180510.

345. Xu R, Chen Y, Luo S, et al. Clinical characteristics and outcomes of peritoneal dialysis-related peritonitis with different trends of change in effluent white cell count: a longitudinal study. *Perit Dial Int* 2013; 33: 436–444. 20130603.

346. Tantiyavarong P, Traitanon O, Chuengsaman P, et al. Dialysate white blood cell change after initial antibiotic treatment represented the patterns of response in peritoneal dialysis-related peritonitis. *Int J Nephrol* 2016; 2016: 6217135. 20160830..

347. Lye WC, Leong SO, van der Straaten J, et al. Staphylococcus aureus CAPD-related infections are associated with nasal carriage. *Adv Perit Dial* 1994; 10: 163–165.

348. Szeto CC, Chow KM, Wong TY, et al. Feasibility of resuming peritoneal dialysis after severe peritonitis and tenckhoff catheter removal. *J Am Soc Nephrol* 2002; 13: 1040–1045.

349. Matuszkiewicz-Rowinska J. Update on fungal peritonitis and its treatment. *Perit Dial Int* 2009; 29: S161–S165.

350. Gudit S, Sudhakar P, Ram R, et al. Peritoneal scintigraphy in the diagnosis of adhesions. *Perit Dial Int* 2010; 30: 112–113.

351. Ram R, Swarnalatha G and Dakshinamurty KV. Reinitiation of peritoneal dialysis after catheter removal for refractory peritonitis. *J Nephrol* 2014; 27: 445–449. 20140204.

352. Majkowski NL and Mendley SR. Simultaneous removal and replacement of infected peritoneal dialysis catheters. *Am J Kidney Dis* 1997; 29: 706–711.

353. Posthuma N, Borgstein PJ, Eijsbouts Q, et al. Simultaneous peritoneal dialysis catheter insertion and removal in catheter-related infections without interruption of peritoneal dialysis. *Nephrol Dial Transplant* 1998; 13: 700–703.

354. Crabtree JH and Siddiqi RA. Simultaneous catheter replacement for infectious and mechanical complications without interruption of peritoneal dialysis. *Perit Dial Int* 2016; 36: 182–187. 20151001.

355. Viron C, Lobbedez T, Lanot A, et al. Simultaneous removal and reinsertion of the PD catheter in relapsing peritonitis. *Perit Dial Int* 2019; 39: 282–288. 20190309.

356. Singhal MK, Vas SI and Oreopoulos DG. Treatment of peritoneal dialysis catheter-related infections by simultaneous catheter removal and replacement. Is it safe? *Perit Dial Int* 1998; 18: 565–567.

357. Lui SL, Yip T, Tse KC, et al. Treatment of refractory pseudomonas aeruginosa exit-site infection by simultaneous removal and reinsertion of peritoneal dialysis catheter. *Perit Dial Int* 2005; 25: 560–563.

358. van Diepen AT, Tomlinson GA and Jassal SV. The association between exit site infection and subsequent peritonitis among peritoneal dialysis patients. *Clin J Am Soc Nephrol* 2012; 7: 1266–1271. 20120628.

359. Twardowski ZJ and Prowant BF. Exit-site study methods and results. *Perit Dial Int* 1996; 16: S6–S31.

360. Elamin S, Khaier ME, Kaballo BG, et al. Low sensitivity of the exit site scoring system in detecting exit site infections in peritoneal dialysis patients. *Clin Nephrol* 2014; 81: 100–104.

361. Eriguchi M, Tsuruya K, Yoshida H, et al. Validation of the exit-site scoring system recommended by the 2005 guidelines of the international society for peritoneal dialysis. *Perit Dial Int* 2011; 31: 698–700.

362. Mahima Keswani M, Kathleen Mallett APRN, Troy Richardson MPH, et al. on behalf of the Standardizing Care to Improve Outcomes in Pediatric End Stage Kidney Disease (SCOPE) Investigators. Interobserver Agreement of Peritoneal Dialysis Exit Site Scoring: Results from the Standardizing Care to Improve Outcomes in Pediatric End Stage Kidney Disease (SCOPE) Collaborative. *Peritoneal Dialysis International*. Epub ahead of print 3 June 2024. DOI: 10.1177/08968608241254278.

363. Warady B. Peronal Communication.

364. Rigo M, Pecoits-Filho R, Lambie M, et al. Clinical utility of a traditional score system for the evaluation of the peritoneal dialysis exit-site infection in a national multicentric cohort study. *Perit Dial Int* 2021; 41: 292–297. 20200828.

365. Nardelli L, Scalamogna A and Castellano G. Utility of ultrasonographic examination in catheter-related infections in peritoneal dialysis: a clinical approach. *J Nephrol* 2023; 36: 1751–1761. 20230320.

366. Granata A, Rahbari E, Di Nicolo P, et al. The underrated role of ultrasound in peritoneal dialysis. *J Ultrasound Med* 2022; 41: 301–310. 20210329.

367. Finkelstein ES, Jekel J, Troidle L, et al. Patterns of infection in patients maintained on long-term peritoneal dialysis therapy with multiple episodes of peritonitis. *Am J Kidney Dis* 2002; 39: 1278–1286.

368. Macchini F, Testa S, Valade A, et al. Conservative surgical management of catheter infections in children on peritoneal dialysis. *Pediatr Surg Int* 2009; 25: 703–707. 20090702.

369. Levy M, Balfe JW, Geary D, et al. Exit-site infection during continuous and cycling peritoneal dialysis in children. *Perit Dial Int* 1990; 10: 31–35.

370. Cervelli MJ e. The Renal Drug Reference Guide. *Adelaide, Australia: Kidney Health Australia* 2007.

371. Taketomo CK, Hurburt J and Kraus DM. *Pediatric Dosage Handbook: Including Neonatal Dosing, Drug Administration, and Extemporaneous Preparations.* 2010.

372. Stevens DL, Bisno AL, Chambers HF, et al. Practice guidelines for the diagnosis and management of skin and soft tissue infections: 2014 update by the Infectious Diseases Society of America. *Clin Infect Dis* 2014; 59: 147–159. 20140618.

373. Hoshii S, Wada N, Honda M, et al. A survey of peritonitis and exit-site and/or tunnel infections in Japanese children on PD. *Pediatr Nephrol* 2006; 21: 828–834. 20060414.

374. Khan W, Bernier SP, Kuchma SL, et al. Aminoglycoside resistance of Pseudomonas aeruginosa biofilms modulated by extracellular polysaccharide. *Int Microbiol* 2010; 13: 207–212.

375. Lo CY, Chu WL, Wan KM, et al. Pseudomonas exit-site infections in CAPD patients: evolution and outcome of treatment. *Perit Dial Int* 1998; 18: 637–640.

376. Kazmi HR, Raffone FD, Kliger AS, et al. Pseudomonas exit site infections in continuous ambulatory peritoneal dialysis patients. *J Am Soc Nephrol* 1992; 2: 1498–1501.

377. Burkhalter F, Clemenger M, Haddoub SS, et al. Pseudomonas exit-site infection: treatment outcomes with topical gentamicin in addition to systemic antibiotics. *Clin Kidney J* 2015; 8: 781–784. 20150912.

378. Vychytil A, Lorenz M, Schneider B, et al. New criteria for management of catheter infections in peritoneal dialysis patients using ultrasonography. *J Am Soc Nephrol* 1998; 9: 290–296.

379. Plum J, Sudkamp S and Grabensee B. Results of ultrasound-assisted diagnosis of tunnel infections in continuous ambulatory peritoneal dialysis. *Am J Kidney Dis* 1994; 23: 99–104.

380. Sachar M and Shah A. Epidemiology, management, and prevention of exit site infections in peritoneal dialysis patients. *Ther Apher Dial* 2022; 26: 275–287. 20210907.

381. Scalamogna A, Nardelli L, Zubidat D, et al. Simultaneous replacement and removal of the peritoneal catheter is effective in patients with refractory tunnel infections sustained by S. aureus. *Int Urol Nephrol* 2023; 55: 151–155. 20220711.

382. Borg D, Shetty A, Williams D, et al. Fivefold reduction in peritonitis using a multifaceted continuous quality initiative program. *Adv Perit Dial* 2003; 19: 202–205.

383. Diaz-Buxo JA, Wick GS and Pesich AA. Using CQI techniques for managing infections in PD patients. *Nephrol News Issues* 1998; 12: 22–24.

384. Schaefer F, Kandert M and Feneberg R. Methodological issues in assessing the incidence of peritoneal dialysis-associated peritonitis in children. *Perit Dial Int* 2002; 22: 234–238.

385. Nataatmadja M, Cho Y and Johnson DW. Continuous quality improvement initiatives to sustainably reduce peritoneal dialysis-related infections in Australia and New Zealand. *Perit Dial Int* 2016; 36: 472–477.

386. Currier H, Heise P and Tal L. Quality improvement strategies and outcomes in pediatric dialysis. In: A Bradley, SRA Warady and F Schaefer (ed) *Pediatric dialysis*. Third ed. Cham: Springer, 2021, pp.81–99.

387. Alicia M, Neu BAW and Schaefer F. Infectious complications of peritoneal dialysis in children. *Pediatric Dialysis* 2021; 16: 265–290.

388. Borzych-Duzalka D. Personal Communication.

389. Warady B. Personal Communication.

390. Ling CW, Sud K, Van C, et al. Pharmacokinetics of culture-directed antibiotics for the treatment of peritonitis in automated peritoneal dialysis: a systematic narrative review. *Perit Dial Int* 2021; 41: 261–272. 20210209.

391. Lam E, Ting Kayla Lien Y, Kraft WK, et al. Intraperitoneal pharmacokinetics of vancomycin in patients on automated peritoneal dialysis. *Clin Transl Sci* 2022; 15: 649–657. 20211109.

392. Roberts DM, Fernando G, Singer RF, et al. Antibiotic stability in commercial peritoneal dialysis solutions: influence of formulation, storage and duration. *Nephrol Dial Transplant* 2011; 26: 3344–3349. 20110215.

393. Williamson JC, Volles DF, Lynch PL, et al. Stability of cefepime in peritoneal dialysis solution. *Ann Pharmacother* 1999; 33: 906–909.

394. de Vin F, Rutherford P and Faict D. Intraperitoneal administration of drugs in peritoneal dialysis patients: a review of compatibility and guidance for clinical use. *Perit Dial Int* 2009; 29: 5–15.

395. Ling CW, Sud K, Patel R, et al. Culture-directed antibiotics in peritoneal dialysis solutions: a systematic review focused on stability and compatibility. *J Nephrol* 2023; 36: 1841–1859. 20230807.

396. Mendes K, Harmanjeet H, Sedeeq M, et al. Stability of meropenem and piperacillin/tazobactam with heparin in Various peritoneal dialysis solutions. *Perit Dial Int* 2018; 38: 430–440. 20180710.

397. So SWY, Chen L, Woo AYH, et al. Stability and compatibility of antibiotics in peritoneal dialysis solutions. *Clin Kidney J* 2022; 15: 1071–1078. 20220117.

398. Knowles MS, Holton E and Swanson RA. *The adult learner: the definitive classic in adult education and human resource development*. New York, NY: Routledge, 2014.

399. Fleming N and Baume D. *Learning styles again: VARKing up the right tree*. Educ Dev, 2006; 7, pp.4–7. http://www.johnsilverio.com/EDUI6702/Fleming_VARK_learningstyles.pdf

400. Falbo Dos Reis P, Barretti P, Marinho L, et al. Pharmacokinetics of intraperitoneal vancomycin and amikacin in automated peritoneal dialysis patients with peritonitis. *Front Pharmacol* 2021; 12: 658014. 20210528.

401. Farkas A, Oikonomou K, Ghanbar M, et al. Population pharmacokinetics of intraperitoneal gentamicin and the impact of varying dwell times on pharmacodynamic target attainment in patients with acute peritonitis undergoing peritoneal dialysis. *Antimicrob Agents Chemother* 2022; 66: 20211213.

402. Manley HJ, Bailie GR, Frye R, et al. Pharmacokinetics of intermittent intravenous cefazolin and tobramycin in patients treated with automated peritoneal dialysis. *J Am Soc Nephrol* 2000; 11: 1310–1316.

403. Elwell RJ, Frye RF and Bailie GR. Pharmacokinetics of intraperitoneal cefepime in automated peritoneal dialysis. *Perit Dial Int* 2005; 25: 380–386.

404. Peerapornratana S, Chariyavilaskul P, Kanjanabuch T, et al. Short-Dwell cycling intraperitoneal cefazolin plus ceftazidime in peritoneal dialysis patients. *Perit Dial Int* 2017; 37: 218–224. 20161013.

405. Leung CB, Szeto CC, Chow KM, et al. Cefazolin plus ceftazidime versus imipenem/cilastatin monotherapy for treatment of CAPD peritonitis–a randomized controlled trial. *Perit Dial Int* 2004; 24: 440–446.

406. de Fijter CW, Jakulj L, Amiri F, et al. Intraperitoneal meropenem for polymicrobial peritoneal dialysis-related peritonitis. *Perit Dial Int* 2016; 36: 572–573.

407. Gilmore JF, Kim M, LaSalvia MT, et al. Treatment of enterococcal peritonitis with intraperitoneal daptomycin in a vancomycin-allergic patient and a review of the literature. *Perit Dial Int* 2013; 33: 353–357.

408. Cheng IK, Chan CY, Wong WT, et al. A randomized prospective comparison of oral versus intraperitoneal ciprofloxacin as the primary treatment of peritonitis complicating continuous ambulatory peritoneal dialysis. *Perit Dial Int* 1993; 13: S351–S354.

409. Arrieta AC, Neely M, Day JC, et al. Safety, tolerability, and population pharmacokinetics of intravenous and oral isavuconazonium sulfate in pediatric patients. *Antimicrob Agents Chemother* 2021; 65: e0029021. 20210716..

410. Gervasoni C, Bergia R, Cozzi V, et al. Is it time to revise linezolid doses in peritoneal dialysis patients? A case series. *J Antimicrob Chemother* 2015; 70: 2918–2920. 20150703.

411. Ma TK, Leung CB, Chow KM, et al. Newer antibiotics for the treatment of peritoneal dialysis-related peritonitis. *Clin Kidney J* 2016; 9: 616–623. 20160704.

412. Yousaf F, Zaidi ST, Wanandy T, et al. Stability of cefepime in pH-neutral peritoneal dialysis solutions packaged in dual-compartment bags. *Perit Dial Int* 2016; 36: 457–459.

413. Pallotta KE, Elwell RJ, Nornoo AO, et al. Stability of tobramycin and ceftazidime in icodextrin peritoneal dialysis solution. *Perit Dial Int* 2009; 29: 52–57.

414. Patel RP, Farawahida S, Shastri M, et al. Physical and chemical stability of ceftazidime and cefazolin in peritoneal dialysis solutions packaged in dual-chamber infusion bags. *Am J Health Syst Pharm* 2013; 70: 1477–1478.

415. Ranganathan D, Naicker S, Wallis SC, et al. Stability of antibiotics for intraperitoneal administration in extraneal 7.5&per; icodextrin peritoneal dialysis bags (STAB study). *Perit Dial Int* 2016; 36: 421–426. 20151022.

416. Wiesholzer M, Winter A, Kussmann M, et al. Compatibility of meropenem with different commercial peritoneal dialysis solutions. *Perit Dial Int* 2017; 37: 51–55. 20160907.

417. Kane MP, Bailie GR, Moon DG, et al. Stability of ciprofloxacin injection in peritoneal dialysis solutions. *Am J Hosp Pharm* 1994; 51: 373–377.

418. Robinson RF, Morosco RS, Smith CV, et al. Stability of cefazolin sodium in four heparinized and non-heparinized dialysate solutions at 38 degrees C. *Perit Dial Int* 2006; 26: 593–597.

419. Bookstaver PB, Rokas KE, Norris LB, et al. Stability and compatibility of antimicrobial lock solutions. *Am J Health Syst Pharm* 2013; 70: 2185–2198.

Appendix – PD Modality and Antibiotic Dosing

Challenges exist with selecting IP antibiotic dosing regimens for patients undergoing APD, as the majority of pharmacokinetic studies for IP antibiotics were derived from patients undergoing CAPD.[390] Various pharmacokinetic and pharmacodynamic properties of the antibiotic may be impacted during APD resulting in underexposure to antibiotics. For example, shorter dwell times and more frequent exchanges utilized during APD result in increased antibiotic clearance and shorter half-lives. For time-dependent antibiotics, such as beta-lactams, this may result in less-than-optimal antibiotic exposure as the antibiotic concentrations will not remain above the minimum inhibitory concentration (MIC) for an adequate portion of the dosing period.[390] For vancomycin, the duration of the dwell time may influence the dose of vancomycin provided

Table 10. Stability of antibiotics added to peritoneal dialysis solutions.

Drug	PD solution			Stability	Storage conditions		
	Dextrose-based	Icodextrin-based	pH-neutral		Refrigeration	Room temperature	37°C
Cefazolin	✓	✓	✓	1 day	✓	✓	✓
	✓	✓	✓	8 days		✓	
		✓	✓	7 days			
				14 days			
Cefepime	✓	✓	✓	14 days	✓[392]	✓	✓[397]
	✓	✓	✓[412]	4 days	✓[393]	✓	✓
	✓		✓[412]	7 days			
				12 h			
				2 days			
				7 days			
Ceftazidime	✓	✓	✓	4 days	✓	✓	✓
	✓	✓	✓	7 days	✓	✓[413,414]	✓
	✓	✓	✓	2 days			✓
				14 days			
				8 hs			
				24 h			
				12 h			
Vancomycin	✓	✓[415]	✓	28 days	✓	✓	✓
	✓	✓	✓	14 days	✓	✓	✓
				1 day		✓	
				1 day			
				4 days			
Daptomycin[c]	✓		✓	5 days	✓	✓	✓
	✓		✓	12 h	✓		✓
	✓		✓	1 day			
				1 day			
				6 h			
Gentamicin	✓	✓	✓	14 days	✓	✓	✓
				<24 h		✓	
Tobramycin	✓	✓	✓	1 days	✓	✓	✓
		✓		14 days		✓[395]	✓
		✓		7 days		✓	
				1 day			
				<24 h			
Meropenem + heparin	✓	✓		7 days	✓[396]		✓
	✓			10 h			
Meropenem		✓[416]		7 days	✓		
Ciprofloxacin [417]	✓	✓	✓	14 days	✓[253]	✓	✓
	✓	✓	✓	7 days			✓
		✓		1 day			
				2 days			

[a]Adapted from Li et al.[27]
[b]When added to bicarbonate component of bag prior to mixing for room temperature and refrigeration; after mixing at 37°C
[c]Daptomycin degradation occurs more rapidly at higher dextrose concentrations and increased temperatures

Table 11. Compatibility of medications frequently added to PD solutions.[a,397]

	Cefazolin	Ceftazidime	Gentamicin	Meropenem	Vancomycin	Heparin
Cefazolin		✓	✓[415]	N/A	N/A	✓[418]
Ceftazidime	✓		N/A	N/A	✓	✓
Gentamicin	✓	N/A		N/A	✓[419]	[b]
Meropenem	N/A	N/A	N/A		N/A	✓
Vancomycin	N/A	✓	✓	N/A		✓
Ciprofloxacin	N/A	N/A	N/A	N/A	N/A	[c]

[a]Adapted from So et al.

[b]Due to known incompatibility of gentamicin and heparin at variable concentrations, extreme caution is advised. Available literature supports improved compatibility at lower gentamicin concentrations and elevated temperature, such as would be encountered in PD solutions.

[c]Due to known incompatibility of ciprofloxacin and heparin at increasing ciprofloxacin concentrations, it is recommended to avoid this combination until further studies are done.

as longer dwell times will allow for more complete peritoneal absorption compared to shorter dwell times. Patients with more rapid exchanges may require more frequent vancomycin dosing.[391] Overall, there is limited guidance for dosing of peritoneal antibiotics in pediatric patients undergoing APD, but dwell times, frequency of exchanges, and pharmacokinetic/dynamic properties of the antibiotic should be considered. Research is needed to explore whether necessary modifications are required (e.g., antibiotic concentration modifications to those with low fill volumes or with residual kidney function) to ensure optimal treatment.

Appendix B – Drug Delivery and Stability

Stability and compatibility of antimicrobials in PD solution is an important factor when considering treatment options (Table 10). Drug stability is determined by the degradation of the drug in solution, which is influenced by temperature and humidity and should generally be less than 10% for a drug to be considered stable.[392] Data suggest that many antibiotics are stable for variable times when added to available dialysis solutions. Vancomycin (25 mg/L) is stable for 28 days in dextrose-based dialysis solution stored at room temperature, although higher ambient temperatures will significantly reduce the duration of stability to just 1 day. Gentamicin (8 mg/L) is stable in dextrose-based and icodextrin-based solutions for 14 days at a wide range of temperatures, but the duration of stability is reduced by admixture with heparin. Conversely, the stability of gentamicin in pH-neutral PD solutions is <24 hours at room temperature. Cefazolin (500 mg/L) is stable in dextrose-based solutions for at least 8 days at room temperature, or for 14 days refrigerated; addition of heparin has no adverse influence. Ceftazidime is less stable; concentrations of 125 mg/L are stable for 4 days at room temperature in dextrose-based solutions and 2 days in icodextrin-based or pH neutral solutions. Cefepime is stable in dextrose-based dialysis solution for 14 days, if the solution is refrigerated.[393] These data are derived from duration-of-stability studies. However, it is important to recognize that because of significant differences in the constitution of current PD solutions in terms of buffers, osmotic agents, and pH, stability data cannot be extrapolated from one PD solution to another.[394]

Compatibility studies of multiple drugs in PD solutions supports the admixture of gentamicin with vancomycin or cefazolin, but aminoglycosides should not be combined with penicillins due to chemical incompatibility.(Table 11) Newer studies have demonstrated that meropenem added to dextrose-based PD solutions achieves longer stability under refrigeration when heparin is also added to the solution.[395,396] The addition of heparin to PD solution has also been studied individually with cefazolin, ceftazidime and vancomycin and compatibility was evident in all cases.[397]

Additional studies are needed to confirm the stability of antibiotics in various PD solutions at the concentrations used and the temperatures encountered (37 °C) in clinical practice to ensure optimal outcomes. Information is also needed on newer agents that will be necessary to treat the emergence of resistant organisms that may no longer respond to agents with known stability data.